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Abstract 
 
Cutaneous malignant melanoma (CMM) is a disease that has had a significant impact on the lives of 
Australians, affecting 1 in 17 people. Around 10% of those diagnosed have a family history of 
melanoma and in the majority of these cases there is underlying predisposition that makes them 
more susceptible to melanoma development. Known high-risk loci (CDKN2A, CDK4) account for 
approximately half of these families. There remains, therefore, a large gap in knowledge regarding 
the causes of susceptibility to CMM.  
Uveal malignant melanoma (UMM) is a rare type of melanoma that forms in the uveal tract of the 
eye. Unlike cutaneous melanoma, ultraviolet radiation does not contribute to the formation of 
UMM. To date, only one gene has been identified that contributes to risk of uveal melanoma: 
BAP1. 
The main objective of this thesis was to discover the underlying germline mutations that contribute 
to increased risk in high-density CMM and UMM families lacking mutations in any of the known 
melanoma risk loci. The key techniques that were used to achieve this were whole-genome and 
exome sequencing of multiple cases from these families. By targeting novel variants that segregated 
with disease in families, truncating mutations leading to CMM development were found in POT1, 
ACD and TERF2IP (Chapters 4 and 5). This technique was also used to discover truncating 
germline BAP1 mutations in a UMM family from Denmark (Chapter 7). A second method of gene 
discovery that was used was the candidate gene approach. This first involved a literature search to 
discover likely candidates for melanoma susceptibility. The protein-coding regions of the chosen 
genes were then Sanger sequenced to identify novel variants in probands from melanoma families. 
This method was used to interrogate the role of PALB2, SOX10 and MITF in CMM predisposition 
(Chapter 3).  
The contribution of known melanoma predisposition genes CDKN2A, CDK4 and BAP1 to a 
population-based CMM sample from Queensland was also assessed. This was achieved through a 
combination of targeted pull-down of the selected genes using the Ion Torrent Personal Genome 
Machine, and also single nucleotide polymorphism analysis using Sequenom mass spectrometry. 
Chapters 2 and 6 of this thesis detail the contribution of these genes to CMM and UMM 
predisposition in population-based samples from Australia. 
Overall this project has made a major contribution to the field of familial melanoma genetics. We 
described germline mutations in members of the shelterin complex (POT1, ACD and TERF2IP) in 
CMM, which accounts for 9% of families lacking mutations in previously known risk loci 
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CDKN2A, and CDK4. In combination with a previous finding of mutations in TERT, the work that 
is presented in this thesis has contributed to the discovery of a new pathway related to melanoma 
predisposition and thus represents a significant advance in the field. 
Additionally, we have estimated the contribution of known risk genes CDKN2A and BAP1 to 
susceptibility in a population-based sample of Queensland melanoma cases (N=1,109). We showed 
that CDKN2A accounts for around 1.31% of Queensland melanoma families and BAP1 accounts for 
around 0.63%. Additionally, we showed CDK4 mutations are extremely rare, not being found in 
1,550 melanoma families from Queensland. 
In summary, next-generation sequencing techniques have been an invaluable tool in melanoma 
predisposition gene discovery. We have identified several new genes that contribute to melanoma 
susceptibility when mutated in the familial setting. By discovering and characterising these genes, 
better surveillance and treatment strategies may be available in the future for individuals with 
familial melanoma.  
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Chapter 1 
Introduction  
 
1.1 Significance of melanoma  
 
Melanoma is a cancer that forms from melanocytes, occurring when genetic and epigenetic events 
lead to the development of malignancy. There are several forms of skin cancer but melanoma is the 
most aggressive, accounting for 75% of skin cancer deaths in Australia despite making up only 
2.3% of all skin cancers [1]. Caught in the early stages (I and II) it can be effectively treated with 
local excision; however, by the time it progresses to stage IV, patient prognosis is poor, with a five-
year survival rate of less than 10% [2]. This disease affects the lives of people globally, but 
nowhere more so than in Australia, with Queensland recording the highest incidence of invasive 
cutaneous melanoma in the world [3]. The Australian Institute of Health and Welfare reported over 
12,510 new cases in 2012, making it the fourth most common cancer nationally. The risk of being 
diagnosed with melanoma by the age of 85, in Australia, is 1 in 14 for males and 1 in 24 for females 
[4]. It is also the most common cancer type found in adolescents and young adults, with 2,251 cases 
diagnosed in the 15–39 year old age group in the period 2003–2007. This figure accounts for about 
one quarter of all cancers in this demographic [5]. It is clear that this disease has a profound effect 
in Australia and across the world, and effective screening and treatment strategies are needed to 
combat the burden of this disease. Identifying mutation events that lead to melanoma development 
is one step on this path.  
There are many environmental and genetic factors that play a part in melanomagenesis. While 
exposure to ultraviolet radiation (UVR) has a significant role in melanoma development, there can 
also be an underlying predisposition that contributes to a person’s risk. Studies have shown that 
around 10% of melanoma cases have a family history of the disease [6-11]. Currently, known 
germline variants account for approximately half of the high-density familial cases, leaving a large 
proportion of families with as yet unidentified genetic risk factors. The discovery of these could 
ultimately lead to better treatment strategies and prevention plans for at-risk individuals and their 
families.  
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1.2 Melanoma subtypes 
 
Cutaneous malignant melanoma (CMM) is a form of skin cancer that develops when unregulated 
growth of melanocytes leads to the formation of tumours. There are four subtypes by which primary 
tumours are classified. This stratifies tumours according to their anatomic location and their growth 
features. The subtypes are: superficial spreading melanoma (SSM), lentigo maligna melanoma 
(LMM), nodular melanoma (NM) and acral lentiginous melanoma (ALM) [12, 13].  
SSM is the most common CMM subtype, making up approximately 70% of all cases. These 
melanomas can be found on any part of the body and often arise in a pre-existing naevus, and then 
spread along the epidermis before becoming invasive (Figure 1). Phenotypically, they present with 
irregular borders and varied colours [14].  
LMM is a slow-growing neoplasm, usually occurring on the chronically sun-exposed areas of the 
head and neck. They develop from a freckle-like lesion (Hutchinson’s melanotic freckle) into 
invasive melanoma [15]. The histological features of this type of CMM are atypical melanocytes 
that proliferate at the dermal-epidermal junction. LMM accounts for about 1% of CMM cases and 
usually develops later in life, with an age of diagnosis often in the 60s or 70s [16].  
NM is an invasive melanoma that is generally black in appearance (though it can present with other 
colours on occasion). This is the most aggressive form of melanoma and accounts for around 15% 
of cases, usually occurring in older individuals [14].  
Lastly, ALM is melanoma originating in the epidermis of the palms, soles of the feet or in the nail 
bed. It is the most common form of melanoma in Asian and African-American populations but is 
rarer in Caucasian populations, making up about 5% of CMM cases in the latter group [14].  
There are two types of non-cutaneous melanoma: mucosal and uveal. Unlike CMM, these 
melanoma types are not related to UVR exposure. Mucosal melanoma is quite rare, accounting for 
only 2% of all melanoma cases. This melanoma develops in the mucosal membranes of the body, 
with the most common areas being the nasal passage and oral cavity. Uveal malignant melanoma 
(UMM) occurs in the uveal tract of the eye. This is also a very rare melanoma subtype, occurring in 
around 5.6 per million people in the USA [17]. Refer to Chapter 1 section 1.7 for a more in-depth 
introduction to UMM. 
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Figure 1: Histological progression from normal skin to melanoma. Evolution from normal skin (left panel) to radial growth phase (middle 
panel) to vertical growth phase (right panel). Pagetoid spread is the migration of melanocytes into the epidermis. Adapted from Chudnovsky et 
al., 2005.
Subcutaneous 
tissue 
Dermis 
Epidermis 
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1.3 Pathways to familial cutaneous malignant melanoma development 
 
Approximately 10% of CMM cases occur in individuals that have a relative with melanoma and 
approximately 1% of cases have a strong history of melanoma (two or more first degree relatives 
with the disease). Familial CMM is known to have both genetic and environmental risk factors.  
Firstly, familial melanoma may cluster by chance due to latitude-dependent ambient UVR. A case 
study of capital cities along the Eastern coast of Australia shows this effect well [18]. The trend in 
melanoma incidence increases as latitude decreases, even though the population demographic of 
each location is roughly the same. Melbourne has a melanoma incidence of 26 cases per 105 
individuals, Sydney has a rate of 27.3 cases per 105 individuals and Brisbane has a rate of 44.6 cases 
per 105 individuals. Melanoma rates increase as the latitude becomes smaller, with the cities having 
locations of 37.5oS, 33.6oS and 27.3o
The second pathway through which familial melanoma can occur is the presence of high-penetrance 
mutations in critical genes such as CDKN2A and CDK4 [19]. Mutation of these genes results in a 
Mendelian-like pattern of melanoma development which co-segregates with disease in a manner 
consistent with autosomal dominant inheritance. These high-penetrance genes are often associated 
with high-density CMM families that present with early-onset melanoma, multiple primary 
melanoma and multiple cancer types.  
S respectively. This trend can be seen across the world, not just 
in the Australian population [18]. Figure 2 shows a graphical representation of the UVR gradient in 
Australia. 
The third way that familial melanoma can develop is due to the presence of multiple medium or low 
penetrance genes that, when combined with high UVR exposure, increase a person’s susceptibility 
relative to the general population. The effect of this has been well described in prostate cancer, 
where the association between multi-locus genetic risk profiles and increased risk of cancer 
development compared to the general population has been shown [20]. Examples of medium risk 
genes for CMM are BAP1 and MITF (Chapter 1.4.2) [21, 22] while examples of lower risk genes 
tend to be those responsible for pigmentation and naevus development (Chapter 1.4.3).  
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1.4 Cutaneous melanoma predisposition genes 
 
A proportion of CMM in families and in the general population can be attributed to known 
predisposition genes. These genes can be divided into three categories: high-risk, medium-risk and 
low-risk. High-risk alleles are rare but confer an extremely high chance of CMM development in 
carriers and cause Mendelian-like disease in families (Figure 3). Historically, these have been 
identified through candidate gene sequencing and linkage studies followed by positional cloning. 
Low-risk alleles are found much more frequently in the general population but the effects they 
confer are less profound. Low-risk alleles in CMM have been found through genome-wide 
association studies (GWAS). Medium-risk alleles occur at relatively low frequency and confer a 
more intermediate effect. 
 
 
 
 
Figure 2: UVR incidence and melanoma rates in Australia. Map of Australia showing the 
location of major cities Brisbane, Sydney, and Melbourne, their population, latitude, UVR 
estimates, and standardised melanoma incidence rates. UVI (ultraviolet index) is a measure of UVR 
intensity. Adapted from Cust et al., 2009. 
Brisbane 
Population: 1.86 million 
Latitude: 27.3oS 
UVI annual mean: 7.8 
Annual total UVR: 11,855 
Total incidence per 105: 44.6  
(2001–2005) 
Sydney 
Population: 4.33 million 
Latitude: 33.6oS 
UVI annual mean: 6.2 
Annual total UVR: 9,760 
Total incidence per 105: 27.3 
(2001–2005) 
Melbourne 
Population: 3.81 million 
Latitude: 37.5oS 
UVI annual mean: 5.5 
Annual total UVR: 9,370 
Total incidence per 105: 26.0  
(2001–2005) 
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Figure 3: Gradient of effect of predisposition genes. GWA is genome-wide association. Adapted from Manolio et al., 2009. 
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1.4.1 High-risk genes: CDKN2A and CDK4 
 
The major melanoma predisposition gene is Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) 
which is located at chromosome band 9p21 [8, 23-25]. It is a tumour suppressor that inhibits the 
progression of potential cancer cells by inducing apoptosis or senescence [26]. It is involved in two 
of the most important tumour suppressor pathways, the p53 and retinoblastoma (RB) pathways, and 
encodes two different proteins: p16INK4a and p14ARF (Figure 4) [27].  
P16INK4a (p16) acts in the RB pathway. When DNA damage occurs, p16 binds to cyclin-
dependent kinase 4 and cyclin-dependent kinase 6 (CDK4 and CDK6), inhibiting their activity. This 
in turn inhibits the phosphorylation of pRB, allowing it to sequester E2F, which is responsible for 
transcription of genes that allow cells to move from G1 to S phase in the cell cycle.  Activating this 
tumour suppressor pathway leads to senescence and regulation of damaged cells [26]. The second 
protein encoded by CDKN2A, P14ARF (p14), acts in the p53 pathway. In response to DNA 
damage, p14 raises levels of p53 by interacting with the p53 binding protein, MDM2. This allows 
levels of p53 to become elevated and in turn inhibits cell proliferation by transcription of several 
genes capable of inducing apoptosis. P14 sequesters MDM2 in the nucleus thus abrogating its 
ability to ubiquitinate p53 and target it for proteasomal degradation [30]. Without this process 
damaged cells may continue progressing towards malignancy. 
The contribution of CDKN2A to melanoma predisposition was discovered in 1994 through a 
positional cloning approach following previous linkage studies [8, 23]. Approximately 40% of 
high-density melanoma families carry inactivating germline mutations in CDKN2A. The mutations 
reported in p16 (predominantly missense mutations) occur across the entire length of the protein [8, 
23]. Mutations arising in p14 consist of whole-gene deletions [28], insertions [29], splice mutations 
[30], and base deletions [31]. No missense variants are reported in conjunction with CMM [24]. In 
rare instances, a germline CDKN2A promoter mutation, which causes an aberrant initiation codon, 
is shown to predispose to melanoma [32, 33]. An intronic mutation in CDKN2A has also been 
shown to be associated with CMM in an English population [34]. 
The second melanoma predisposition gene, CDK4, was discovered two years after CDKN2A 
through a candidate gene screening approach [6, 7]. It is an oncogene with two activating mutations 
that predispose to CMM. They result in amino acid substitutions at the same residue encoded in 
exon 2, p.R24C and p.R24H. This is the position at which p16 binds to CDK4, normally inhibiting 
the ability of CDK4 to negatively regulate the RB pathway [6, 35].  
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The largest study to date looking into high-risk melanoma susceptibility genes in high-density 
melanoma families was conducted by the International Melanoma Genetics Consortium 
(GenoMEL), a collaboration of major research groups from across four continents. The study found 
that 41% of familial melanoma was caused by germline variants in CDKN2A (encoding either 
p16INK4a or p14ARF) and CDK4. Specifically, they found 178 out of 466 families had a germline 
p16 mutation, 7 out of 466 families had a p14 mutation and 5 out of 466 families had a CDK4 
mutation. For a complete summary of mutation by geographic region, refer to Table 1. This study 
highlighted the fact that many different mutations within CDKN2A confer an elevated melanoma 
risk, as they were able to capture 57 different mutations within the 178 p16-positive families. This 
research also found mutations in CDKN2A could predispose to pancreatic cancer, as 49 out of 66 
families that presented with both CMM and pancreatic cancer had a mutation in this gene [19]. 
Collectively these two genes account for approximately 41% of the risk in high-density families. 
There is a great need to identify the risk alleles in the remainder of these families in order to better 
understand their disease and provide better clinical outcomes. 
To date, there have only been two published studies determining the population-based frequency of 
CDKN2A mutations in CMM cases. The Genes Environment and Melanoma (GEM) study looked at 
probands from nine different geographical regions in the USA, Canada, Italy and Australia. They 
discovered 65 CDKN2A mutation carriers in a sample of 3,550 affected individuals [36]. This 
equates to a population frequency of approximately 2%. They also calculated the risk of developing 
melanoma in the CDKN2A mutation carriers they had identified, concluding that carriers had a 14% 
risk of melanoma by the age of 50, 23% risk by the age of 70 and 28% risk by the age of 80 [36]. 
Aitken and co-workers also investigated the association between mutations in CDKN2A and 
melanoma in a population-based sample that was derived from families in Queensland. This study 
also assessed whether there is a link between polymorphisms in CDKN2A and melanoma [37]. They 
used a sample of 482 families that had been categorised into high, intermediate and low risk based 
on the density of cases and history of disease of each family. They found that CDKN2A mutations 
occurred only in high-risk individuals in this group, with 9 out of 87 probands harbouring a 
mutation. The occurrence of a Nt500G polymorphism was also found to increase linearly with 
family risk and was found most often in the families that harboured a CDKN2A mutation (though 
this may be reflective of Celtic ancestry). This study extrapolated this data into a cohort of 7,784 
cases that had survey data available, of which 151 fitted the high risk profile. By hypothesising that 
CDKN2A mutations will occur at a similar frequency in the survey group, it was determined that 
CDKN2A mutations occur in 0.2% of melanoma cases in the population-based Queensland sample 
[37]. This calculation was based on a very small number of individuals screened and thus a broader,  
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Table 1: Incidence of high-penetrance mutations in CDKN2A and CDK4 in GenoMEL 
families. Details regarding number of families, melanoma cases, CDKN2A and CDK4 mutations, 
and large deletions are detailed by country. Genomic regions not tested are abbreviated by ‘NT’. 
This is an abridged table taken from the GenoMEL research paper previously described [19]. 
 
city, country families 
total 
CMM 
cases 
confirmed 
CMM 
cases 
p16 p14 CDK4 deletions (p16 or p14) reference 
Brisbane, Australia 102 512 450 18 0 1 0 37, 163, 164 
Sydney Australia 62 258 258 14 0 0 0 32, 165, 166 
Tel Aviv, Israel 1 5 5 0 0 0 NT  
Paris, France 41 146 138 19 0 1 0 7 
Genoa, Italy 13 55 35 9 0 0 0 167 
Emilia-Romagna, Italy 11 36 33 1 0 0 0 168 
Leiden, Netherlands 27 159 159 19 1 0 NT 10, 169 
Barcelona, Spain 12 41 40 5 0 0 0 29, 170 
Stockholm, Sweden 10 37 36 4 0 0 NT 171-173 
Lund, Sweden 15 60 60 8 NT 0 NT 174, 175 
Glasgow, Scotland 10 31 31 6 NT NT NT 176, 177 
Leeds, UK 75 293 169 35 4 1 3 32, 178 
Boston, USA 6 23 13 1 0 0 NT 179 
Washington, USA 42 219 219 19 2 2 1 8, 180 
Philadelphia, USA 9 33 26 2 0 0 NT  
Utah, USA 11 150 150 5 0 NT NT 181 
Toronto, Canada 19 79 45 13 0 0 NT  
TOTAL 466 2137 1867 178 7 5 4  
mutation frequency    0.38 0.03 0.02 0.02  
 
 
 
Figure 4: Alternative transcripts and products of CDKN2A. The exons that encode p16INK4a 
are shown in blue. The exons that encode p14ARF are shown in orange. Adapted from Ruas and 
Peters, 1998. 
P14ARF 
P16INK4a 
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more comprehensive survey is required to fully estimate the impact of CDKN2A mutations in a 
population-based Australian sample. This forms the basis of the first aim of this thesis. 
 
1.4.2 Medium-risk genes: MC1R, MITF and BRCA2 
 
Pigmentation traits are one of the phenotypic characteristics associated with melanoma risk [38]. 
Melanocortin-1 receptor (MC1R) is a key regulator of skin pigmentation and is considered to be a 
medium-penetrance risk allele for melanoma [39]. It is a highly polymorphic gene, with 
polymorphisms in the gene responsible for much of the variability in skin phenotypes in humans 
[40, 41]. Melanin is a pigment that protects the skin from the damage caused by UVR. There are 
two different forms, eumelanin and pheomelanin, and individuals with protein-coding MC1R 
variants show an increased level of pheomelanin compared to eumelanin [42, 43]. It is this increase 
that results in the red-hair and freckling phenotype and an increased sensitivity to UVR [44]. 
Eumelanin has a protective role in the skin and aids to protect melanocytes from UVR induced 
DNA damage [45]. Studies have shown that carriers of an MC1R variant have a relative risk of 
developing melanoma of between 2.2 and 3.9, and that if an individual carries more than one 
variant the risk increases again to between 4.1 and 4.8 [46-48]. Furthermore, MC1R variants can 
serve as a modifier for CDKN2A, causing an increase in the penetrance of CDKN2A mutations from 
50% to 84% and also decreasing the age of onset of disease by 20 years [46, 47, 49].  
Microphthalmia-associated transcription factor (MITF) has also been identified as a medium 
penetrance gene associated with familial and sporadic melanoma. It is located on chromosome 3 
and, of the nine gene isoforms, M-MITF is the melanocyte-specific isoform. It is expressed in 
melanocytes and also in melanoma cells where its function includes regulating the transcription of 
genes involved in cell survival, differentiation and melanogenesis [50]. Mutations in MITF are 
responsible for the development of Waardenburg Syndrome type 2, which is characterised by 
pigment abnormalities that involve the skin, hair and eyes, hearing loss, as well as minor defects in 
the structures that develop from the neural crest [51]. 
Several studies have shown MITF to be somatically dysregulated in melanoma. Cronin et al. found 
MITF to be mutated in 4 out of 50 melanoma cell lines derived from metastatic tumours and 
amplified in a further 4 out of 50 cell lines. With an additional 3 mutations in SRY (sex determining 
region Y)-box 10 (SOX10), an upstream transcription factor, it was shown that mutations in this 
pathway existed in over 20% of metastatic melanoma cell lines [52]. Further to this, screening of 
primary tumours found 2 out of 26 had mutations in MITF and 6 out of 55 had mutations in SOX10, 
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so that, overall, 14% of the primary tumours were affected in this pathway.  In a separate study by 
Garraway et al., MITF was amplified in 3 out of 30 primary CMM, 7 out of 32 metastatic tumours 
and 0 out of 10 benign nevi. This is suggestive of MITF being a lineage-specific oncogene and 
emphasises the importance of MITF in melanomagenesis [53]. 
The focus on MITF in melanocyte biology and somatic melanoma development led to the discovery 
of a germline variant associated with melanoma susceptibility in 2011. Two groups reported 
p.E318K (NM_000248) in families with CMM. In one study, which used whole-genome and exome 
sequencing of melanoma families, the variant was found to co-segregate with melanoma in some, 
but not all, cases in these families, consistent with the notion that this is a medium-penetrance 
variant. They also used case-control studies to show that this is a population variant that confers a 
slightly greater than two-fold risk of developing CMM (OR 2.7). Interestingly this risk is similar to 
that attributed to MC1R alleles associated with red hair [54]. Other associations were made with 
family history of disease, multiple primary melanoma, increased naevus count and non-blue eye 
colour [21]. The second group also described the germline variant increasing the risk of CMM 
development in a familial setting and showed that it also confers an elevated risk of developing 
renal cell carcinoma [55]. 
The role of MITF has also been described in relation to tumour properties. Experiments by Hoek et 
al. show cells in vivo that exhibit low levels of MITF expression have an invasive tumour 
phenotype, while cells exhibiting high levels of MITF expression have a proliferative phenotype 
[56]. The ability of MITF to control the switch between a motile and proliferative state makes it an 
interesting candidate for melanomagenesis. A candidate gene approach interrogating its role in 
CMM predisposition is described in Chapter 3. 
An essential function required for genome stability is the capacity to repair double-stranded breaks 
in DNA. Breast cancer 2, early onset (BRCA2) is a tumour suppressor gene located on chromosome 
13 that is responsible for maintaining genome stability. It does so through its involvement in the 
homologous recombination pathway that facilitates double stranded DNA repair by binding to 
recombination enzyme RAD51 [57-60]. Germline mutations in BRCA2 confer an increased risk of 
developing breast and ovarian cancer, with approximately one-third of familial breast cancer cases 
attributed to mutations in this gene [61, 62]. It is estimated that germline BRCA2 mutations confer a 
relative risk of melanoma development of 2.6 [62, 63]. 
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1.4.3 Low-risk genes: pigmentation and naevus variants 
 
Melanoma risk can be attributed to phenotypic characteristics relating to pigmentation and naevus 
variants. These characteristics include fair skin and hair colour, freckling, poor tanning response 
and high naevus counts [64]. GWAS have been used to determine a large number of genes that can 
be attributed to these phenotypes. To date, 16 low-penetrance variants have been discovered using 
this method (Table 2). Genes associated with pigmentation are SLC45A2, TYR, HERC2/OCA2, 
MC1R and ASIP [65-69], while the gene PLAG2G6 is strongly associated with naevus development 
[70]. GWAS have also linked a number of SNPs to an increased risk of CMM development. These 
SNPs are located in or near the following genes: PARP1, CASP8, TERT/CLPTMIL, 
CDKN2A/MTAP, ATM, CCND1, MC1R, MX2 and a region on locus 1q21.3 [67, 69, 71, 72]. A 
study by Gudbjartsson et al. used a candidate gene approach combined with GWAS to identify 
ASIP and TYR as being associated with increased risk of both CMM and basal cell carcinoma [73]. 
Many of these GWAS findings are associated with low-penetrance risk and are linked to hair 
colour, eye colour and naevus count, which is consistent with observations that have been made 
through epidemiological studies [74]. They also point to some new regions not associated with 
these traits (e.g. ATM, CCND1, MX2, and SETDB1) for consideration when trying to uncover the 
key genetic events occurring during melanomagenesis [66, 67, 71].  
 
Table 2: Low-risk variants found through genome-wide association studies. SNPs listed have 
been found to be associated with CMM and/or pigment and naevus traits.  
Gene SNP Odds ratio Pigment Naevus Melanoma Reference 
PARP1 rs3219090 0.89 No No Yes [71] 
1q21.3 
Multiple genes rs7412746 0.9 No No Yes [71] 
CASP8 rs13016963 1.14 (1.09, 1.19) No Weak Yes [67] 
SLC45A2 rs35390 0.36 (0.23, 0.53) Yes No No [67] 
TERT/CLPTMIL rs401681 0.87 (0.81, 0.94) No Weak Yes [72] 
CDKN2A/MTAP rs7023329 0.83 (0.78, 0.88) No Weak Yes [69] 
TYR rs1393350 1.30 (1.21, 1.39) Yes No No [69] 
ATM rs1801516 0.84 (0.79, 0.89) No No Yes [67] 
CCND1 rs1485993 1.11 (1.04, 1.18) No No Yes [67] 
HERC2/OCA2 rs1129038 and rs12913832 0.97 Yes No No [66] 
MC1R rs258322 1.70 (1.54, 1.87) Yes No Yes [69] 
ASIP rs1015362 and rs4911414 ~1.20 to ~1.29 Yes No No [65] 
MX2 rs45430 0.88 (0.85, 0.92) No No Yes [67] 
PLA2G6 rs2284063 0.85 (0.79, 0.91) No Yes No [70] 
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1.5 Candidate melanoma susceptibility genes 
 
1.5.1 PALB2 
 
PALB2 is a BRCA2 interacting protein that is essential for BRCA2 DNA repair functions [75]. It 
physically binds to both BRCA1 and BRCA2 and is necessary for proper tumour suppressor 
activity [76]. Germline mutations in BRCA2 are known to predispose to cancers of the breast, ovary 
and pancreas, as well as confer an increased risk of CMM (relative risk of 2.6 [62, 63]), suggesting 
by association that PALB2 may also play a role in tumour development in these cancer types. A 
study published in 2007 showed that germline mutations in this gene are associated with an 
increased breast cancer risk [77]. Probands from breast cancer families that were wild type for 
BRCA1 and BRCA2 were sequenced and results showed that 10 out of 923 affected individuals 
harboured a truncating mutation in PALB2 in contrast to 0 out of 1,084 controls. The variants 
showed imperfect segregation with disease, with approximately half of the pedigrees showing 
partial segregation. This implies that this is likely to be a medium to low penetrance gene in regards 
to breast cancer risk. In one family there was a case that had developed both primary melanoma and 
breast cancer; this is suggestive that PALB2 mutations may also infer risk of other cancer types 
[77]. A population-based study into breast cancer risk associated with germline PALB2 mutations 
has been carried out by Tischkowitz and colleagues. They identified five cases with pathogenic 
mutations out of the 559 cases that were screened and found no mutation in the 565 matched 
controls. From this they were able to infer a 5.3 fold increase in breast cancer risk in mutation 
carriers [78].    
There have been other associations made between PALB2 mutation and cancer. Several studies have 
investigated germline variants in regard to increased pancreatic cancer risk. Jones et al. looked at 
probands from 96 families with pancreatic cancer and identified truncating nonsense mutations in 
three of the families. In the 1,084 controls that they screened, no PALB2 mutations were seen [79]. 
A more recent study, looking at germline mutation in families that have both breast and pancreatic 
cancer, found no mutations in the 77 families that were screened. This included 22 probands that 
had both cancer types [79, 80].  
Since individuals with mutations in BRCA2 have an increased risk of developing several cancer 
types (breast, ovary, pancreas, prostate, melanoma) it is feasible that a mutation in PALB2, a gene 
that physically and functionally interacts with BRCA2, could lead to an increased risk of developing 
each of these other cancer types also [76], and this has indeed been shown for breast cancer and 
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pancreatic cancer. The first study to examine the association between PALB2 mutations and 
melanoma screened 53 families with multiple cases of melanoma that were CDKN2A wild type. No 
mutations were found in any of the 13 exons or exon boundaries of PALB2. This led to the 
conclusion that PALB2 may not be associated with melanoma, or that alternatively it is a low 
frequency risk gene, with mutations being rare events that were not detected in this small sample 
[81]. Thus this gene remains a good candidate for melanoma susceptibility since the published 
reports have not been able to unambiguously conclude a role for PALB2 in melanoma 
predisposition. 
 
1.5.2 SOX10 
 
SOX10 encodes a transcription factor that is expressed in tissues derived from the neural crest [82]. 
It plays a key biological role in melanocyte development and function, which includes the 
transcriptional control of MITF, the master regulator of pigment cells [83]. This interaction makes 
SOX10 a good candidate melanoma risk gene. Researchers have addressed the interaction between 
this pathway and disease progression. Referring to a paper previously discussed, there has been a 
link showing that MITF and SOX10 are somatically mutated in a mutually exclusive pattern in 
metastatic melanoma. The study by Cronin and colleagues identified frameshift or nonsense 
mutations in 3 out of 50 tumour cell lines from metastatic melanoma. Furthermore, 6 out of 55 
primary tumours also harboured mutations in this gene [52]. This makes SOX10 a candidate for 
further study as there is an established link to melanocyte function and somatic development of 
melanoma.  
 
1.6 Somatic mutations in cutaneous malignant melanoma 
 
A spectrum of somatic mutational events occurs in CMM. Mutations in v-raf murine sarcoma viral 
oncogene homolog B (BRAF) are the most common found in primary melanomas [84]. This gene 
encodes a kinase that acts in the mitogen-activated protein kinase pathway (MAPK) and regulates a 
variety of processes that include growth, survival and migration of cells [85]. Cells harbouring a 
BRAF mutation have an activation of kinase activity that results in continuous growth signals [86]. 
Somatic mutations in BRAF occur in up to 70% of primary melanomas, with a single point 
mutation, p.V600E, accounting for approximately 90% of these [87-90]. Melanomas lacking 
somatically mutated BRAF often carry mutations in another component of the MAPK pathway, 
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NRAS [91, 92]. Between 15% and 30% of primary melanomas lacking BRAF mutations have an 
NRAS mutation [87, 93]. PTEN is also frequently mutated in melanoma. It is a tumour suppressor 
that prevents uncontrolled cell growth through regulation of cell migration and apoptosis [94]. The 
types of somatic mutations acquired by tumours vary according to histological subtype, with BRAF 
and NRAS mutations usually occurring in SSM on intermittently sun-exposed areas of the skin. 
Somatic mutations in the tyrosine receptor, KIT, occur predominantly in ALM and mucosal 
melanoma (Chapter 1.2), with these subtypes often having wild type BRAF [95].  
 
1.7 Uveal malignant melanoma 
 
Uveal malignant melanoma (UMM) occurs on the uvea and develops from melanocytes that are 
located in the eye. There are three types of UMM: choroid, ciliary body and iris [96]. Unlike 
cutaneous melanoma, UMM is very rare, with the United States reporting an incidence of 5.6 cases 
per million per year in the years 1973 to 2008 [17]. The number of newly reported cases of UMM 
over this time frame has remained at a relatively steady rate, suggesting that the influence of UVR 
on UMM seems smaller than the association that is observed with CMM [96]. Melanoma can also 
occur on the conjunctiva of the eye and this is the exception to this pattern. Its incidence does 
follow the UVR gradient and hence it is better described as a cutaneous melanoma as it occurs on 
the skin, though it is within the structure of the eye [97].  
A 2004 study developed an identification system for UMM that clusters primary UMM tumours 
into two distinct molecular groups based on their gene expression profiles. Tumours that group into 
the class 1 profile rarely metastasise and are regarded as low-grade primaries, while tumours that 
group into the class 2 profile are highly metastatic and are regarded as high-grade primaries. This 
gene expression profile shows that class 2 tumours have clusters of up-regulated genes on 
chromosome 8q and down-regulated genes on chromosome 3, a region that has been previously 
implicated in UMM [22, 98]. Class 2 tumours have also been associated with monosomy 3, 
suggesting that they may have lost a tumour suppressor gene on chromosome 3 and that a mutation 
on the remaining allele may lead to the development of disease [99]. 
To date, there have been only a few genes implicated in the development of UMM; this suggests 
that there are still undiscovered genes that might be involved in its genesis. There is some evidence 
of familial clustering of UMM and a study by Jönsson et al. found linkage to 9p21-q22 in three 
Danish UMM families, however the gene responsible for the linkage peak has yet to be determined 
[100]. Interestingly, CDKN2A has been implicated in only a single UMM family. This family also 
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presented with CMM. No UMM families have mutations in CDK4. This indicates that the major 
predisposition genes in CMM do not play a significant role in familial UMM [19]. 
 
1.8 Somatic mutations in uveal melanoma: GNAQ, GNA11 and BAP1 
 
A novel recurrent somatic mutation in GNAQ, located at chromosome 9p21, encoding an alpha 
subunit of hetrotrimeric G proteins, was found in UMM. The mutation occurred in a panel of UMM 
tumours and blue nevi and were all acquired somatically at a hotspot located at p.Q209 [101]. 
Subsequent to this study, GNA11, a paralogue of GNAQ located on chromosome 19p13.3, was 
sequenced and also found to be mutated in UMM [102]. This later screening revealed that mutations 
in these two genes were mutually exclusive. Overall, GNAQ p.Q209 mutations were found in 55% 
of blue nevi, 45% of primary UMM and 22% of metastatic tumours. In GNA11, mutations at 
p.Q209 were found in 7% of blue nevi, 32% of primary UMM and 57% of metastatic tumours. A 
second hotspot was also discovered at position p.R183 in both genes. Combing the data from these 
investigations showed that 83% of UMM had a somatic mutation in either GNAQ or GNA11. This 
work indicates that this pathway plays a major role in the somatic development of UMM and further 
to this, the presence of these mutations in benign uveal naevi seems to implicate GNAQ and GNA11 
in early mutational events that occur in UMM development [96]. It is of note that although GNAQ 
and GNA11 have been shown to be somatically mutated in UMM they have so far not been 
associated with predisposition to UMM.  
BRCA1 associated protein-1 (BAP1) is a tumour suppressor gene located on chromosome 3. A 
study by Harbour and colleagues demonstrated that 84% of metastasising class 2 UMM had an 
inactivating somatic mutation in BAP1. These mutations were found through a combination of 
whole exome and Sanger sequencing. Initially, two class 2 tumours that had lost a copy of 
chromosome 3 were selected for exome sequencing along with their matched normal DNA samples. 
It was discovered that both tumours had a mutation in BAP1 (p.W196X and p.Q322fsX100) that 
was not found in the matched normal sample, indicating they were somatically acquired. To more 
fully investigate these mutations, a panel of 26 class 1 tumours and 29 class 2 tumours were then 
genotyped by Sanger sequencing. A single BAP1 mutation was identified in the class 1 group while 
in contrast 26 out of 31 metastatic UMM in the high-risk category had a mutation. Fifteen of these 
variants resulted in the termination of the protein and 6 affected the UCH (ubiquitin carboxy-
terminal hydrolase) domains [103]. 
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1.9 Uveal malignant melanoma predisposition gene, BAP1 
 
The original study by Harbour and colleagues also identified a single germline BAP1 mutation that 
was a frameshift mutation and occurred in a patient with a class 2 UMM tumour [103]. This opened 
up the possibility that BAP1 mutations could confer predisposition to UMM. Since this research 
was completed, there have been a small number of studies published that focus on BAP1 germline 
mutation and its association with cancer risk. One of these studies looked at two American 
mesothelioma families, from Wisconsin and Louisiana, and showed association between germline 
changes in BAP1 and mesothelioma in individuals that had no known exposure to asbestos or 
erionite, the strongest environmental risk factors [104]. Both of these families have developed 
multiple cancer types, though mesothelioma is the dominant disease. The Wisconsin family had 
confirmed cases of ovarian, breast and renal cancer, while the Louisiana family harboured two cases 
of prostate cancer, a pancreatic cancer, two cases of CMM and a case of UMM. By overlaying data 
from array-comparative genomic hybridization analysis and linkage analysis the researchers 
uncovered changes that encompassed the BAP1 locus in two tumour samples, which led to a more 
specific interrogation of BAP1 through Sanger sequencing. In the Wisconsin family, a splice variant 
was found to be responsible for disease as it co-segregated in four mesothelioma cases and two 
ovarian cases. In the Louisiana family, a truncating mutation, p.Q684X, was found to co-segregate 
with disease in three individuals with mesothelioma, two of whom also presented with CMM, with 
the third individual having UMM [104]. This work proved that BAP1 is associated with 
predisposition to several cancer types, including UMM. A third study into BAP1 mutation further 
supported these findings by interrogating the germline sequence of 53 UMM cases, five of which 
had a family history of melanoma. They identified three germline mutations in three probands: two 
variants were non-pathogenic,  a synonymous variant c.1026C>T and intronic variant c.123-48T>G, 
but the third was a truncating mutation, p.Q267X, in a family with mesothelioma, meningioma and 
UMM [105]. This mutation segregates with disease in individuals from whom DNA is available and 
is present only in one individual that is cancer free. Genotyping of three tumours from this family 
also revealed loss of heterozygosity (LOH) on the short arm of chromosome 3 for all samples and in 
each case a loss of the wild type allele in the tumour. A study of BAP1 in malignant pleural 
mesothelioma found inactivating somatic mutations in 23% of samples tested [106]. By 
interrogating recurrent genomic copy number alterations, 25 candidate genes were identified. BAP1 
was selected from this group as a possible driver mutation as it had the highest rate of non-
synonymous variation. This work supports the finding of germline predisposition to mesothelioma 
found by other researchers.   
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Another study to document germline BAP1 mutations shows its alteration in two families presenting 
with an autosomal dominant syndrome characterised by a variety of melanocytic tumours, including 
naevi, CMM and also UMM [107]. Both families had a case with UMM and in one family there 
were also three CMM cases. Segregation analysis has shown that germline BAP1 mutation in these 
families predisposes to these tumours and co-segregates with the disease phenotype. A frameshift 
mutation occurred in both families, the first located at p.Q436NfsX135 and the other at 
p.M687EfsX28. Once again array-comparative genomic hybridization has shown that there are 
losses affecting chromosome 3 that effectively leaves only a mutated copy of BAP1 in the tumours. 
Collectively, these studies have validated BAP1 as a tumour suppressor, which when mutated can 
lead to the development of several cancer types, including CMM, UMM and mesothelioma [22]. It 
is of note that all germline mutations described in the literature are truncating. Refer to Table 3 for a 
summary of known deleterious BAP1 germline variants published up to the date this thesis was 
started. Further literature is outlined in Chapters 6 and 7.  
 
 
 
Table 3: Published deleterious germline variants in BAP1 shown to predispose to cancer. 
Information on protein change, cancer type and a reference is given. 
Protein change Cancer type Reference 
p.E402fsX32 UMM [103] 
c.IVS7-2A<G  
p.I72fsX7 mesothelioma [104] 
p.Q436NfsX135 
p. M687EfsX28 melanocytic tumours [107] 
p.Q687X CMM, UMM, meningioma, mesothelioma [105] 
p.R60X, p.D236fs, p.R385X,  
p.E611fs, p.A634fs, p.K659X CMM, UMM [108] 
p.Q684X  
p.P147fsX48 
CMM, UMM, mesothelioma, 
melanocytic tumours [109] 
p.K25fsX43 UMM [110] 
p.Y241X CMM, mesothelioma [111] 
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1.10 Next-generation sequencing in cancer gene discovery 
Whole-genome sequencing captures mutations occurring in the coding and non-coding fractions of 
the genome that includes promoter regions, exons, introns and intergenic regions. It gives 
researchers the ability to detect single point mutations as well as insertion/deletions and other more 
complex chromosomal aberrations. In the broader sense it can be used to detect structural 
rearrangements including chromosomal translocations and copy number changes (Figure 5) [112]. 
There has been a lot of success using this method of gene discovery in both the somatic and 
germline disease settings as researchers are now able to characterise the genetic landscape 
associated with different disease phenotypes. In the somatic application, a tumour sample is 
matched to the patient’s normal DNA to identify mutational events that have occurred in the 
tumour. This method of discovery has been a useful tool in many cancer research projects, 
including studies in acute myeloid leukaemia, prostate cancer and lung cancer [113-115], among a 
rapidly increasing number of cancer types. In the familial setting, a comparison is made between 
affected family members to identify common germline mutations that may underlie disease 
predisposition. 
An alternative to whole-genome sequencing is to focus on particular chromosomal regions of 
interest. This provides cost-advantages as well as smaller volumes of data, which are easier to 
manipulate at the analysis stage. Exome sequencing is an effective way to screen the entire protein 
coding fraction of the genome and it typically covers a 50 to 62 Mb region. The limitation of exome 
sequencing is the inability to detect structural changes across the chromosomes; however, the lower 
costs and high-sensitivity in detecting mutational events make it a powerful tool for discovering 
gene variants associated with disease [116]. Exome sequencing is the main gene discovery 
technology used in this thesis, the outcomes of which are described in Chapters 4, 5 and 7. 
Sequencing using Ion Torrent Personal Genome Machine (PGM; Life Technologies, USA) is an 
even more targeted method of mutation discovery. This technology allows sequencing of multiple 
gene regions in a high-throughput and cost-effective manner. Targeted sequencing covers up to 1 
Mb per pool and allows the user to multiplex up to 64 samples in a single run. Chapter 2 of this 
thesis outlines the methods and outcomes of the population-based screen of CMM cases from 
Queensland, performed using the PGM. 
As a whole, next-generation sequencing (NGS) represents a rapid and comprehensive method for 
identifying predisposition genes in order to identify genetic alterations underlying disease 
development in both the somatic and the familial setting. 
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Figure 5: Genetic alterations detected by whole-genome sequencing. Sequence reads are 
indicated by bars. Point mutations, insertion/deletions and copy number alterations are depicted. 
Paired-end reads (joined by dotted lines) show identification of translocations. Adapted from 
Yoshida et al., 2013.   
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1.10.1 Whole-genome and exome sequencing in melanoma tumours  
The first melanoma whole-genome sequence was completed in 2010, on a commonly used 
melanoma cell line COLO-829 and its matched lymphoblastoid cell line (LCL). This was the first 
opportunity to catalogue the full complement of somatic mutational events and structural changes 
occurring in CMM and resulted in the identification of several novel potential melanoma driver 
genes [117]. This technique was able to identify 88% of previously known mutations in this sample 
and also uncovered a total of 33,345 somatic base substitutions, with a subset showing a 97% 
confirmation rate through Sanger sequencing. Analysis of the complete mutation list showed that 
only 292 variants occurred in a protein-coding region and when this list was further broken down, 
only 187 caused a non-synonymous change. One of the key features of melanoma biology 
highlighted by the study is the identification of a mutation signature indicative of DNA damage 
acquired through UVR exposure. Most of the base substitutions were C>T or G>A. In fact, 92% of 
mutations occurred with this patterning compared to the 53% that would be expected by chance. 
Another feature of this study is the demonstration of preferential DNA repair on the transcribed 
DNA strand as opposed to the non-transcribed strand. There were 2,773 C>T changes on the 
transcribed strand in contrast to 4,058 on the non-transcribed strand.   
The first exome sequencing study in the melanoma field was carried out by Wei et al. The group 
sequenced DNA from 14 metastatic tumours and the corresponding matched normal DNA samples. 
They discovered a mutation in the transformation/transcription domain-associated protein, TRRAP 
that occurred in a hotspot (p.S722F) in two samples. When this was expanded into a larger case set, 
they found this specific mutation in 6 out of 167 samples. This study also found the gene GRIN2A 
(glutamate receptor, ionotropic, N-methyl D-aspartate 2A) mutated in around 30% of melanoma 
samples. This came out of the initial exome sequencing that identified a mutation event in GRIN2A 
in 6 out of 14 metastatic melanoma exomes [118]. An important finding that came out of this study 
was the discovery of the high rate of mutation in melanoma, which is much higher than that seen in 
most other cancers (the exception being lung cancer from smokers) [119]. This demonstrates that 
gene discovery in melanoma is a complex puzzle and that there is likely to be many passenger 
mutations to sift through in order to find the important driver mutations that cause disease 
development and progression. Exome sequencing by other groups has also uncovered other somatic 
mutations of functional importance, such as the role of the MAPK family of genes in melanoma. In 
a similar approach using melanoma samples and matched normal DNA samples, somatic non-
synonymous mutations in MAP2K1, MAP2K2, MAP3K5 and MAP3K9 have been reported in 
melanoma cell lines and tumours [120, 121]. 
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1.10.2 Whole-genome and exome sequencing in familial melanoma  
Linkage studies of high-density melanoma prone families suggest that there is a great deal of 
genetic heterogeneity associated with melanoma predisposition. A technique to address this issue of 
heterogeneity is to consider families individually rather than as a group. By assessing the entire 
genome or exome of affected family members and searching for variants that are common between 
cases, genes responsible for increased melanoma risk can be uncovered.  
A NGS approach in families is the main discovery tool used in this thesis. High-density families 
were prioritised as they seemed more likely to carry a genetic predisposition rather than cluster by 
chance. Between 1 and 6 melanoma cases were selected from each pedigree. Individuals that were 
the furthest apart genetically were selected as they would share fewer novel variants and would 
therefore narrow down the gene list. Individuals with multiple primary melanomas, early onset 
disease, or multiple primary cancers (where CMM is one of the cancers) were also selected as they 
had a greater disease burden and were again likely to have a greater genetic risk. The majority of 
the NGS was out-sourced to a South-Korean based company, Macrogen. These samples were 
sequenced using Agilent SureSelect enrichment kits on the Illumina Hiseq2000 platform. Early 
whole-genome and exome data was generated by Complete Genomics, or by sequencing facilities at 
the National Cancer Institute (USA) or the Translational Genomics Research Institute (USA). Refer 
to Table 4 for a complete list of whole-genomes and exomes sequenced and the centres at which 
this was carried out. 
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1.10.3 Next-generation sequencing data analysis 
 
Given the large data sets that are generated by whole-genome and exome sequencing, a robust 
bioinformatics pipeline is essential to generate usable variant calls that can be filtered to obtain a 
target list of genes for follow up. For the sequencing projects outlined in this thesis the following 
bioinformatics were applied to the raw sequence data: 
1. The sequence output was mapped to the UCSC human genome reference build 19 using the 
Burrows-Wheeler alignment algorithm [122].  
2. SNPs and insertion/deletions were annotated using bcftools and SAMtools mpileup with 
disabled base alignment quality computation [123]. Each sample had an average of 90,000-
100,000 variants compared to the human genome reference sequence.  
3. Quality score of reads had to be greater than or equal to 70. 
4. Number of reads of the alternate allele had to be greater than two and equate to at least 20% 
of the total number of reads. 
5. Synonymous and non-protein changing variants were excluded. 
6. Common SNPs with minor allele frequency greater than 1% found in dbSNP version 135, 
The 1000 Genomes Project April 2012 release or the NHLBI Grand Opportunity 
Sequencing Project (ESP6500) were excluded.  
7. Common sequencing artefacts were removed along with any region of duplication in the 
genome.  
After the filtering process samples typically had 100–200 novel (or very rare) germline variants 
when considering the entire exome (Figure 6). 
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Figure 6: Bioinformatics pipeline for whole-genome and exome sequencing data sets
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1.11 QFMP and GenoMEL, resources for melanoma gene discovery 
The Queensland Familial Melanoma Project (QFMP) is a family and twin study that originated in 
Queensland, Australia in 1987. The aim of the study was to better understand the relationship 
between UVR exposure and individual susceptibility to melanoma [124]. Initially, over 10,000 
individuals with CMM were identified through the Queensland Cancer Registry and were asked to 
participate in this state-wide study. Cases were asked to fill out a questionnaire pertaining to family 
history, pigmentation, freckling, mole count and likelihood of sunburn. In the instance where an 
individual had a family history of melanoma, the first degree relatives and affected cases were also 
ascertained. Overall, 1,897 families took part, 738 of which provided a blood sample for DNA 
extraction and/or LCL production [125]. A follow-up study in 2002 to 2005 updated data and 
collected additional blood samples from families. This included low-risk individuals with no family 
history of CMM, two-case families categorised as intermediate-risk and families with three or more 
cases categorised as high-risk. The largest family collected in this study has 15 members affected 
with melanoma. From the total cohort, 15 families presented with both UMM and CMM and 34 
families had at least 5 members with CMM; all of these have been genotyped and are wild type for 
CDKN2A and CDK4. Along with DNA samples, there is also phenotypic information available on 
these individuals and disease information derived from the cancer and death registries. There is also 
linkage data (unpublished) available for the majority of these large families that provides a starting 
point for prioritising novel variants discovered by NGS.  
The International Melanoma Genetics Consortium (GenoMEL) is a valuable resource in melanoma 
gene discovery. It consists of pooled family samples from across Europe, Asia, North America and 
Australia and is the largest familial melanoma sample to date [19]. The Australian sample consists 
of families in the QFMP along with families from the Australian Melanoma Family Study (AMFS) 
[18], which has been collected in New South Wales, Queensland and Victoria, and includes 9 
families with both UMM and CMM cases. The use of these dense melanoma families provides a 
significant tool for gene discovery and as the price of whole-genome and exome sequencing 
continues to fall, NGS becomes a feasible option for discovering melanoma risk alleles.  
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1.12 Objectives 
 
The primary objective of this thesis was to identify and characterise novel (not previously been 
associated with melanoma predisposition) high-penetrance melanoma predisposition genes by 
applying NGS techniques and candidate gene sequencing to affected members of cutaneous 
melanoma-prone families collected as part of the QFMP and through GenoMEL [19, 124]. A total 
of 231 genomes/exomes from 100 families were sequenced over the course of this study. There 
were 91 samples from UMM families and 140 samples from CMM families. This formed the core 
of this project and is the basis for much of the research described in Chapters 4, 5 and 7. For a 
breakdown of samples sequenced refer to Table 4. Genes selected for the candidate gene 
sequencing project that used traditional Sanger sequencing techniques are outlined in Chapter 3. 
The secondary objective of this thesis was the identification of novel medium or low penetrance 
variants that may also account for melanoma predisposition in the general population. Case-control 
analysis was the basis of this study with the cases obtained through the QFMP [124]. In addition to 
cases collected through the QFMP, we also had access to extensive cohorts of sporadic melanoma 
patients and age-matched controls from Queensland, in which these variants were further 
investigated. The control group used in this study were the parents of twins ascertained as part of 
the Brisbane Twin Naevus Study [126]. The available samples included: 1,550 family probands, 
139 sporadic cases and 1,630 controls. 
 
1.13 Hypotheses 
 
I. A small proportion of the Queensland familial melanoma cohort will have mutations in 
CDKN2A and CDK4.  
II. Some families who do not have germline mutations in CDKN2A and CDK4 will have high 
penetrance mutations in novel genes.  
III. Families who do not have high penetrance mutations will have multiple low or medium 
penetrance gene variants that in combination contribute to melanoma susceptibility.  
IV. Families with a combination of uveal and cutaneous melanoma represent a distinct genetic 
sub-group of familial melanoma.  
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1.14 Specific aims of the study 
 
1. To assess the contribution of CDKN2A, CDK4 and BAP1 mutations to melanoma 
susceptibility in a population-based sample of melanoma cases (the QFMP).  
2. To use a combination of whole-genome, exome and candidate gene sequencing to identify 
both novel high and low penetrance melanoma predisposition genes using high density 
melanoma families.  
3. To determine whether variants within candidate genes identified in Aim 2 segregate with 
melanoma within the ‘discovery’ families.  
4. To assess whether variants within candidate genes identified in Aim 2 segregate in an 
independent series of families.  
5. To assess selected novel candidate genes identified in Aim 2 as possible low penetrance 
melanoma risk variants in case-control samples.  
 
28 
 
Table 4: Melanoma family samples with whole-genome or exome sequencing data 
Family ID Sample ID NGS type Sequencing centre 
CMM or 
UMM 
family 
Meiosis 
between 
cases 
Cases 
sequenced 
in family 
Origin 
5 5-6 Exome Macrogen UMM 3 3 France 
5 5-12 Exome Macrogen UMM 3 3 France 
5 5-15 Exome Macrogen UMM 3 3 France 
594 594-1 Exome Macrogen UMM 5 2 France 
594 594-12 Exome Macrogen UMM 5 2 France 
908 908-1 Exome Macrogen UMM 2 2 France 
908 908-8 Exome NIH UMM 2 2 France 
1374 1374-1 Exome NIH UMM 4 2 France 
1374 1374-10 Exome Macrogen UMM 4 2 France 
LM10 mm564 Exome Macrogen CMM 3 3 Sweden 
LM10 mm615 Exome Macrogen CMM 3 3 Sweden 
LM10 mm648 Exome Macrogen CMM 3 3 Sweden 
LM23 mm396 Exome Macrogen CMM 2 2 Sweden 
LM23 mm641 Exome Macrogen CMM 2 2 Sweden 
LM48 mm638 Exome Macrogen CMM 2 2 Sweden 
LM48 mm700 Exome Macrogen CMM 2 2 Sweden 
LM57 mm56 Exome Macrogen CMM 1 2 Sweden 
LM57 mm64 Exome Macrogen CMM 1 2 Sweden 
LM74 mm1611 Exome Macrogen UMM 4 2 Sweden 
LM74 mm770 Exome Macrogen UMM 4 2 Sweden 
LM78 mm774 Exome Macrogen UMM 3 2 Sweden 
LM78 mm784 Exome Macrogen UMM 3 2 Sweden 
LM82 mm809 Exome Macrogen UMM 2 1 Sweden 
LM86 mm823 Exome Macrogen UMM 1 1 Sweden 
Umeå-family 04/2949D Exome Macrogen UMM 3 2 Sweden 
Umeå-family 04/3108D Exome Macrogen UMM 3 2 Sweden 
Lynch-family 419-01 Exome Macrogen UMM 1 3 Sweden 
Lynch-family 419-03 Exome Macrogen UMM 1 3 Sweden 
Lynch-family 419-08 Exome Macrogen UMM 1 3 Sweden 
1 210349 Exome Macrogen UMM 1 2 Denmark 
1 90389 Exome Macrogen UMM 1 2 Denmark 
2 10254 Exome Macrogen UMM 1 1 Denmark 
3 3-1 Exome Macrogen UMM 4 3 Denmark 
3 3-2 Exome Macrogen UMM 4 3 Denmark 
3 3-3 Exome Macrogen UMM 4 3 Denmark 
F100 110736 Exome Macrogen CMM 1 2 Denmark 
F100 210949 Exome Macrogen CMM 1 2 Denmark 
F117 200564 Exome Macrogen CMM 3 1 Denmark 
F172 190342 Exome Macrogen CMM 1 2 Denmark 
F172 220839 Exome Macrogen CMM 1 2 Denmark 
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Family ID Sample ID NGS type Sequencing centre 
CMM or 
UMM 
family 
Meiosis 
between 
cases 
Cases 
sequenced 
in family 
Origin 
F174 070650 Exome Macrogen CMM 1 2 Denmark 
F174 090146 Exome Macrogen CMM 1 2 Denmark 
F207 020946 Exome Macrogen CMM 1 2 Denmark 
F207 160655 Exome Macrogen CMM 1 2 Denmark 
F250 080545 Exome Macrogen UMM 3 2 Denmark 
F250 311080 Exome Macrogen UMM 3 2 Denmark 
F302 270550 Exome Macrogen CMM 4 2 Denmark 
F302 280944 Exome Macrogen CMM 4 2 Denmark 
F73 020830 Exome Macrogen CMM 1 2 Denmark 
F73 221143 Exome Macrogen CMM 1 2 Denmark 
F77 130948 Exome Macrogen CMM 1 2 Denmark 
F77 200450 Exome Macrogen CMM 1 2 Denmark 
33 33-01 Exome Macrogen UMM 2 2 Netherlands 
33 33-04 Exome TGen UMM 2 2 Netherlands 
3352 3352-209 Exome TGen UMM 3 1 USA 
00002 00002-001 Exome Macrogen UMM 2 1 QIMR 
00016 00016-001 Exome Macrogen UMM 1 1 QIMR 
00023 00023-001 Exome Macrogen UMM single case 1 QIMR 
00029 00029-001 Exome Macrogen UMM single case 1 QIMR 
00041 00041-001 Exome Macrogen UMM 1 1 QIMR 
00052 00052-001 Exome Macrogen UMM 1 1 QIMR 
00058 00058-001 Exome Macrogen UMM single case 1 QIMR 
20014 20014-001 Exome Macrogen UMM 4 1 QIMR 
20015 20015-002 Exome Macrogen UMM 3 2 QIMR 
20015 20015-001 Exome Macrogen UMM 3 2 QIMR 
40094 40094-001 Genome Macrogen CMM spouses 2 QIMR 
40094 40094-003 Genome Macrogen CMM spouses 2 QIMR 
40138 40138-007 Exome Macrogen CMM 3 3 QIMR 
40138 40138-009 Genome Macrogen CMM 3 3 QIMR 
40138 40138-010 Exome Macrogen CMM 3 3 QIMR 
40354 40354-002 Exome Macrogen CMM 5 3 QIMR 
40354 40354-007 Exome Macrogen CMM 5 3 QIMR 
40354 40354-058 Exome Macrogen CMM 5 3 QIMR 
40374 40374-006 Exome Macrogen CMM 2 3 QIMR 
40374 40374-008 Exome Macrogen CMM 2 3 QIMR 
40374 40374-010 Exome Macrogen CMM 2 3 QIMR 
40449 40449-001 Exome Macrogen CMM 4 3 QIMR 
40449 40449-003 Genome CompGen CMM 4 3 QIMR 
40449 40449-004 Exome Macrogen CMM 4 3 QIMR 
40800 40800-006 Genome CompGen CMM 4 3 QIMR 
40800 40800-011 Exome Macrogen CMM 4 3 QIMR 
40800 40800-015 Exome Macrogen CMM 4 3 QIMR 
40804 40804-002 Exome Macrogen CMM 2 3 QIMR 
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Family ID Sample ID NGS type Sequencing centre 
CMM or 
UMM 
family 
Meiosis 
between 
cases 
Cases 
sequenced 
in family 
Origin 
40804 40804-005 Exome Macrogen CMM 2 3 QIMR 
40804 40804-006 Exome Macrogen CMM 2 3 QIMR 
40849 40849-002 Exome Macrogen CMM 3 3 QIMR 
40849 40849-007 Exome Macrogen CMM 3 3 QIMR 
40849 40849-010 Exome Macrogen CMM 3 3 QIMR 
40851 40851-003 Exome Macrogen UMM 3 4 QIMR 
40851 40851-005 Exome QIMR UMM 3 4 QIMR 
40851 40851-006 Exome Macrogen UMM 3 4 QIMR 
40851 40851-007 Genome Macrogen UMM 3 4 QIMR 
40872 40872-002 Exome Macrogen CMM 4 4 QIMR 
40872 40872-007 Exome Macrogen CMM 4 4 QIMR 
40872 40872-009 Exome Macrogen CMM 4 4 QIMR 
40928 40928-001 Exome Macrogen CMM 3 3 QIMR 
40928 40928-003 Exome Macrogen CMM 3 3 QIMR 
40928 40928-004 Exome Macrogen CMM 3 3 QIMR 
40929 40929-001 Exome Macrogen CMM 4 4 QIMR 
40929 40929-004 Exome Macrogen CMM 4 4 QIMR 
40929 40929-005 Exome Macrogen CMM 4 4 QIMR 
40929 40929-016 Exome Macrogen CMM 4 4 QIMR 
40972 40972-007 Genome CompGen UMM 3 3 QIMR 
40972 40972-012 Genome Macrogen UMM 3 3 QIMR 
40972 40972-015 Exome Macrogen UMM 3 3 QIMR 
40993 40993-007 Exome Macrogen CMM 1 1 QIMR 
40999 40999-001 Exome Macrogen CMM 2 3 QIMR 
40999 40999-003 Genome CompGen CMM 2 3 QIMR 
40999 40999-004 Exome Macrogen CMM 2 3 QIMR 
41015 41015-001 Exome Macrogen CMM 3 3 QIMR 
41015 41015-009 Exome Macrogen CMM 3 3 QIMR 
41015 41015-015 Exome Macrogen CMM 3 3 QIMR 
41070 41070-001 Exome Macrogen UMM 2 1 QIMR 
41096 41096-002 Exome Macrogen CMM 2 3 QIMR 
41096 41096-004 Exome Macrogen CMM 2 3 QIMR 
41096 41096-005 Exome Macrogen CMM 2 3 QIMR 
41102 41102-002 Exome Macrogen CMM 2 3 QIMR 
41102 41102-003 Genome Macrogen CMM 2 3 QIMR 
41102 41102-012 Exome Macrogen CMM 2 3 QIMR 
41109 41109-001 Exome Macrogen CMM 5 4 QIMR 
41109 41109-003 Exome Macrogen CMM 5 4 QIMR 
41109 41109-007 Exome Macrogen CMM 5 4 QIMR 
41109 41109-016 Exome Macrogen CMM 5 4 QIMR 
41111 41111-002 Exome Macrogen CMM 2 2 QIMR 
41111 41111-007 Exome Macrogen CMM 2 2 QIMR 
41114 41114-001 Exome Macrogen CMM 3 3 QIMR 
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Family ID Sample ID NGS type Sequencing centre 
CMM or 
UMM 
family 
Meiosis 
between 
cases 
Cases 
sequenced 
in family 
Origin 
41114 41114-003 Exome Macrogen CMM 3 3 QIMR 
41114 41114-005 Exome Macrogen CMM 3 3 QIMR 
41116 41116-003 Exome Macrogen UMM 4 3 QIMR 
41116 41116-004 Exome TGen UMM 4 3 QIMR 
41116 41116-018 Exome Macrogen UMM 4 3 QIMR 
41142 41142-002 Exome Macrogen CMM 4 2 QIMR 
41142 41142-004 Exome Macrogen CMM 4 2 QIMR 
41155 41155-002 Exome Macrogen CMM 4 3 QIMR 
41155 41155-003 Genome Macrogen CMM 4 3 QIMR 
41155 41155-020 Exome Macrogen CMM 4 3 QIMR 
41164 41164-001 Genome Macrogen UMM 2 4 QIMR 
41164 41164-002 Genome CompGen UMM 2 4 QIMR 
41164 41164-003 Exome Macrogen UMM 2 4 QIMR 
41164 41164-005 Exome Macrogen UMM 2 4 QIMR 
41167 41167-001 Exome Macrogen UMM 2 3 QIMR 
41167 41167-003 Genome Macrogen UMM 2 3 QIMR 
41167 41167-005 Exome Macrogen UMM 2 3 QIMR 
41168 41168-005 Exome Macrogen CMM 1 2 QIMR 
41168 41168-006 Exome Macrogen CMM 1 2 QIMR 
41170 41170-004 Exome Macrogen CMM 5 4 QIMR 
41170 41170-007 Exome Macrogen CMM 5 4 QIMR 
41170 41170-008 Exome Macrogen CMM 5 4 QIMR 
41170 41170-016 Exome Macrogen CMM 5 4 QIMR 
41192 41192-006 Exome Macrogen UMM 2 1 QIMR 
41193 41193-001 Exome Macrogen UMM 3 3 QIMR 
41193 41193-005 Exome Macrogen UMM 3 3 QIMR 
41193 41193-007 Exome Macrogen UMM 2 3 QIMR 
41194 41194-001 Exome Macrogen CMM 3 4 QIMR 
41194 41194-004 Exome Macrogen CMM 3 4 QIMR 
41194 41194-008 Exome Macrogen CMM 3 4 QIMR 
41194 41194-009 Exome Macrogen CMM 3 4 QIMR 
41197 41197-001 Genome Macrogen CMM 2 2 QIMR 
41197 41197-004 Exome Macrogen CMM 2 2 QIMR 
41202 41202-001 Genome Macrogen CMM 3 3 QIMR 
41202 41202-005 Exome Macrogen CMM 3 3 QIMR 
41202 41202-009 Exome Macrogen CMM 3 3 QIMR 
41216 41216-001 Exome Macrogen CMM 7 4 QIMR 
41216 41216-004 Exome Macrogen CMM 7 4 QIMR 
41216 41216-006 Exome Macrogen CMM 7 4 QIMR 
41216 41216-013 Exome Macrogen CMM 7 4 QIMR 
41219 41219-001 Genome Macrogen UMM 6 5 QIMR 
41219 41219-004 Genome Macrogen UMM 3 2 QIMR 
41219 41219-015 Exome Macrogen UMM 6 5 QIMR 
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Family ID Sample ID NGS type Sequencing centre 
CMM or 
UMM 
family 
Meiosis 
between 
cases 
Cases 
sequenced 
in family 
Origin 
41219 41219-020 Exome Macrogen UMM 6 5 QIMR 
41219 41219-022 Exome Macrogen UMM 6 5 QIMR 
41219 41219-030 Exome Macrogen UMM 3 2 QIMR 
41220 41220-003 Exome Macrogen CMM 1 3 QIMR 
41220 41220-005 Exome Macrogen CMM 2 3 QIMR 
41220 41220-006 Exome Macrogen CMM 2 3 QIMR 
41229 41229-001 Genome Macrogen CMM 1 4 QIMR 
41229 41229-002 Exome Macrogen CMM 1 4 QIMR 
41229 41229-003 Exome Macrogen CMM 1 4 QIMR 
41229 41229-004 Exome Macrogen CMM 1 4 QIMR 
41233 41233-004 Exome Macrogen CMM 5 2 QIMR 
41233 41233-007 Exome Macrogen CMM 5 2 QIMR 
41234 41234-001 Genome Macrogen CMM 1 2 QIMR 
41234 41234-002 Exome Macrogen CMM 1 2 QIMR 
41248 41248-003 Exome Macrogen CMM 7 2 QIMR 
41248 41248-014 Genome Macrogen CMM 7 2 QIMR 
41250 41250-002 Exome Macrogen CMM 1 2 QIMR 
41250 41250-003 Genome Macrogen CMM 1 2 QIMR 
41254 41254-001 Exome Macrogen UMM 6 3 QIMR 
41254 41254-004 Genome Macrogen UMM 6 3 QIMR 
41254 41254-027 Exome Macrogen UMM 6 3 QIMR 
41294 41294-001 Genome Macrogen CMM 5 3 QIMR 
41294 41294-002 Exome Macrogen CMM 5 3 QIMR 
41294 41294-013 Exome Macrogen CMM 5 3 QIMR 
41334 41334-003 Exome Macrogen CMM 4 3 QIMR 
41334 41334-004 Exome Macrogen CMM 4 3 QIMR 
41334 41334-006 Exome Macrogen CMM 4 3 QIMR 
41348 41348-001 Genome Macrogen UMM 1 2 QIMR 
41348 41348-802 Exome Macrogen CMM 1 2 QIMR 
41397 41397-001 Exome Macrogen UMM 1 1 QIMR 
41517 41517-001 Exome Macrogen UMM 2 2 QIMR 
41517 41517-003 Exome Macrogen UMM 2 2 QIMR 
50003 50003-001 Exome Macrogen UMM 2 3 QIMR 
50003 50003-004 Exome Macrogen UMM 2 3 QIMR 
50003 50003-005 Exome Macrogen UMM 2 3 QIMR 
00-006 1413 Exome Macrogen CMM 4 3 QIMR 
00-006 1462 Exome Macrogen CMM 4 3 QIMR 
00-006 2304 Exome Macrogen CMM 4 3 QIMR 
41185 41185-001 Exome Macrogen CMM 7 5 QIMR 
41185 41185-007 Exome Macrogen CMM 7 5 QIMR 
41185 41185-008 Exome Macrogen CMM 7 5 QIMR 
41185 41185-011 Exome Macrogen CMM 7 5 QIMR 
41185 41185-022 Exome Macrogen CMM 7 5 QIMR 
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Family ID Sample ID NGS type Sequencing centre 
CMM or 
UMM 
family 
Meiosis 
between 
cases 
Cases 
sequenced 
in family 
Origin 
1003 1003-017 Exome TGen UMM 2 1 UK 
20963 975 Exome Macrogen UMM 3 1 WICR 
21065 1067 Genome CompGen CMM 3 1 WICR 
22070 2071 Genome CompGen UMM 6 2 WICR 
22070 2080 exome Macrogen UMM 6 2 WICR 
22108 2109 Exome Macrogen UMM 2 2 WICR 
22108 2110 Exome TGen UMM 2 2 WICR 
22198 2198 Exome Macrogen UMM 3 2 WICR 
22198 2200 Exome TGen UMM 3 2 WICR 
22309 2310 Exome Macrogen UMM 1 1 WICR 
22354 2835 exome TGen CMM 6 1 WICR 
22412 8683 Exome Macrogen UMM 2 1 WICR 
22669 2669 Genome CompGen CMM 4 3 WICR 
22669 2673 Exome Macrogen CMM 4 3 WICR 
22669 2680 Exome Macrogen CMM 4 3 WICR 
31662 1755 Exome Macrogen UMM 4 3 WICR 
31662 1762 Exome Macrogen CMM 4 3 WICR 
31662 1764 Genome CompGen CMM 4 3 WICR 
32155 2163 Exome Macrogen UMM 2 1 WICR 
 
QIMR is the Queensland Institute of Medical Research, Brisbane, Australia 
WICR is the Westmead Institute for Cancer Research, Sydney, Australia 
Macrogen is a NGS sequencing service provider 
CompGen refers to Complete Genomics 
NCI is the National Cancer Institute, USA 
TGen is the Translational Genomics Research Institute 
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Chapter 2 
Prevalence of germline BAP1, CDKN2A and CDK4 mutations in an 
Australian population-based sample of cutaneous melanoma cases 
 
Manuscript 1 
Lauren G. Aoude, Michael Gartside, Peter Johansson, Jane M. Palmer, Judith Symmons, Nicholas 
G. Martin, Grant W. Montgomery, Nicholas K. Hayward. Prevalence of germline BAP1, CDKN2A 
and CDK4 mutations in an Austrlian population based sample of cutaneous melanoma cases. Twin 
Research and Human Genetics (manuscript submitted 2/10/2014). 
 
2.1 Relevance to thesis aims 
 
This manuscript assesses the contribution of BAP1, CDKN2A and CDK4 mutations to a population-
based sample of cutaneous melanoma cases from Queensland. Australia, and in particular 
Queensland, has the world’s highest rate of CMM. Currently, the genetic contribution to the 
majority of these cases is unexplained. Further characterisation of these risk factors could help 
better manage the disease in the future. This manuscript describes the use of a targeted pull-down 
sequencing approach to genotype a large sample of cases in a cost-effective way using Ion Torrent 
Personal Genome Machine (PGM) platform. This addresses Aim 1 of this thesis by capturing the 
contribution of know high-risk melanoma genes to CMM development in Queensland. Cases from 
the QFMP (N=1109) were sequenced using the PGM to look for mutations in CDKN2A and BAP1. 
Point mutations (p.R24C, p.R24H) in CDK4 were assessed using the Sequenom mass spectrometry 
platform.  
There have only been only two population-based studies of germline CDKN2A mutation published 
to date [36, 37]. This report captures a better estimate of CDKN2A and CDK4 contribution to CMM 
in the Queensland population. Furthermore, this study reports three novel mutations (p.R22W, 
p.G35R and p.I49F) and shows that the total observed variants in CDKN2A accounted for 
approximately 1.31% of population-based CMM samples in Queensland. BAP1 has been only 
recently shown to predispose to melanoma and its contribution to CMM development in the general 
population is unreported. This is the first study to deduce the overall contribution of BAP1 to CMM 
predisposition. We show that mutations in BAP1 are found in 0.63% of population-based CMM 
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cases in a geographic area with high ambient UVR. Genotyping showed that no case in the QFMP 
(N=1550) was a carrier of either of the known pathogenic variants in CDK4 encoding either p.R24C 
or p.R24H substitutions. Overall, 1.9% of all probands of Queensland CMM families harboured 
mutations in a known high-penetrance melanoma susceptibility gene.  
 
2.2 Contribution of candidate 
 
I designed the Ampliseq panel to assess the contribution of CDKN2A and BAP1 with the guidance 
of Michael Gartside. I sequenced 21 chips (Ion 318v2) on the Ion Torrent platform. This included 
the library preparation and amplification, binding of the Ion Sphere particles to the library on the 
One Touch 2 (OT2) and sequencing of samples using the PGM. I also performed all the data 
analysis for variants reported through the Torrent Suite software. I then performed the Sanger 
sequencing validation of variants to confirm they were true and not an artefact of the sequencing 
pipeline.  I also performed the genotyping of the CDK4 p.R24C and p.R24H variants on the 
Sequenom MassArray platform using iPLEX chemistry. I wrote and edited the manuscript under the 
supervision of Nicholas Hayward. 
 
2.3 Contribution of other authors 
 
Michael Gartside provided training on the Ion Torrent OT2 and PGM as well as training on the use 
of the Torrent Suite of analysis software.  He also assisted with the library preparation and the 
sequencing of chips 1 to 6 on the Ion Torrent platform. Samples were collected by Nicholas 
Hayward, Nicholas Martin and Grant Montgomery. Jane Palmer and Judith Symmons collected the 
patient data relating to the families described in the manuscript. Peter Johansson provided the 
bioinformatics support for the Ion Torrent targeted pull-down data. Nicholas Hayward conceived 
the study design and edited the manuscript. All authors read and approved of the manuscript. 
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Abstract 
 
Mutations in CDKN2A and CDK4 contribute to susceptibility in approximately 40% of high-density 
cutaneous melanoma (CMM) families and about 2% of unselected CMM cases. BAP1 has been 
more recently shown to predispose to CMM and uveal melanoma (UMM) in some families; 
however, its contribution to CMM development in the general population is unreported. We sought 
to determine the contribution of these genes to CMM susceptibility in a population-based sample of 
cases from Australia. We genotyped 1,109 probands from Queensland families and found that 
approximately 1.31% harboured mutations in CDKN2A, including some with novel missense 
mutations (p.R22W, p.G35R and p.I49F). BAP1 missense variants occurred in 0.63% of cases but 
no CDK4 variants were observed in the sample. This is the first estimate of the contribution of 
BAP1 and CDK4 to a population-based sample of CMM and supports the previously reported 
estimate of CDKN2A germline mutation prevalence.  
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Introduction 
 
Many environmental and genetic factors play a part in melanomagenesis. While exposure to 
ultraviolet radiation (UVR) plays a significant role in melanoma development, an underlying 
genetic predisposition can also contribute to an individual’s risk. Studies have shown that ~10% of 
cutaneous malignant melanoma (CMM) cases occur in people that have a family history of 
melanoma (Gruis et al., 1995; Hussussian et al., 1994; MacGeoch et al., 1994; Soufir et al., 1998; 
Walker et al., 1995; Zuo et al., 1996). Known high-risk genes account for melanoma susceptibility 
in a proportion of these families. The major melanoma predisposition locus is Cyclin-Dependent 
Kinase Inhibitor 2A (CDKN2A) on chromosome 9, which encodes two tumour suppressors, 
p16INK4A and p14ARF, that inhibit progression of potential cancer cells by inducing senescence 
or apoptosis, respectively (de Snoo & Hayward, 2005; Palmieri et al., 2009). CDKN2A is thus 
involved in two of the most important tumour suppressor pathways, the p53 and the retinoblastoma 
(RB) pathways.  
The largest study of germline mutations in CDKN2A to date was conducted by the International 
Melanoma Genetics Consortium (GenoMEL) in which 466 families from North America, Europe, 
Asia and Australia were screened for mutations in CDKN2A and CDK4 (Goldstein et al., 2006). The 
study found that 41% of high-density families (defined by case-load depending on the region of 
origin) had germline variants, with 38% carrying a p16 mutation, 1.5% carrying a p14 mutation and 
1% carrying a CDK4 mutation. This study reported 57 unique melanoma-associated mutations in 
p16. In contrast, only two variants in CDK4 have been attributed to melanoma risk; they occur at 
the same codon and give rise to amino acid substitutions p.R24C and p.R24H (Soufir et al., 1998; 
Zuo et al., 1996). This is the position at which p16 binds to CDK4, normally inhibiting the ability of 
CDK4 to negatively regulate the RB pathway (Zuo et al., 1996). A study into the prevalence of 
CDKN2A and CDK4 mutations in CMM cases from a Greek hospital-based sample found that 5% 
of cases (16 of 320) harboured a mutation in one of these genes (Nikolaou et al., 2011). Mutations 
were most common in those with a family history (2 of 9) or multiple primary melanomas (4 of 7).  
To date, there have been only two published studies determining the prevalence of high-risk 
predisposition genes in population-based samples of CMM cases. The Genes Environment and 
Melanoma (GEM) study genotyped probands from nine different geographical regions in the USA, 
Canada, Italy and Australia (Begg et al., 2005). They discovered 65 CDKN2A mutation carriers in a 
sample of 3,550 affected individuals, equating to a population frequency of approximately 2%. A 
second study looked at the contribution of CDKN2A to melanoma to a population-based sample of 
40 
 
cases from Queensland, assessing the link between both novel CDKN2A mutations and 
polymorphisms in CMM cases (Aitken et al., 1999). The sample comprised 482 families and 
CDKN2A mutations only occurred in high risk individuals in this group, with 9 out of 87 high-risk 
families harbouring a mutation. This study extrapolated this data to a cohort of 7,784 cases that had 
survey data available, of which 151 fitted the high risk profile. By hypothesising that CDKN2A 
mutations will occur at a similar frequency in the survey group, it was estimated that CDKN2A 
mutations might occur in 0.2% of melanoma cases in the population-based Queensland sample 
(Aitken et al., 1999). This calculation was based on a very small number of individuals screened 
and thus a broader more comprehensive study of the Queensland Familial Melanoma Project 
(QFMP) is required to get a better estimate of prevalence and to more fully understand the 
prevalence of CDKN2A mutations in this population-based sample.  
BRCA-1 associated protein-1 (BAP1) is a tumour suppressor gene located on chromosome 3. In 
2010, a seminal study reported the occurrence of BAP1 somatic mutations in a panel of sporadic 
uveal melanoma (UMM) cases; notably, a single UMM case also carried a germline BAP1 mutation 
(Harbour et al., 2010).  Since then, BAP1 has been linked to predisposition of a spectrum of cancer 
types including UMM, CMM, mesothelioma, renal cell carcinoma, basal cell carcinoma, as well as 
a distinct type of benign melanocytic tumour (Abdel-Rahman et al., 2011; Aoude et al., 2013; 
Carbone et al., 2012; Cheung et al., 2013; de la Fouchardiere et al., 2014; Harbour et al., 2010; 
Hoiom et al., 2013; Njauw et al., 2012; Popova et al., 2013; Testa et al., 2011; Wadt et al., 2014; 
Wiesner et al., 2011). Population-based and clinic-based studies of BAP1 germline mutation 
prevalence in UMM cases have been reported and show that BAP1 contributes to only a small 
proportion of cases overall (3-4%) (Aoude et al., 2013; Njauw et al., 2012). While CMM is 
associated with the BAP1 tumour spectrum, the contribution of germline mutations in this gene to a 
population based-sample of CMM cases has not been reported.  
The primary aim of this study was to more fully quantify the contribution of constitutional 
CDKN2A and CDK4 mutations in an Australian population-based sample of CMM cases. A 
secondary aim was to determine the prevalence of germline BAP1 mutations in this sample. 
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Methods and Materials 
 
Ethics 
Written consent was obtained for each participant in this study. Ethics approval was obtained from 
the QIMR Berghofer Human Research Ethics Committee (HREC).  
 
Study cohort 
Samples were ascertained as part of the Q-MEGA project, a population-based study from 
Queensland investigating the associations between genes and environment in CMM development 
(Baxter et al., 2008). Q-MEGA is made up of 4 distinct CMM case sample collections: childhood, 
adolescent, men over 50 and the Queensland Familial Melanoma Project (QFMP) (Aitken et al., 
1996). Individuals that presented with histologically confirmed CMM and were reported to the 
Queensland Cancer Registry between the years 1982 and 1990 were approached to participate in the 
study. This accounted for approximately 95% of CMM cases diagnosed in Queensland over this 
period (Aitken et al., 1996). Cases were asked to fill out a questionnaire pertaining to family 
history, pigmentation, freckling, mole count and likelihood of sunburn. In the instance where an 
individual had a family history of melanoma, the first degree relatives and affected cases were also 
ascertained. A follow up study in 2002 - 2005 collected updated data and additional blood samples. 
A total of 1,897 individual families were sampled and stratified into three categories according to a 
standardized family risk index, previously described (Aitken et al., 1994). Generally, although there 
are a few exceptions, individuals with no family history of CMM were categorised as low-risk, two-
case families were categorised as intermediate-risk and families with three or more cases were 
categorised as high-risk. Additionally twins with CMM collected in Queensland and New South 
Wales were included (Shekar et al., 2009). For the current study a random selection of cases from 
across Q-MEGA was used (Table 1). 
 
Sample preparation 
Blood samples were obtained from 1,109 family probands ascertained through the QFMP (Aitken et 
al., 1996). Genomic DNA was extracted using a standard salting out method (Miller et al., 1988). 
 
Targeted Sequencing of CDKN2A and BAP1 using the Ion Torrent PGM  
Melanoma cases were assessed for variants in BAP1 and CDKN2A in a targeted sequencing 
approach. Using Ion AmpliSeq library kits (Life Technologies, CA, USA), 10 ng of genomic DNA 
from each proband were amplified using custom designed primer pools. The AmpliSeq panel was 
designed with a coverage of 40X across all regions with amplicon lengths of 150 bp to 250 bp. 
42 
 
BAP1 and CDKN2A had coverage 96% and 97% respectively. Ion Xpress barcode adapters 1-64 
were used to pool samples. Unamplified libraries were purified using Agencourt Ampure XP 
reagent (Beckman Coulter, CA, USA) in order to eliminate fragments < 100 bp and increase the 
proportion of on-target reads. Libraries were equalised to ~100 pM using Ion Library Equalizer kits 
then combined into a single sample. A portion of the library (4 µl) was then diluted in 21 µl 
nuclease-free water to create a working stock. Using OT2 200 Kits (Life Technologies, CA, USA), 
clonal amplification and template enrichment of the Ion Sphere particles was performed. The 
template quality was assessed using a Qubit 2.0 (Life Technologies, CA, USA). Finally, Ion 318v2 
chips were run on a Personal Genome Machine (Life Technologies, CA, USA) with 500 run flows 
per chip.  
Overall, 1,109 samples had mean sequence coverage of 30X and therefore the sequencing of these 
samples was considered to be of sufficient depth to give accurate mutation data. Sequence data were 
analysed using Torrent Suite software (Life Technologies, CA, USA). SAMTOOLS was used to 
detect SNPs (Li et al., 2009). In order to minimise the false positive rates, filtering criteria were 
applied to the output. Firstly, variants were required to have minimum of 4 reads for the reference 
and 4 reads for the alternative alleles. The variant allele also had to compromise at least 20% of the 
total read count. Quality score had to be > 40. Synonymous variants were excluded as well as 
variants occurring commonly in the NHLBI Exome Sequencing Project (ESP6500) (minor allele 
frequency >0.001). This sculpted the final list of variants which were verified using Sanger 
sequencing. As a previous study has reported the CDKN2A mutations in the QFMP high-risk cohort 
(Aitken et al., 1999), CDKN2A genotyping of these samples was not repeated here but the published 
results were included in the overall prevalence statistics. Sanger sequencing was used to validate the 
CDKN2A and BAP1 variants identified through targeted sequencing. See Supplementary Table S1 
for the list of primers used. Supplementary Material is available on the Cambridge Journals Online 
website. 
 
CDK4 genotyping using the Sequenom MassArray 
The two known familial melanoma variants in CDK4 (p.R24C and p.R24H) were genotyped in the 
QFMP probands using a Sequenom iPLEX gold assay (Sequenom Bioscience, CA, USA). The 
MassArray designer software was used to design the forward, reverse and extension primers for 
p.R24C (acgttggatgagtggctgaaattggtgtcg, acgttggatgtcacactcttgagggccac and gcactgtggggatcac) and 
p.R24H (acgttggatgagtggctgaaattggtgtcg, acgttggatgtcacactcttgagggccac and ttggccactgtggggatca). 
IPLEX Gold PCR amplification reactions were set up according to standard manufacturer protocols. 
Cluster plots were analysed using Typer Analyzer software 4.0. 
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Results 
 
Targeted sequencing of an unselected population of CMM cases from Queensland, Australia 
revealed 6 of 1,055 cases harbour a missense variant in CDKN2A (Table 2).  We report a single 
incidence of each of the following variants occurring in p16 (NM_000077): p.L16P, p.R22W, 
p.G35R and p.I49F. We also report two incidences of p.G101W (rs104894094), a common founder 
mutation in European melanoma populations (Goldstein et al., 2006). We found a recurrent 
mutation, p.A121T (rs199888003), in p14 (NM_058195) in two cases. As this residue is not overly 
conserved in primates (Rhesus, Figure 1), this is likely to be a non-deleterious mutation and is 
therefore not included in the overall prevalence statistics. Seventy-two cases carried the well-
documented CDKN2A p.A148T polymorphism, giving it a minor allele frequency (MAF) of 
0.0353. The MAF reported for this variant in the European American cohort (N = 4300) of the 
ESP6500 is 0.0225, which correlates well with the occurrence in our sample. CDKN2A p.A148T 
has also been omitted from the prevalence statistics. Of the variants seen here, three are novel (not 
previously reported in dbSNP, ESP6500 or the 1000 Genomes project) and have not been 
previously reported to the Leiden Open Variation Database (p.R22W, p.G35R and p.I49F). All 
occur at evolutionarily conserved amino acids (Figure 1), and although none of these variants have 
been reported as somatic mutations in CMM in the COSMIC (catalogue of somatic mutations in 
cancer) database, p.G35R has been seen in ovarian and pancreatic cancers (Table 3). 
The incidence of CDKN2A mutation in the QFMP high-risk probands has been reported previously 
(Supplementary Table S2) (Aitken et al., 1999). We did not re-genotype CDKN2A in these samples 
here, as the results for over 95% of the cases are in the report by Aitken et al., 1999. In that study, 
Sanger sequencing found that 9 of 87 probands had a CDKN2A mutation. When these results are 
combined with those of the current study, we find that 1.31% (15 of 1142) of the Australian 
population-based CMM sample carries a CDKN2A mutation affecting p16. The childhood cohort 
has also been partly reported on previously, with the p.L16P mutation being found in a case 
presenting with multiple primary melanomas by the age of 12 (Whiteman et al., 1997), the results of 
which have been replicated here. 
Genotyping of CDK4 p.R24C and p.R24H showed that no proband in this population-based sample 
is a carrier of a melanoma-associated CDK4 mutation. 
Targeted sequencing of this unselected population of CMM cases from Queensland, Australia found 
7 out of 1,109 cases harbour a missense variant in BAP1 (Table 2). Two novel variants occurred in 
the ubiquitin carboxy-terminal hydrolase domain (p.G121R and p.R150C), one novel variant 
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occurred in the BARD1 interacting domain (p.P222T), two novel variants occurred outside of any 
known domain (p.N446I and p.P519A) and a recurrent variant (p.V604M) was seen in two 
probands in the BRCA1 interacting domain (Figure 2). In our study the minor allele frequency for 
p.V604M is 0.0018, compared to the MAF reported in the ESP6500 of 0.000154. Overall, 0.63% of 
cases harboured a missense variant in BAP1. 
Since some missense mutations in BAP1 have been shown to affect alternative splicing (Wadt et al., 
2012; Popova et al., 2013), the Automated Splice Site and Exon Definition Analyses (ASSEDA) 
online tool (https://splice.uwo.ca), was used to assess whether BAP1 mutations in this study might 
create cryptic acceptor/donor sites (Rogan et al., 2003). No splice site alterations were predicted. 
Mutations in BAP1 occurred in highly conserved residues across species (Figure 1) and the five 
novel mutations (p.G121R, p.R150C, p.P222T, p.N446I and p.P519A) were predicted to be 
damaging by SIFT and/or Polyphen 2 (Table 2). 
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Discussion 
 
We identified CDKN2A missense mutations in 0.57% of melanoma cases in the intermediate, low, 
twin, childhood, adolescent and men over 50 cohorts of the QFMP. When this data is combined 
with that for the QFMP high-risk group published by Aitken et al. 1999 (Aitken et al., 1999), 1.31% 
of the overall Queensland population-based sample of CMM cases carried a CDKN2A mutation. 
The estimate for CDKN2A we report here is in keeping with that reported (~2%) in the GEM study 
(Begg et al., 2005). As might be expected, since CDKN2A mutation has been associated with an 
increased risk of development of cancer in general (Mukherjee et al., 2012), CDKN2A mutation-
positive families are often enriched for other cancers (Tables 3 and 4), although absolute numbers 
are too low in the QFMP families to show statistically significant association with any particular 
cancer type other than melanoma.  
The CDKN2A p.G35R mutation has been reported to occur somatically in the COSMIC (catalogue 
of somatic mutations in cancer) database, but here we report for the first time its occurrence in the 
germline of an individual presenting with melanoma and colorectal cancer. A study using both 
functional and computational prediction of p16 mutations has found that the pathogenicity of this 
mutation is uncertain (Scaini et al., 2014). The p.A148T variant was observed at a frequency of 
6.8% in the Queensland melanoma cases. This substitution is generally not thought to be 
deleterious, but the functional effect of this variant has been debated in the literature (Debniak et al., 
2005; Spica et al., 2006). It has been shown to occur more frequently in Celtic populations and 
therefore its potential association with CMM risk may be due to its prevalence in a more melanoma-
prone population (Aitken et al., 1999).   
We found that 0.63% of CMM cases harboured germline missense mutations in BAP1. This 
mutation rate is similar to that reported by Njauw et al (Njauw et al., 2012) when they screened a 
hospital-based sample of 193 CMM families for BAP1 mutation and reported 1 truncating mutation 
(0.5%). To date, all disease-associated variants in BAP1 have been shown to truncate the protein. 
The variants we report here are all missense mutations that occur at highly conserved residues in 
mammals (Figure 2). None were predicted to alter splicing, thus at this stage it is not clear whether 
they are responsible for melanoma susceptibility in these individuals, or if they represent rare, 
benign polymorphisms.  
We did not observe any mutations in CDK4. This result is in keeping with the low frequency of 
mutations of this gene reported in the literature. To date, only 17 families worldwide have been 
documented to carry CDK4 mutations (Puntervoll et al., 2013; Soufir et al., 1998; Zuo et al., 1996). 
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All reported pathogenic mutations in p14 have been splice mutations, whole gene deletions or 
insertions (Harland et al., 2005; Mistry et al., 2005; Randerson-Moor et al., 2001; Rizos et al., 
2001). Currently, no pathogenic missense mutations are known to occur in p14. 
In summary, we report 3 novel variants in CDKN2A and 3 previously reported mutations, along 
with 7 novel missense variants in BAP1. Germline mutations that we observe for the two genes 
combined (~2%) thus account for only a small proportion of all CMM cases in this population. This 
suggests that genes other than the high-penetrance familial melanoma genes are responsible for the 
bulk of CMM susceptibility in the general population. 
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Table 1 
 Number of samples sequenced for CDKN2A and BAP1 variants 
study group total number available 
number sanger 
sequenced 
number Ion torrent 
sequenced 
high 91 87~ 54^ 
intermediate 414 194~ 243 
low 1392 201~ 565 
men over 50 178 none 65 
childhood 101 31* 48 
adolescents 298 none 105 
twins 125 none 29 
 
~ Aitken et al., (1999) JNCI  
* Whiteman et al., (1997) JNCI  
^ BAP1 sequencing only 
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Table 2  
Variants in BAP1 and CDKN2A identified through targeted sequencing 
sample risk group gene exon position reference NT change 
AA 
change rsID 
ESP6500
MAF* SIFT 
PolyPhen 
2 
GERP 
++ 
006090 low BAP1 5 52441988 NM_004656 c.361G>C p.G121R - - damaging damaging 5.14 
002203 low BAP1 7 52441322 NM_004656 c.448C>T p.R150C - - damaging damaging 5.38 
009341 intermediate BAP1 9 52440388 NM_004656 c.664C>A p.P222T - - damaging damaging 5.69 
011937 high BAP1 13 52437824 NM_004656 c.1337A>T p.N446I - - tolerated damaging 4.76 
052809 intermediate BAP1 13 52437606 NM_004656 c.1555C>G p.P519A - - damaging damaging 5.7 
050611 intermediate BAP1 14 52437234 NM_004656 c.1810G>A p.V604M - 0.000154 tolerated benign 1.49 
051964 low BAP1 14 52437234 NM_004656 c.1810G>A p.V604M - 0.000154 tolerated benign 1.49 
006528 low CDKN2A (p14) 2 21971040 NM_058195 c.361G>A p.A121T rs199888003 0.000154 tolerated na 2.33 
002507 low CDKN2A (p14) 2 21971040 NM_058195 c.361G>A p.A121T rs199888003 0.000154 tolerated na 2.33 
012039 childhood CDKN2A (p16) 1 21974780 NM_000077 c.47T>C p.L16P - - damaging damaging 4.14 
050731 intermediate CDKN2A (p16) 1 21974763 NM_000077 c.64C>T p.R22W - - damaging damaging -0.43 
010255 low CDKN2A (p16) 1 21974724 NM_000077 c.103G>A p.G35R - - damaging 
probably 
damaging 4.84 
051362 intermediate CDKN2A (p16) 1 21974682 NM_000077 c.145A>T p.I49F - - damaging damaging 4.22 
008197 low CDKN2A (p16) 2 21971057 NM_000077 c.301G>T p.G101W rs104894094 - damaging 
probably 
damaging 5.49 
061542 adolescent CDKN2A (p16) 2 21971057 NM_000077 c.301G>T p.G101W rs104894094 - damaging 
probably 
damaging 5.49 
 
 * European American population; na is not available; GERP++ is an estimate of the constrained elements in the human genome. 
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Table 3  
CDKN2A mutations reported in publically available databases LOVD and COSMIC  
AA change present in LOVD 
present in 
COSMIC 
CMM 
present in COSMIC in other cancers 
p.L16P yes no biliary tract carcinoma, upper aerodigestive tract 
p.R22W no no no 
p.R24P yes yes CNS (glioma), soft tissue sarcoma 
p.G35R no no ovary, pancreas 
p.I49F no no no 
p.G101W yes yes lung carcinoma 
 
LOVD is the Leiden Open Variation Database 3.0 which lists published germline CDKN2A 
variants in cancer; COSMIC is the Catalogue of Somatic Mutations in Cancer v68. 
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Table 4  
Summary of cancers in families with germline BAP1 and CDKN2A mutations 
proband gene AA change risk group ages of onset of CMM 
other cancers in 
proband (age) other cancers in family (age) 
6090 BAP1 p.G121R low 45, 72   2203 BAP1 p.R150C low 32, 57 breast (57)  9341 BAP1 p.P222T intermediate 36  CMM (37) 1599 BAP1 p.L342F Intermediate 47, 49   
11937 BAP1 p.N446I high 53 lung (65), lung (68) CMM (60) 
52809 BAP1 p.P519A intermediate 41  CMM (36) 50611 BAP1 p.V604M intermediate 64  CMM (33) 51964 BAP1 p.V604M low 59   lung (65) 
6528 CDKN2A (p14) p.A121T low 69   2507 CDKN2A (p14) p.A121T low 38  lung (65), colorectal (64) 
12039 CDKN2A (p16) p.L16P childhood 12, 18, 22  
CMM (19), CMM (21), CMM (23), CMM 
(25), CMM (43), CMM (44), Lung (40) 
50731 CDKN2A (p16) p.R22W intermediate 45,   
CMM (26), pancreas (52), oesophageal (76), 
prostate (58), stomach (63) 
10255 CDKN2A (p16) p.G35R low 78 colorectal (86) stomach (45), breast (66), oesophagus (60) 
51362 CDKN2A (p16) p.I49F intermediate 26, 26, 27, 29, 45   CMM (38), breast (38), breast (48), lung (84) 
8197 CDKN2A (p16) p.G101W low 47, 71  CMM (28), CMM (44) 61542 CDKN2A (p16) p.G101W adolescent 18, 30, 30, 35   CMM (36), cervix (31), lung (69) 
 
CMM is cutaneous malignant melanoma; MPM is multiple primary melanomas 
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Figure 1 Conservation across species.  
Conservation of protein altering missense variants in BAP1 and CDKN2A. 
 
 
 
Figure 2 Germline variants in functional domains and protein interaction regions of BAP1. 
All germline variants found in the population-based sample of cutaneous melanoma cases are 
shown in relation to their position in the protein. The arrows show the position of germline 
variants.UCH is the ubiquitin carboxy-terminal hydrolase domain; HBM is the HCFC1 binding 
motif; ULD is the UCH37-like domain. Binding sites for genes BARD1, BRCA1 and YY1 are 
depicted by their gene symbols. 
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Supplementary Material 
 
Supplementary Table S1  
Primers for Sanger sequencing validation 
Amplicon Primer Sequence 
BAP1 exon 5 forward TGGGTATTTGGTAGGTGCTTG 
BAP1 exon 5 reverse CCCGCAACTGCATCTAAAAAC 
BAP1 exon 6 and 7 forward TCCACCCATAGTCCTACCTGA 
BAP1 exon 6 and 7 reverse GGGCAATATGGTGTAGGGTGA 
BAP1 exon 9 forward TTCCAGATAGGCCCCTCATAC 
BAP1 exon 9 reverse GTGGTTAGCTGAAGCCCAGAT 
BAP1 exon 11 forward GGGGAGACTGTGAGCTTTTCT 
BAP1 exon 11 reverse ATCAGGCAGAGGAACCTAGCA 
BAP1 exon 13 forward TTCTGGGTACTGCTGGGTATG 
BAP1 exon 13 reverse GGACACTTTGTGGTCACTTGG 
BAP1 exon 14 forward CGTGTTGACTGCATACGCTAC 
BAP1 exon 14 reverse CCAATCTTCACACCAAAGTTCC 
P16 exon 1 forward ACGCACTCAAACACGCCTTTG 
P16 exon 1 reverse CAAACTTCGTCCTCCAGAGTC 
P16 exon 2 forward CAGAAGTTCGGAGGATATAATG 
P16 exon 2 reverse GGGCTGAACTTTCTGTGCTG 
P14 forward CCTCGCTTTCCTTTCTTCCT 
P14 reverse CGGTTATCTCCTCCTCCTCC 
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Supplementary Table S2  
Summary of cancers in high-risk families reported by Aitken et al., 1999 
Proband Gene Variant Ages of onset of CMM Other cancers in proband (age) Other cancers in family (age) 
001790 CDKN2A (p16) p.R24P 28, 29, 36, 40  
MPM (4 additional cases),  CMM (42), CMM (65), CMM (65), CMM 
(72), CMM (72), breast (84), bladder (43), uterus (76) 
006581 CDKN2A (p16) p.L32P 30, 43, 51, 56 pancreas (54) CMM (33), MPM (3 cases), bronchogenic (59), bowel (50), lung (65) 
004197 CDKN2A (p16) p.G35A 31, 31, 31, 32, 35  
CMM (39), CMM (40), CMM (41), CMM (45), CMM (51), CMM (54), 
CMM (70), breast (39), lymphoma (62), Hogkins lymphoma (37), non-
Hogkins lymphoma (52) 
005526 CDKN2A (p16) p.M53I 37  
CMM (34), CMM (53), MPM (2 cases), ovary (41), carcinomatosis 
(49), caecum (83), liver (56) 
003301 CDKN2A (p16) p.M53I 26, 27, 27, 37  
CMM (23), CMM (26), CMM (27), CMM (52), MPM (9 cases), rectum 
(43), prostate (72), breast (43), breast (48), breast (56), bile duct (64) 
004478 CDKN2A (p16) p.D108N 36, 38, 39, 46, 49, 58, 59, 63, 63, 64, 66, 66  CMM (19), CMM (46), MPM (28) 
002622 CDKN2A (p16) 24 bp deletion 28  CMM (37), CMM (44) 
000397 CDKN2A (p16) 24 bp duplication 38, 43, 43, 44, 44, 48, 49, 53  
CMM (27), CMM (30), CMM (33), CMM (40), CMM (41), MPM (2 
cases), lung (60), carcinomatosis (79) 
002899 CDKN2A (p16) Nt46delC 47  CMM (27), CMM (34), CMM (40),  MPM (3 cases), stomach (52) 
 
CMM is cutaneous malignant melanoma 
MPM is multiple primary melanomas
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Chapter 3 
Assessment of PALB2, SOX10 and MITF as candidate melanoma 
susceptibility genes 
 
3.1 SOX10 and MITF  
 
3.1.1 Introduction 
 
In order to address the second aim of this study, a candidate gene approach was used to search for 
novel melanoma predisposition genes. Genes for this study were selected based on a survey of the 
literature to identify candidates that may have a role in familial melanoma but are as yet undefined 
in the familial melanoma research landscape. 
 The first gene investigated as a candidate for predisposition encoded the transcription factor SRY 
(sex determining region Y)-box 10 (SOX10). It has been associated with Waardenburg syndrome, a 
rare genetic disorder for which characteristics include deafness, neural crest defects and 
pigmentation abnormalities [127]. SOX10 acts in the pigmentation pathway and has a key role in the 
in the embryonic development of melanocytes. It also controls the transcription of microphthalmia-
associated transcription factor (MITF). Cronin and colleagues investigated the role of SOX10 in 
somatic melanoma development and found that 20% of metastatic cell lines harbour mutations in 
either MITF or SOX10 [52]. It is yet to be ascertained whether SOX10 could also be involved in 
melanoma predisposition, which makes it a good candidate for this study.  
The next logical gene to interrogate was MITF. It also plays a role in melanocyte development and 
is the master regulator of melanocyte function [83].  Like SOX10, mutations in MITF can also lead 
to the development of Waardenburg syndrome [128]. Reports of germline MITF mutations in CMM 
were published in 2011. Two groups reported a novel germline variant, p.E318K, which increases 
the risk of melanoma development in the familial and sporadic settings [21, 55]. I was a lead author 
on one of the manuscripts describing p.E318K (rs149617956) in melanoma predisposition (Nature. 
2011 Nov 13;480 (7375):99-103). This study identified 31 melanoma-prone families that carried the 
p.E318K variant, which segregated in some but not all of the families identified (log of odds score 
of 2.7). The variant was analysed in an Australian case-control study, which showed a significantly 
higher frequency in the cases (34 out of 2059) compared to the controls (14 out of 1953). Among 
cases, the risk allele occurred more frequently in those with multiple primary melanoma (OR 4.22, 
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95% CI 1.52–10.91), family history of melanoma (OR 2.95, 95% CI 1.23–6.92), or a combination 
of both (OR 8.37, 95% CI 2.58–23.80). These findings were also replicated in a UK case-control 
sample. The variant allele was also shown to be associated with increased naevus count and non-
blue eye-colour. The manuscript was published in the first year of my PhD but has not been 
included as a chapter of this thesis as the majority of the experimental work was done prior to 
commencing my candidature. Refer to the appendix for the full manuscript. It is clear that p.E318K 
plays an important role in melanoma predisposition; whether other variants in MITF may also lead 
to an increased risk of CMM development is yet to be ascertained. 
 
3.1.2 Methods 
 
Ethics 
Written consent was obtained for each participant in this study. Ethics approval for this project was 
obtained from the Human Research Ethics Committees (HREC) of the QIMR Berghofer Medical 
Research Institute.  
 
Samples 
Probands from dense melanoma families were selected for mutational screening. They were 
selected on the basis of case load (a minimum of 3 cases in the families) and/or having cases with 
multiple primary melanomas. As described by Yokoyama et al. [21] these are factors strongly 
associated with MITF p.E318K mutation and therefore could be a starting point for a screen of 
SOX10 as a candidate predisposition gene or the discovery of further MITF variants. Families with 
mutations in CDKN2A or CDK4 were excluded from the panel. A total of 182 probands were 
selected with a family profile that adhered to study boundaries.  
 
Sanger sequencing  
Sanger sequencing was used to detect pathogenetic mutations in SOX10 and MITF in the selected 
probands. SOX10 genotyping was carried out on 92 samples while 182 samples were interrogated 
for mutations in MITF. PCR reactions were run using ABI goldTaq PCR reagents. For a complete 
list of primers refer to Table 5. 
 
  
61 
 
Exome sequencing  
CMM families (N=23) with a combination of whole-genome and whole-exome sequencing data 
were also included in the study. Each of these families had data available on up to three affected 
members. The sequencing was performed on the Illumina Hiseq 2000 platform using Illumina 
TrueSeq enrichment kits. A BWA alignment algorithm was used to map the sequencing output to 
the UCSC human genome reference build 19 [122]. SNPs and indels were annotated using 
SAMTOOLS [123]. Before analysis, the data set was filtered using a stringent set of cut-offs. 
Quality score was required to be greater than 70; number of alternate reads had to be greater than 2; 
and at least 20% of all reads had to be called with the alternate allele. This gave us confidence that 
the remaining data set would have a minimal false positive rate.  
 
Case-control analysis 
Novel and rare non-synonymous variants that were identified using Sanger sequencing methods and 
whole-genome/exome sequencing methods were analysed in a case-control cohort to determine 
whether they might be low to medium penetrance CMM predisposition variants. The case-control 
cohort was derived from an Australian population and includes a wide cross-section of cases from 
the QFMP[124] (N=1,630) with varied personal and family histories of melanoma. A portion of 
probands in this set were obtained from dense melanoma families while others are sporadic 
melanoma cases. This cohort also includes cases with diverse age of onset of CMM ranging from 
childhood disease to late onset melanoma. Controls (N=1,690) used in this panel were parents of 
twins ascertained as part of the Brisbane Twin Naevus Study [126].  
Sequenom MassArray genotyping using iPLEX chemistry was run on this case-control sample. 
Variants were multiplexed on the Sequenom iPLEX gold system using 10ng of genomic DNA. The 
results were analysed using Typer Analyzer software 4.0. 
 
3.1.3 Results 
 
Sanger sequencing of 92 probands combined with exome sequencing data (N=23) for the three 
exons of SOX10 (NM_006941) found only known single nucleotide polymorphisms within the 
coding region of the gene (Table 6), all of which were synonymous and therefore did not result in a 
protein change. The variants observed were p.D6D (rs149435516), p.N275N (rs200437243) and 
p.H309H (rs139884). Case-control analysis for SOX10 variants was not performed as these all 
resulted in a synonymous change.  
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Exome sequence data (N=23) along with Sanger sequencing data of 182 probands for disease-
causing mutations in MITF revealed three non-synonymous variants (Table 7). One of the variants, 
p.R72H was novel, that is, not previously reported in dbSNP or ESP6500. A case-control analysis 
showed that it was present only in the discovery family. The second variant p.T91M (rs201247895) 
has been previously reported. A case-control analysis identified two CMM cases and no controls 
with the variant. One individual had early onset CMM (at age 18years), and their mother, who was 
also a carrier, developed UMM, aged 68 years. The second individual with a p.T91M variant was a 
sporadic CMM case that similarly had early onset melanoma, at the age of 35 years. The third 
variant that was observed in this gene was the p.E318K variant previously identified as 
predisposing to melanoma (see Appendix). 
 
3.1.4 Discussion 
 
The data presented here shows no evidence that SOX10 is involved in CMM predisposition as all 
variants that were observed resulted in a synonymous change to the protein and hence is not likely 
to be disease causing. There is also no evidence of further mutations in MITF causing melanoma 
predisposition since the two observed variants, p.R72H and p.T91M, do not occur in the melanocyte 
specific MITF-M isoform. Overall, candidate gene analysis showed no evidence that germline 
SOX10 mutations contribute to melanoma susceptibility and did not find evidence of other relevant 
variants in MITF predisposing to CMM. 
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Table 5: Primers for Sanger sequencing of SOX10 and MITF 
Amplicon Primer sequence 
SOX10 exon 1 forward GTGGGCGTTGGACTCTTTG 
SOX10 exon 1 reverse CCTCTAGCTTCGGGTGGATT 
SOX10 exon 2 forward TCTGAGGCTGTTATTCCTTGG 
SOX10 exon 2 reverse GTCAGTGGAGACAGG 
SOX10 exon 3.1 forward CAACAAGAGCGAAACTCCATC 
SOX10 exon 3.1 reverse AAAGCCCAGGTGAAGACAGAG 
SOX10 exon 3.2 forward ACCTTTGATGTGGCTGAGTTG 
SOX10 exon 3.2 reverse CTGTGTGCCCTGTTCCTTG 
MITF-M exon 1 forward TTATAGAAAGTAGAGGGAGGGATAGTC 
MITF-M exon 1 reverse GCTGTTTATTATTTGATGCCATAAG 
MITF-M exon 2 forward TTTGTGCCTGAAGGAAGAGC 
MITF-M exon 2 reverse GAGGTGTGGGACATGCTGTT 
MITF-M exon 3 forward GCCATCAGCTTTGTGTGAAC 
MITF-M exon 3 reverse GGATCACACCTTCCTGAAAAC 
MITF-M exon 4 forward GTGGAAAGAGGACAGTTACTTCTTAG 
MITF-M exon 4 reverse CTTGAGGTGTTTCCAGGGTT 
MITF-M exon 5 forward TCAAAGGGAACTGGTTGAGG 
MITF-M exon 5 reverse CTGTCCATTTCCTGATAAGACAAA 
MITF-M exon 6 forward GCTTCTGTATGTTTGGGAAATG 
MITF-M exon 6 reverse GGAGAGTTGATTCCTACAGCTG 
MITF-M exon 7 forward GCTAAATGCATACATGGCACTG 
MITF-M exon 7 reverse GTAAAGAAGTCTCCCCTCTCCC 
MITF-M exon 8 forward TCCATGTAACCAAGCACCAC 
MITF-M exon 8 reverse GGATATAATGAGCCATAGGGGA 
MITF-M exon 9 forward GGCTTAAAAGTCCTCTGTGCTC 
MITF-M exon 9 reverse CTTACCTGAAGGGGTTTTCTTG 
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Table 6: SOX10 variants  
Nucleotide 
change 
Amino 
acid rs ID 
Proportion of 
probands with 
variant 
MAF 
in probands MAF* 
c.18C>T p.D6D rs149435516 6/90 0.0333 0.031 
c.825C>T p.N275N rs200437243 1/92 0.0054 na 
c.927T>C p.H309H rs139884 het- 45/92; hom- 35/92 T- 0.375; C- 0.625 0.366 
   na is not available 
* minor allele frequency reported by ESP6500 
 
Table 7: MITF variants  
Nucleotide 
change 
Amino 
acid Transcript rs ID 
Frequency 
in cases^ MAF* Comment 
c.215G>A p.R72H NM_006722 na 1/1690 na not isoform M 
c.272C>T p.T91M NM_197178 rs201247895 2/1690 0.0116 not isoform M 
c.952G>A p.E318K NM_000248  rs149617956 not typed 0.314 already published 
   na is not available 
^ refers to Australian case-control sample 
* minor allele frequency reported by ESP6500 
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3.2 PALB2  
 
Manuscript 2 
Lauren G. Aoude, Mai Xu, Zhen Zhen Zhao, Michael Kovacs, Jane M. Palmer, Peter Johansson, 
Judith Symmons, Jeffrey M. Trent, Nicholas G. Martin, Grant W. Montgomery, Kevin M. Brown 
and Nicholas K. Hayward. Assessment of PALB2 as a candidate melanoma susceptibility gene. 
PLOS One
 
. 2014 June; 9(6):e100683. 
3.2.1 Relevance to thesis aims 
 
The final gene that was selected through the candidate gene approach was partner and localizer of 
BRCA2 (PALB2). The selection process was based on evidence from the literature that the PALB2 
protein interacts with BRCA2 to enable double-strand break repair through homologous 
recombination. The BRCA2 interaction makes PALB2 a good candidate melanoma susceptibility 
gene as it has been documented that aside from breast cancer, germline mutations in BRCA2 can 
lead to CMM and other cancer types, including those of the ovary, stomach and prostate. Anecdotal 
evidence has shown that PALB2 mutation carriers have presented with melanoma, though 
predominantly breast and pancreatic cancers have been reported.  
The aim of this study was to assess PALB2 as a candidate melanoma predisposition gene. In doing 
so I sought to determine whether PALB2 functions as a general tumour suppressor, for which 
melanoma is part of the disease spectrum, or whether certain high-penetrance germline mutations of 
PALB2 are responsible for melanoma development in some high-density melanoma families. This 
addresses Aim 2 of this study by searching for novel melanoma predisposition genes in high-
density melanoma families from Queensland.  
Here we report a germline missense mutation in PALB2 (p.V78I) that incompletely segregates with 
disease in a family with cutaneous melanoma and breast cancer. We also found a known deleterious 
PALB2 mutation (rs118203998) causing a premature truncation of the protein (p.Y1183X) in an 
individual with four different cancer types, including melanoma. Neither of these variants was 
found in 1,630 melanoma probands analysed as part of an Australian case-control set. Overall, the 
impact of these extremely rare mutations on melanoma susceptibility is uncertain and larger studies 
are needed to assess families with these and potentially other rare PALB2 mutations. 
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3.2.2 Contribution of candidate 
 
I performed the analysis of the exome sequencing data and Sanger sequencing validation of variants 
that were part of this data set. I also performed all of the co-segregation analysis to determine 
whether variants segregated with disease in the given families. I performed the case-control analysis 
on 1,630 cases and 1,690 controls to determine the contribution of the non-synonymous variants on 
melanoma predisposition. I performed the quantitative PCR to assess copy number variation 
observed in exome data.  I wrote and compiled the manuscript under the guidance of my principal 
supervisor, Nicholas Hayward. 
 
3.2.3 Contribution of other authors 
 
Sanger sequencing of the protein coding region of PALB2 in melanoma probands was performed by 
Mai Xu and Michael Kovacs. Zhen Zhen Zhao performed the case-control analysis of two of the 
missense variants. Jane Palmer and Judith Symmons collected the patient data relating to the 
families described in the manuscript. Peter Johansson performed the copy number analysis using the 
whole-genome and exome data. Kevin Brown and Jeffery Trent helped design the experiments, 
Nicholas Martin and Grant Montgomery contributed samples to this study. Nicholas Hayward 
helped design the experiments and edited the manuscript. All authors read and approved of the 
manuscript. 
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Introduction
Familial melanoma represents approximately 5–10% of all
cutaneous malignant melanoma (CMM) cases and it is estimated
that approximately 40% of familial cases can be attributed to
known high penetrance genes. The cause of increased risk of
melanoma development in the remaining families is largely
unknown but might be due to a combination of low or medium
penetrance gene mutations or to rare high penetrance mutations
that are as yet undiscovered. A plausible candidate that might
contribute to the melanoma risk landscape in certain individuals is
partner and localizer of BRCA2 (PALB2). PALB2 has a role in
DNA repair, which it does by binding to BRCA1 and BRCA2 to
facilitate homologous recombination for repair of double-strand
breaks. It also has a role in facilitating a DNA checkpoint response
and disruption to this complex can lead to instability of the DNA
damage response pathway [1]. Germline mutations in its
interacting partner BRCA2 are known to predispose to cancers
of the breast, ovary and pancreas, as well as confer a moderate
increased risk of CMM (relative risk of 2.6 [2,3]), suggesting by
association that PALB2 may also play a role in tumour
development in these cancer types.
There have been several diseases attributed to germline
mutation in PALB2, the first reports were in Fanconi anemia
(FA) patients with the FA-N subtype [4,5]. Carriers were affected
by bi-allelic mutation in PALB2 that led to the onset of early
childhood cancers, along with other FA disease traits including
growth retardation and congenital malformation. Looking at the
family histories of these cases, 4/8 families had a history of breast
cancer, suggesting that like BRCA2, mono-allelic mutations in
PALB2 may lead to the development of breast cancer.
From this observation, germline PALB2 mutations were
subsequently shown to be associated with breast cancer risk
[6,7]. Rahman and colleagues investigated a cohort of 923 breast
cancer cases of which 10 individuals presented with mono-allelic
truncating PALB2 mutations, while a set of 1,084 controls
harboured no truncating mutations. Segregation analysis showed
that in approximately half of these families the variants did not
completely co-segregate with disease, suggesting that PALB2 acts
as a medium-penetrance rather than high-penetrance gene for
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breast cancer risk [6]. A study published at the same time by Erkko
et al., reported a founder mutation, c.1592delT, present in 0.2%
of the Finnish population, but 1% of breast cancer cases unselected
for family history and 2.7% of families with multiple cases of breast
and/or ovarian cancer [7]. This shows a clear role for PALB2 in
breast cancer development. Since these initial reports, there has
been a wide array of population-based studies describing the
prevalence of PALB2 in breast cancer cases with incidence ranging
from 0.5% to 2.6% [8–18].
An association between germline PALB2 mutation and
increased pancreatic cancer risk has also been established. After
identifying bi-allelic inactivation of PALB2 in a tumour from a
familial pancreatic cancer patient, Jones and colleagues investi-
gated germline PALB2 variation in 96 probands with a family
history of pancreatic cancer and identified truncating mutations in
three individuals [19]. In another study, the screening of 254
pancreatic cancer cases, including 101 with a family history of the
disease, led to the report of a 6.7 kb deletion of PALB2 in an
individual with both breast and pancreatic cancer. This was the
only conclusively inactivating mutation found in this sample set
[20]. A study looking at European familial pancreatic cancer
discovered truncating mutations in 3/81 cases, all of which were
from families with cases of breast cancer, suggesting that these
mutations may preferentially occur in families with both of these
cancer types [21]. Consistent with this, another study reported that
4.8% of families with both cancer types harboured truncating
PALB2 mutations [22], higher than the rate previously reported in
studies investigating breast cancer alone. Although a study that
followed on from this looked at 77 families with breast cancer,
pancreatic cancer, or a combination of both, but found no
mutations [23]. Because PALB2 germline truncating mutations are
relatively rare, the full spectrum of cancer predisposition
associated with these mutations has yet to be fully characterized.
This is clear from the differing reports relating PALB2 to breast
and pancreatic cancer development.
Multiple studies have reported melanoma in families harbour-
ing inactivating PALB2 mutations, including individuals with
diagnoses of both melanoma and breast or pancreatic cancer [6]
[24]. These data implicate PALB2 as a possible melanoma
susceptibility gene, although Sabbaghian and colleagues found
no association between germline PALB2 mutation and CMM risk
in a screen of 53 probands from multi-case CDNK2A mutation-
negative melanoma families, and Yang failed to identify PALB2
mutations in 23 CMM families that are CDKN2A mutation-
positive and contain a subset of families (n = 11) with pancreatic
cancer also [25]. Given the small size of these studies, the
association between PALB2 and melanoma risk remains unclear.
We therefore sought to determine the incidence of germline
PALB2 mutations in a larger series of 201 CDKN2A and CDK4
mutation-negative melanoma families, including 63 with con-
firmed cases of breast, pancreatic, or multiple other types of
cancer.
Methods
Ethics
Written consent was obtained from each participant in this
study. Ethics approval was obtained from the QIMR Berghofer
Human Research Ethics Committee (HREC).
Sample collection
Samples were ascertained as part of the Queensland Familial
Melanoma Project (QFMP), a population based study of
melanoma in Queensland, Australia [26]. Genomic DNA was
extracted from whole blood using standard salting out methods. In
some instances DNA was extracted from transformed lympho-
blastoid cell lines.
Samples
Selection criteria for inclusion of families were those with:
CMM plus breast and/or pancreatic cancer (n = 52); individuals
who had developed three or more different cancer types, where
CMM was one of the cancers (n = 3); a minimum of three CMM
cases (n = 127). A total of 182 families met these criteria. No
additional criteria relating to age of onset of the cancers, or degree
of relationship between affected members were imposed. All
families have previously been shown to lack pathogenic mutations
in known high risk melanoma susceptibility genes, CDKN2A, CDK4
and BAP1 [27,28]. In the instance where multiple DNA samples
were available for sequencing, the youngest available CMM case
was chosen as the proband for each family. Where affected
individuals within a family were of a comparable age and an
individual presented with multiple primary melanomas, they were
then selected as the proband.
In addition to this, whole-genome and whole-exome sequencing
data from some QFMP families (n = 19) was interrogated. These
families were selected for sequencing as they had a minimum of
three affected members. Within this group, 16/19 families had
cases with multiple primary melanoma, and 8/19 families had
occurrences of breast cancer. Six families also included individuals
that had developed three different cancer types. A total of 24
exomes and 15 genomes were interrogated, with up to 3 cases
sequenced within a family. None of the cases sequenced carried
deleterious variants in breast cancer susceptibility genes BRCA1 or
BRCA2.
Sanger sequencing
In order to look for pathogenic mutations in PALB2, Sanger
sequencing was used to screen the 13 exons as well the exon
boundaries of the 182 selected probands for protein altering
variants. The complete list of M13-tagged primers and sequencing
methods can be found in Methods S1.
Whole-genome and exome sequencing
Whole-genome sequencing for 12 samples and exome sequenc-
ing for 25 samples was performed using the Illumina Hiseq 2000
platform combined with the Agilent SureSelect Human All Exon
V4+UTRs enrichment kits (Methods S1). 100 bp paired-end reads
were generated with samples having a mean coverage of 96X. A
further three genomes were sequenced by Complete Genomics.
Using the BWA alignment algorithm, the sequence output was
mapped to the UCSC human genome reference build 19 [29].
SNPs and indels were detected using bcftools and SAMtools
mpileup with disabled BAQ computation [30]. Each sample had
on average 90,000–100,000 variants compared to the human
genome reference sequence. Variants were filtered for stringency
using a quality score (.40), alternate reads (.2 and .20% of all
reads at a given position). Variants from next-generation
sequencing data sets were validated using Sanger sequencing
methods. Whole-genome and exome sequencing data may be
made available for research purposes upon request to the authors.
Copy number analysis at the PALB2 locus
To assess the possibility that some probands may have partial or
complete gene deletions of PALB2 we interrogated the whole-
genome or exome data from those patients where data was
available. Briefly, to normalise for different coverage per sample,
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the number of reads for each exon was divided by the number of
reads across the entire sample. The median value for each exon
was then calculated across all samples. This value was used to
estimate copy-number variation per exon of PALB2. In instances
where a copy number value for a given exon in an individual was
estimated to be less than half of the median value across all
patients, quantitative PCR using SYBR Green and exon-specific
primers was then used to assess the validity of the bioinformatics
output.
Case-control analysis
All protein-changing variants that were identified by Sanger
sequencing and exome sequencing were analysed in a case-control
set derived from two Australian studies to determine whether they
might be low to medium penetrance CMM predisposition
variants. A Sequenom iPLEX was run on 3320 individuals which
included 1,690 probands derived from the QFMP [26]. These
individuals were sampled from Queensland, Australia and include
both cases with a first degree relative with CMM (n= 1551); and
also sporadic cases with no family history of melanoma (n= 139).
The cases included individuals with a wide spectrum of age of
disease onset that ranges from childhood disease to late onset
melanoma.
The control sample (n = 1630) were parents of twins ascertained
as part of the Brisbane Twin Naevus Study [31]. They were asked
to self report and had no history of melanoma at the time of
sample collection.
In order to analyse the significance of observed protein altering
variants found through sequencing methods, a chi-squared test
was used to compare the cases and controls.
Results
We sequenced the entire protein coding sequence of PALB2 in
the panel of CMM cases described above. We identified eight
missense variants, four synonymous variants and one nonsense
variant. Of these, 11 were present in NHLBI Exome Sequencing
Project (ESP6500) [32], dbSNP or the 1000 Genomes Project (see
Table 1 for a full list of variants). No proband for which whole-
genome (n= 12) or exome (n = 25) sequence data were available
was found to carry a partial or complete deletion of PALB2.
A missense variant, p.V78I (c.G432A, NCBI accession
NM_024675), not listed in dbSNP but reported previously in a
study of families with breast/ovarian and pancreatic cancers [33],
was identified via Sanger sequencing and found in a female who
presented with two primary CMM, at ages 51 and 71, and breast
cancer at age 55. Co-segregation analysis showed incomplete
Figure 1. Co-segregation analysis of PALB2 variants in two high-risk CMM families. Individuals that have melanoma (MM) are represented
by black circles (female) and black boxes (male). The age of diagnosis of each cancer is indicated in brackets. A line through a symbol indicates that
the person is deceased. Individuals carrying a PALB2 mutation are indicated by an ‘M’, while those wild-type for the variant are indicated by ‘WT’.
Other cancer types are also indicated on the pedigree. Unaffected siblings are represented by a diamond with the number indicating the number of
siblings. The arrow indicates the proband in each family.
doi:10.1371/journal.pone.0100683.g001
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segregation with disease in the remainder of the family (Figure 1).
Only two of the four individuals affected with CMM in this family
carry PALB2 p.V78I, the second carrier being a sibling who had
developed CMM at age 67. A protein-truncating variant,
p.Y1183X, was found in a five case CMM family that was
analysed via exome sequencing. This variant, rs118203998, was
originally identified in a breast cancer family by Rahman and
colleagues [6] and has since been reported by several other groups
in patients diagnosed with breast cancer, pancreatic cancer, and
Fanconi anaemia [5,6,8,34]. The individual carrying this mutation
in our study has been diagnosed with four different primary cancer
types, including melanoma (twice, initially diagnosed at age 55),
bladder cancer (at age 58), leukaemia (at age 76), and non-small
cell lung cancer (at age 77). This variant did not co-segregate with
melanoma in this family as no other affected family member was
found to be a carrier.
Genotyping a collection of 1,690 CMM probands, as well as
1630 Australian population controls, showed that PALB2
p.Y1183X was not observed in any other individual. This is
consistent with results found by Rahman [6]. This variant is also
not seen in the 1000 Genomes Project, nor is it seen in any
population of the ESP6500, and is listed in dbSNP as having
unknown population frequency.
The p.V78I was observed in two controls. Personal history of
non-melanoma cancers was not collected at the time of the study
setup. It is unclear whether these individuals may have been
affected by any other form cancer. The other seven rare missense
variants we identified in the family collection were found at low
frequency in the case-control panel (Table 2). None were
significantly over-represented in melanoma cases.
Discussion
To assess the contribution of PALB2 to melanoma predisposi-
tion we sequenced the protein-coding region of PALB2 in
probands from 201 melanoma families lacking pathogenic
mutations in know melanoma susceptibility genes. This is the
largest study reported to date to assess the relationship between
germline PALB2 mutation and melanoma risk. We have identified
a missense mutation (chr16:23647635, p.V78I) that incompletely
segregates with disease in a family with cutaneous melanoma and
breast cancer. We have also identified a further 7 previously
reported missense variants for which the PALB2 protein function
is undetermined. Genotyping of these variants did not reveal any
significant differences in allele frequency between cases and
controls, with the exception of one variant which occurred more
frequently in controls (rs45568339). These data do not support a
role for these rare PALB2 variants in melanoma susceptibility.
We also found a known deleterious mutation (rs118203998)
causing a premature truncation of the protein (Y1183X) in an
individual with four different cancer types, including melanoma.
Neither this nor p.V78I variant has a population frequency
reported in the 1000 Genomes Project or the ESP6500.
Interestingly, the truncating mutation, p.Y1183X, has been
reported by four previous studies. A report discusses three children
with Fanconi anaemia that carried a PALB2 p.Y1183X mutation.
Each of these cases presented with an early childhood cancer at
ages 0.7, 1.0 and 2.3 years with neuroblastoma, Wilms’ tumour
and medulloblastoma respectively [5]. Rahman and colleagues
also reported this mutation in three individuals with breast cancer
[6]. Interestingly, in one of the families an individual with this
genotype was diagnosed with melanoma at age 47, prior to
developing breast cancer. In a third study, PALB2 p.Y1183X was
associated with breast cancer in a person presenting with two
T
a
b
le
2
.
C
as
e
-c
o
n
tr
o
l
an
al
ys
is
o
n
n
o
n
-s
yn
o
n
ym
o
u
s
P
A
LB
2
va
ri
an
ts
.
lo
ca
ti
o
n
p
ro
te
in
ch
a
n
g
e
n
u
cl
e
o
ti
d
e
ch
a
n
g
e
rs
ID
F
re
q
u
e
n
cy
in
ca
se
s
(n
=
1
6
9
0
)
F
re
q
u
e
n
cy
in
co
n
tr
o
ls
(n
=
1
6
3
0
)
ch
i-
sq
u
a
re
p
-v
a
lu
e
h
e
t
ca
rr
ie
rs
h
o
m
ca
rr
ie
rs
h
e
t
ca
rr
ie
rs
h
o
m
ca
rr
ie
rs
Ex
o
n
4
p
.V
7
8
I
c.
2
3
2
G
.
A
–
1
0
0
0
–
–
Ex
o
n
4
p
.L
3
3
7
S
c.
1
0
1
0
T
.
C
rs
4
5
4
9
4
0
9
2
7
9
2
7
1
0
0
.5
6
5
0
.4
5
2
Ex
o
n
4
p
.Q
5
5
9
R
c.
1
6
7
6
A
.
G
rs
1
5
2
4
5
1
2
8
9
1
2
2
4
3
1
0
2
.9
8
1
0
.0
8
4
Ex
o
n
5
p
.E
6
7
2
Q
c.
2
0
1
4
G
.
C
rs
4
5
5
3
2
4
4
0
1
0
5
0
9
4
1
0
.1
4
8
0
.7
0
0
Ex
o
n
7
p
.P
8
6
4
S
c.
2
5
9
0
C
.
T
rs
4
5
5
6
8
3
3
9
8
0
1
8
0
4
.2
0
2
0
.0
4
0
Ex
o
n
8
p
.V
9
3
2
M
c.
2
7
9
4
G
.
A
rs
4
5
6
2
4
0
3
6
1
3
0
1
3
0
0
.0
0
9
0
.9
2
4
Ex
o
n
8
p
.L
9
3
9
W
c.
2
8
1
6
T
.
G
rs
4
5
4
7
8
1
9
2
6
0
9
0
0
.7
1
5
0
.3
9
8
Ex
o
n
9
p
.G
9
9
8
E
c.
2
9
9
3
G
.
A
rs
4
5
5
5
1
6
3
6
7
3
0
6
6
0
0
.1
4
8
0
.7
0
0
Ex
o
n
1
3
p
.Y
1
1
8
3
X
c.
3
5
4
9
C
.
G
rs
1
1
8
2
0
3
9
9
8
1
0
0
0
–
–
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
0
6
8
3
.t
0
0
2
Assessment of PALB2 as a Candidate Melanoma Susceptibility Gene
PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e100683
primary breast cancers. The mother of this proband was also a
mutation carrier and had developed both breast cancer and
pancreatic cancer [34]. Pancreatic and breast cancers have been
previously associated with a PALB2 mutation but this study was
the first instance of it occurring in an individual with both cancer
types. Lastly a population-based study of breast cancer predispo-
sition by Tischowitz et al. found a family in which three cases had
this genotype [8]. In our study we present an individual with two
primary melanomas, bladder cancer, leukaemia and non-small cell
lung cancer who is a carrier of the PALB2 p.Y1183X variant.
Taking into consideration that this specific mutation has been seen
in one other individual with melanoma, this suggests that PALB2
may play a role as a melanoma susceptibility gene and that this
mutation could predispose to other cancers whose spectrum of
disease extends beyond Fanconi anaemia, breast cancer or
pancreatic cancer.
When we consider truncating mutations alone, as Rahman and
colleagues did in relation to breast cancer susceptibility [6], the
data overall are not strongly supportive of PALB2 being a
melanoma susceptibility gene. Larger sample sizes will clearly be
needed to better characterize the spectrum of cancers associated
with deleterious PALB2 mutations along with a larger sample of
melanoma-only families to unambiguously determine the role of
PALB2 in melanoma susceptibility.
Supporting Information
Methods S1 Additional information on whole-genome and
exome sequencing, Sanger sequencing, and iPLEX methods.
(DOCX)
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Supplementary Methods  
 
Whole-genome and whole-exome Sequencing 
Whole-genome (N=12) and exome sequencing (N=25) was outsourced to Axeq Technologies in 
Seoul, South Korea. Sequencing was performed on the Illumina HiSeq 2000 platform using the 
Agilent SureSelect Human All Exon V4+UTRs enrichment kits. The data output was 100bp paired 
end reads with a median coverage of 96x. A further 3 genomes were sequenced using Complete 
Genomics. The sequencing data for each samples was mapped to the Human Genome build 19 
(hg19) using the BWA alignment algorithm [1]. SNPs and indels were detected using bcftools and 
SAMtools mpileup with disabled BAQ computation [2]. Any variant that was found in dbSNP or 
the 1000 Genomes project was flagged to generate both a data set of novel mutations and also a data 
set of known mutations. Each sample had on average 90,000-100,000 variants compared to the 
human genome reference sequence. Variants were filtered for stringency using a quality score of 
>40, >2 alternate reads and >20% of all reads at a given position being the alternate read.  
 
Sanger Sequencing  
Sanger sequencing was used to identify mutation events in PALB2 in a cohort of familial melanoma 
cases. PCR reactions were run using ABI goldTaq PCR reagents. Standard manufacturer’s protocol 
was followed. Refer to Supplementary table S1 for a list of the primers used.  
 
Sequenom iPLEX 
The PALB2 variants were multiplexed using the Sequenom iPLEX gold system which allows up to 
36 variants to be genotyped concurrently using 10ng of genomic DNA. The iPLEX Gold PCR 
amplification reactions were carried out in four 384-well plates according to supplier protocol and 
then transferred onto SpectroCHIP arrays using the MassARRAY Nanodispenser. The chips were 
then transferred to the Sequenom mass spectrometer where the data was generated. The results were 
analysed using the Typer Analyzer software 4.0. 
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Supplementary Table S1: Primers used for Sanger sequencing of PALB2 
Exon Forward primer Reverse primer 
exon 1 AACTGGGTCCCGGTGTCG GCCTAAAACCCTGGGAAAGC 
exon 2 & 3 TGACTCCACCTTTCCACTTGC AAGAACAATAGCCAAAATATACCTGGG 
exon 4-1 ATTCATCTGCCTGAATGAAATG TGCTACTGATTTCTTCCTGTTCC 
exon 4-2 AGCTGCCAAGCAGAAGAAAG ACCTTTAGGAGGAATGTGTTCAAG 
exon 4-3 CACCAGGGCGACTACAGTTC AAGAGGAGAGGTTGCTTCCAG 
exon 4-4 CCCAGTGACACTCTTGATGG AGGAAGTGCCAGGCAAATAG 
exon 5-1 TTGTCATCAGTGAAACAGATTGTC GAAAGGCCCGTCTTTGTATG 
exon 5-2 AAACCAGTGGAGCCCTTTG CACTTGCAGGGTGGTATGTG 
exon 5-3 GACTCAGTCTGTCTTGCCAGTG AAGCAAGTCATGCTGTTTACATTC 
exon 6 AGTGGGTAATGCAGGCAGAC GCCAATAGGTTGGCATAGAAAC 
exon 7 CCACAAAGCTCTTTCTTTTCACC GCCTTGCATGGTCATAGCTC 
exon 8 GATTAAACAAAAATGAAACAACCAAGC GGTTATTACCTGCACTTAAAACCAGC 
exon 9 TAATATTAAAAGGTTACTCCTCACATCACC ACAGAAAAACGAGATCCTAGTTACCC 
exon 10 TCAACAATGCGGAGAAGGG CTCTCTTATTTAATCTTCACAACAACCC 
exon 11 GGCAAAATTAACCCACAGTTC ACTGCTTATGACTTACTGCTCTCAC 
exon 12 TCAGAGCCTATCGGTCATTGC GCCTTTCAGAATGTCCCACC 
exon 13-1 CAATAGCCAACAGACCTCTAAGGC TCATTTTAAGTGTCATTCAGATATTCTCC 
exon 13-2 AGGTTCCTGGAAGGTGACG GCCATTTGAAGCTTTATGTACACC 
M13 tag TGTAAAACGACGGCCAGT CAGGAAACAGCTATGACC 
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POT1 loss-of-function variants predispose to familial melanoma 
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4.1 Relevance to thesis aims 
 
This chapter describes an unbiased sequencing approach to search for novel melanoma 
predisposition genes in high-density CMM families. It uses whole-genome and exome data to 
identify novel variants that are segregating with disease in these families and identifies mutations in 
a novel gene that predisposes to CMM in high-density families. Unlike the candidate gene approach 
in Chapter 3, this method considers all variants in the data set in order to find genes that have not 
been previously associated with melanoma development but may play a role in melanomagenesis. 
Variants were selected if they segregated with disease in families, had an obvious deleterious effect 
on the protein or were mutated in several families. This approach has proven effective by 
uncovering mutations in the Protection of Telomeres 1 gene (POT1) in melanoma families. Given 
that this gene has been recently described to have a high frequency of somatic mutations in chronic 
lymphocytic leukaemia [129], it was a strong contender for a cancer predisposition gene. 
This chapter addresses Aims 2 to 4 of my thesis, as NGS was used to identify loss-of-function 
mutations in POT1, occurring in high-density melanoma families from Australia and from the UK. 
Three missense mutations (p.Y89C, p.Q94E and p.R273L) occurred in the highly conserved 
oligonucleotide/oligosaccharide-binding (OB) domains of POT1, which facilitate the binding of 
POT1 to single-stranded telomeric repeats. Structural modelling predicted that the missense 
mutations would disrupt the binding of the OB-domains with telomeric DNA, which was confirmed 
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by an electromobility shift assay. A splice acceptor mutation (c.1687-1G>A) was also seen in the 
data set. RT-PCR showed that this resulted in the truncation of the protein 12 amino acids after the 
mutation site. Furthermore, experimental data has shown that carriers of POT1 missense mutations 
have longer telomeres, which may be a major contribution to CMM development.  
This study has shown that POT1 is involved in a CMM predisposition in high-density families. 
Given that mutations in the TERT promoter have been shown in both tumours and sporadic CMM 
[130, 131], it demonstrates that telomere dysregulation is a newly found pathway contributing to 
CMM susceptibility. In addition, the pedigrees we describe are enriched for other cancers, 
suggesting that POT1 mutations may predispose to cancers other than CMM.  
 
4.2 Contribution of candidate 
 
This was a large collaborative effort between international research groups and contained elements 
that were outside the scope of this thesis. My role was in the analysis of the whole-genome and 
exome data from Australia, Sweden and Denmark, as well as the validation of variants using Sanger 
sequencing methods. I carried out the RT-PCR experiments to determine the effect of the splice 
mutation on the POT1 protein. I was also responsible for the preparation of Australian samples 
including extraction of DNA and RNA from whole blood as well as the synthesis of cDNA. I wrote 
methods that pertained to my experiments and compiled the sequencing and histology data of 
Queensland CMM cases. I also compiled tables and edited the manuscript. 
 
4.3 Contribution of other authors 
 
Nicholas K. Hayward, David J. Adams, Carla Daniela Espinoza-Robles, Julia A. Newton Bishop, 
Timothy Bishop and Mark Harland designed the study and wrote the manuscript. Samples were 
provided by Nelleke A. Gruis, Grant W. Montgomery, Nicholas G. Martin and Helen Snowden. 
NGS data analysis and experiments were performed by Antonia L. Pritchard, Mitchell S. Stark, 
Michael G. Gartside, Jessamy C. Tiffen Mia Petljak, Jimmy Z. Liu, Jiyeon Choi, Matthew 
Makowski and Kevin M. Brown. Carla Daniela Espinoza-Robles performed NGS data analysis for 
the UK families and the controls. Peter Johansson, Zhihao Ding and Thomas M. Keane provided the 
bioinformatics support. Zhihao Ding performed the analysis of exome data to determine telomere 
length. Protein modelling and EMSAs were performed by Víctor Quesada, Andrew J. Ramsay and 
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Carlos López-Otín. Jane M. Palmer and Judith Symmons contacted the families and collected the 
patient data and samples for the Australian cases. All authors read and approved of the manuscript. 
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Deleterious germline variants in CDKN2A account for  
around 40% of familial melanoma cases, and rare variants  
in CDK4, BRCA2, BAP1 and the promoter of TERT have  
also been linked to the disease2–5. Here we set out to identify 
new high-penetrance susceptibility genes by sequencing 84 
melanoma cases from 05 pedigrees recruited in the UK,  
The Netherlands and Australia that were negative for variants 
in known predisposition genes. We identified families where 
melanoma cosegregates with loss-of-function variants in the 
protection of telomeres  gene (POT1), with a proportion of 
family members presenting with an early age of onset and 
multiple primary tumors. We show that these variants either 
affect POT1 mRNA splicing or alter key residues in the highly 
conserved oligonucleotide/oligosaccharide-binding (OB) 
domains of POT, disrupting protein-telomere binding and 
leading to increased telomere length. These findings suggest 
that POT1 variants predispose to melanoma formation via a 
direct effect on telomeres.
Cutaneous malignant melanoma accounts for around 75% of skin 
cancer deaths, with around 10% of cases having one first-degree rela-
tive and 1% of cases having two or more first-degree relatives who 
have had a diagnosis of this disease6. As only around half of familial 
melanoma cases can be attributed to variants in known predisposition 
genes, principally CDKN2A, a substantial proportion of genetic risk 
for melanoma remains elusive. To identify new mediators of germline 
genetic risk, we sequenced 184 melanoma cases from 105 pedigrees. 
The cases sequenced came from pedigrees with between 2 and 
11 cases of melanoma (169 cases) or were single cases that presented 
with either multiple primary melanoma (MPM), multiple primary 
cancers (one of which was melanoma) and/or an early age of onset 
(before the fourth decade of life; 15 cases) (Online Methods and 
Supplementary Tables 1 and 2). Sequencing of two-case pedigrees 
was preferentially performed for those families enriched with cases of 
MPM. All cases were previously found to be negative for pathogenetic 
variants in CDKN2A and CDK4.
After performing exome (168 samples) or whole-genome 
(16 samples) sequencing, we called and filtered variants, keeping 
only those predicted to affect protein structure or function. Notably, 
we found no known pathogenetic variants in BAP1 or BRCA2, and 
we confirmed that all samples had wild-type CDKN2A and CDK4. 
We further filtered the calls, taking forward only non-polymorphic 
variants (Online Methods). When we sequenced more than one 
member of a pedigree, we retained only cosegregating variants, 
whereas all variants were considered from pedigrees in which only 
one affected family member was sequenced. As a result, a total of 
23,051 variants remained for downstream analysis. Focusing on the 
28 pedigrees for which sequence data were available for 3 or more 
family members, we found 320 genes carrying cosegregating protein-
changing variants (Supplementary Table 3). Of particular interest 
were five genes that showed previously unreported variants in more 
than one of these pedigrees (POT1, MPDZ, ACD, SMG1 and NEK10). 
Analysis of the missense and disruptive variants (nonsense, splice 
acceptor or donor, and frameshift) in these genes led us to identify 
a five-case pedigree (UF20) carrying a POT1 variant encoding a 
p.Tyr89Cys change (GRCh37 chromosome 7, g.124503684T>C) in 
the highly conserved N-terminal OB domain of the protein7,8 and 
a six-case family (AF1) carrying a splice-acceptor variant between 
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exons 17 and 18 (g.124465412C>T) of POT1, which was scored as 
deleterious by the MaxEntScan algorithm9 and was shown to affect 
transcript splicing by RT-PCR and sequencing (Fig. 1, Table 1, 
Supplementary Figs. 1a–c and 2, and Supplementary Tables 4 and 5). 
Scrutiny of the remaining sequenced pedigrees, including those in 
which only one family member had been sequenced, identified two 
additional individuals from distinct families with nonsynonymous 
changes in POT1 affecting the OB domains (UF31: g.124503670G>C, 
p.Gln94Glu; UF23: g.124493077C>A, p.Arg273Leu) (Fig. 1, Table 1, 
Supplementary Figs. 1d,e and 3, and Supplementary Tables 4 
and 5). Remarkably, the POT1 codon for the Gln94 residue affected 
in pedigree UF31 has been found to be a target for recurrent somatic 
alteration (p.Gln94Arg) in chronic lymphocytic leukemia (CLL), 
where ~5% of cases carry POT1 mutations that cluster in the sequences 
encoding the OB domains10.
To gather further evidence for an association between POT1 
variants and familial melanoma, we compared the representation 
of POT1 variants in our familial melanoma cases with variants in 
controls. Notably, the presence of POT1 variants in 4 of 105 families 
with melanoma represented a statistically significant enrichment of 
variants (P = 0.016, excluding a discovery pedigree) compared with 
a control data set of 520 exomes from individuals sequenced as part 
of the UK10K project (see URLs) in which we found only 1 missense 
variant located outside the OB domains of POT1 (Online Methods, 
Supplementary Fig. 4 and Supplementary Table 6). Furthermore, 
none of the 4 POT1 variants identified in our melanoma pedigrees were 
found by genotyping 2,402 additional population-matched controls 
(Online Methods and Supplementary Table 6). Interestingly, 
genotyping of these positions across a matched cohort of 1,739 
population-based sporadic melanoma cases identified 1 individual 
who carried the POT1 variant encoding p.Arg273Leu who presented 
with early-onset MPM similar to the phenotype presented by the 
familial cases (Online Methods and Supplementary Table 5).
All of the missense variants we identified in POT1 disrupt 
amino acids that are completely conserved throughout eutherians 
(Fig. 1b) and are more evolutionarily conserved than the average 
for other OB domain residues (Online Methods). Analysis of 
carrier individuals identified through genome and/or exome sequenc-
ing or by targeted PCR resequencing of additional family members 
showed that all nine carriers of POT1 variants from the familial 
cohort had developed melanoma, presenting with one primary 
(four cases) to eight melanomas at 25 to 80 years of age (Fig. 1 and 
Supplementary Fig. 3). One variant carrier from these familial cases 
also developed breast cancer at 65 years, and another developed small 
cell lung cancer at 50 years (pedigree UF20). Other malignancies 
in the untested first- or second-degree relatives of variant carriers 
included melanoma (pedigrees UF20 and UF31), endometrial 
cancer (pedigree UF20) and brain tumors (pedigrees UF20 and UF23). 
Intriguingly, the pedigree with the splice-acceptor variant (AF1) had a 
member with a history of melanoma and CLL, in keeping with a role 
for POT1 in CLL development10,11. Collectively, these data suggest a 
possible role for germline POT1 variants in susceptibility to a range 
of cancers in addition to melanoma.
To test whether the identified missense variants disrupted telomere 
binding as was observed for somatic mutations found in CLL, we 
examined the structure of POT1 protein bound to a telomere-like 
polynucleotide (dTUdAdGdGdGdTdTdAdG) (Protein Data Bank 
(PDB) 3KJP)12,13. According to this model, all 3 altered residues 
(Tyr89, Gln94 and Arg273) were among 24 residues located in close 
proximity (<3.5 Å) to the telomeric polynucleotide10 (Fig. 2a). Arg273 
interacts with the oxygen at position 2 of telomeric deoxythymidine 7, 
whereas Gln94 and Tyr89 both interact with the G deoxynucleotide at 
position 4. Therefore, as described for the somatic mutations in CLL, 
the POT1 variants we identified are expected to weaken or abolish 
the interaction of POT1 with telomeres. Analysis of the nucleotides 
coding for these 24 OB domain residues identified 1 nonsynonymous 
change in 6,498 control exomes14 compared with 3 in 105 families 
with melanoma, emphasizing a highly significant enrichment of 
variants in the melanoma cohort (P = 1.54 × 10−5) (Online Methods 
and Supplementary Tables 6 and 7).
To further test whether the OB domain variants we identified 
disrupted POT1 function, we assessed the ability of in vitro- 
translated POT1 Tyr89Cys, Gln94Glu and Arg273Leu proteins to 
bind to (TTAGGG)3 sequences. Electrophoretic mobility shift assays 
showed a complete abolition of POT1-DNA complex formation with 
mutant POT1 (Fig. 2b and Supplementary Fig. 5). Notably, the POT1 
p.Tyr36Asn and p.Tyr223Cys alterations recently described in CLL10, 
which seem to be functionally analogous to the variants we describe 
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Figure 1 Rare variants in POT1 found in familial melanoma pedigrees. (a) We identified four pedigrees carrying deleterious variants in POT1. Shown are a  
five-case pedigree (UF20) and a six-case pedigree (AF1) carrying the disruptive p.Tyr89Cys OB domain variant and a splice-acceptor variant, respectively.  
Note that pedigrees have been adjusted to protect the identity of the families without loss of scientific integrity. POT1 genotypes for all samples available 
for testing are shown in blue, and other types of cancer are indicated. CMM, cutaneous malignant melanoma; CLL, chronic lymphocytic leukemia; WT, wild 
type. Diamonds represent individuals of undisclosed sex. The cases that were sequenced have a red outline. All melanomas were confirmed by histological 
analysis, with the exception of two cases (marked by asterisks). The number of primary melanomas in each subject is indicated; age of onset in years is 
shown in parentheses. Half-filled symbols represent other cancers. (b) Highly conserved residues of POT1 are altered in familial melanoma. Shown are the 
positions of the variants identified on the POT1 protein (top) and on an amino acid alignment (missense variants; bottom).
©
20
14
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
Nature GeNetics  ADVANCE ONLINE PUBLICATION 
l e t t e r s
here, promote uncapping of telomeres, telomere length extension and 
chromosomal aberrations and thereby promote tumorigenesis10.
Given the role of POT1 in telomere length maintenance, we 
next asked whether melanoma cases from pedigrees with mutated 
POT1 had telomere lengths that differed from those of non-carrier 
melanoma cases. Using exome sequence data from 41 cases, includ-
ing 3 members of pedigree UF20, we estimated the telomere length 
of each subject by counting TTAGGG repeats15. This analysis showed 
that all three members of pedigree UF20 had telomeres that were 
significantly longer than those in melanoma cases with wild-type 
POT1 (P < 0.0002; Fig. 2c and Supplementary Fig. 6). This result 
was confirmed by telomere-length PCR, which also showed longer 
telomeres for subjects carrying the p.Gln94Glu and p.Arg273Leu 
variants compared to melanoma cases without POT1 variants 
(P = 3.62 × 10−5; Fig. 2d and Supplementary Fig. 7). Thus, missense 
variants in the OB domains of POT1 not only abolish telomere 
binding but are also associated with increased telomere length, a key 
factor influencing melanoma risk16. Notably, OB domain variants that 
disrupt the interaction of POT1 with telomeric single-stranded DNA 
are thought to function as dominant-negative alleles10,17, yet, as we 
show here, they are compatible with life, suggesting that additional 
somatic events are required to promote tumorigenesis.
The identification of POT1 mutations in CLL and the probable 
susceptibility of our POT1-mutated familial melanoma pedigrees to 
other tumor types suggest that POT1 might have a more general role in 
tumorigenesis. To investigate this possibility, we examined pan-cancer 
data from the Catalogue of Somatic Mutations in Cancer (COSMIC)18 
and IntOGen19 databases (data from The Cancer Genome Atlas 
table 1 POT1 variants identified in familial melanoma pedigrees
Pedigree
Number of 
cases in 
pedigree
Number of 
carriers/tested 
cases
Genomic  
change
Coding  
mutationa Exon
Amino  
acid change Variant type
Bioinformatic prediction tools23–25
SIFT PolyPhen-2 CAROL
UF20 5 4/4 g.124503684T>C c.266A>G  8 p.Tyr89Cys Missense Deleterious Probably  
damaging
Deleterious
AF1 6 3/3 g.124465412C>T c.1687–1G>A – – Splice acceptor 
(intronic, between 
exons 17 and 18)
– – –
UF31 2 1/1 g.124503670G>C c.280C>G  8 p.Gln94Glu Missense Tolerated Probably  
damaging
Deleterious
UF23 2 1/2b g.124493077C>A c.818G>T 10 p.Arg273Leuc Missense Deleterious Probably  
damaging
Deleterious
aThe reference transcript, taken from the Ensembl database (release 70), is POT1-001 (ENST00000357628). bA second case within this pedigree had a different clinical presentation (solitary 
melanoma in situ) in the sixth decade of life and did not carry the p.Arg273Leu variant. cThis variant was also detected in a melanoma case from a population-based case-control series that 
presented with MPMs and an early age of onset (Online Methods).
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P < 0.0002Figure 2 Missense variants in POT1 disrupt the 
interaction between POT1 and single-stranded 
DNA and lead to elongated telomeres. (a) Shown 
are the locations of the POT1 Tyr89, Gln94  
and Arg273 residues in the two N-terminal OB  
domains (green). A telomere-like polynucleotide 
sequence is shown in orange. Interacting  
nucleotides in the telomeric sequence are 
labeled in gray. All three substitutions are  
predicted to disrupt the association of POT1 
with telomeres. (b) Mutant Tyr89Cys, Gln94Glu 
and Arg273Leu POT1 proteins are unable to  
bind telomeric (TTAGGG)3 sequences as shown 
by an electrophoretic mobility shift assay.  
The Tyr223Cys POT1 mutant was used as a  
positive control representing a known disruptive 
alteration10. (c) Calculation of telomere  
length from exome sequence data. The method 
used has been described previously15.  
Relative adjusted telomere lengths for the  
3 sequenced members of pedigree UF20 are  
shown alongside the mean telomere length 
of 38 (all other) melanoma cases that were 
sequenced alongside them but were wild type  
for POT1. Error bars, 1 s.d. A Wilcoxon  
rank-sum test was performed comparing the 
telomere lengths of the 3 Tyr89Cys cases to  
that for the 38 non-carrier controls. (d) PCR-based estimates of telomere length. Adjusted mean −∆Ct values, which correlate positively with telomere  
length, for POT1 missense variant carriers and non-carrier family controls are shown against a distribution of values from 252 melanoma cases recruited 
from the Leeds Melanoma cohort that are wild type at the above-mentioned positions (Online Methods). All measurements have been adjusted for  
age at blood draw and sex. The black line represents a Gaussian kernel density estimate for this set using Silverman’s rule of thumb22 for bandwidth 
smoothing. Orange dots, members of pedigree UF20; pink dots, members of pedigree UF31; blue dots, members of pedigree UF23; red dots, individual 
CT1663 from the Leeds Melanoma case-control study carrying the p.Arg273Leu variant (supplementary table 5). The number of biological replicates  
for each individual ranged from one to four, each with two technical replicates, for the POT1 missense variant carriers and non-carrier family controls. 
Two technical replicates were performed for the 252 POT1 non-carrier cases. Error bars, s.e.m.
©
20
14
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
4  ADVANCE ONLINE PUBLICATION Nature GeNetics
l e t t e r s
(TCGA) and the International Cancer Genome Consortium (ICGC)) 
from 14 cancer types and found that somatic POT1 mutations 
were more likely to be missense (P < 0.03), to alter residues in close 
proximity to DNA (P < 0.02) and to have a higher functional bias 
(P < 0.03) than expected by chance (Online Methods). These results 
suggest that, although they are rare, somatic POT1 mutations may 
drive tumorigenesis across multiple histologies.
Here we describe germline variants in the gene encoding the 
telomere-associated protein POT1 in almost 4% of familial melanoma 
pedigrees negative for mutations in CDKN2A and CDK4 and in 2 of 
34 pedigrees (5.8%) with ≥5 cases, making POT1 the second most 
frequently mutated high-penetrance melanoma gene reported thus 
far. This work and a companion study describing germline POT1 
variants in Italian, French and US families with melanoma20, together 
with a recent report of a TERT promoter variant2, substantially extend 
understanding of a newly discovered mechanism predisposing 
to the development of familial melanoma. As the dysregulation of 
telomere protection by POT1 has recently been identified as a target 
for potential therapeutic intervention21, it may be possible that the 
early identification of families with POT1 variants might facilitate 
better management of their disease in the future.
URLs. UK10K Sequencing Project, http://www.uk10k.org/; European 
Genome-phenome Archive (EGA), https://www.ebi.ac.uk/ega/; 
dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/; PyMOL 
Molecular Graphics System, Version 0.99, http://www.pymol.org/.
MeTHODs
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Sequence data have been deposited in the 
European Genome-phenome Archive (EGA), hosted at the European 
Bioinformatics Institute, under accession EGAS00001000017.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINe MeTHODs
Case samples and DNA extraction. The families included in this study 
were recruited to a UK Familial Melanoma Study directed by the Section 
of Epidemiology and Biostatistics, University of Leeds (Leeds, UK); the Leiden 
University Medical Center (Leiden, The Netherlands); and the Queensland 
Familial Melanoma Project (QFMP)26. Informed consent was obtained under 
the Multicentre Research Ethics Committee (UK): 99/3/045 (UK Familial 
Melanoma Study cases), Protocol P00.117-gk2/WK/ib (Leiden cases) and 
from the Human Research Ethics Committee of the QIMR Berghofer Medical 
Research Institute for QFMP cases. Genomic DNA was extracted from periph-
eral blood using standard methods.
Pedigrees and clinical presentation. The pedigrees in this study are listed 
by institute and by sequencing center in Supplementary Table 1. All pedi-
grees, the number of cases of melanoma in each pedigree and the number 
of cases that were whole-genome sequenced are listed in Supplementary 
Table 2. To help anonymize the pedigrees, ages were rounded up to the 
nearest 5-year tier.
Sequence alignment and analysis. DNA libraries were prepared from 5 µg of 
genomic DNA, and exonic regions were captured with the Agilent SureSelect 
Target Enrichment System, 50 Mb Human All Exon kit. Whole-genome librar-
ies were prepared using the standard Illumina library preparation protocol. 
Paired-end reads of between 75 and 100 bp were generated on the HiSeq 
2000 platform and mapped to the reference GRCh37/hg19 human genome 
assembly using the Burrows-Wheeler Aligner (BWA)27. Reads were filtered for 
duplicates using Picard28 and were recalibrated and realigned around indels 
using the Genome Analysis Toolkit (GATK) package29 (Familial Melanoma 
Study and Leiden data). Exome capture and sequencing resulted in an average 
of 84% of target bases being covered by ≥10× across the autosomes and sex 
chromosomes. Whole genomes were sequenced to at least 27× mapped cover-
age. Data for POT1 variant carriers have been released (EGAS00001000017). 
Variants were then called using SAMtools mpileup30 and filtered for qual-
ity. The variant collection was filtered to remove positions found in Phase 1 
of the 1000 Genomes Project October 2011 release31 and the dbSNP 135 release 
(see URLs). Variants were also filtered for positions found in a collection of 
805 in-house control exomes. Only variants in exonic regions, as defined in 
Ensembl release 70, were taken forward for analysis. Positions resulting in 
protein-altering changes were then identified using the Ensembl Variant Effect 
Predictor, version 2.8 (Ensembl release 70)32, a combination of VCFTools33 and 
custom scripts. Variants marked as ‘transcript_ablation’, ‘splice_donor_variant’, 
‘splice_acceptor_variant’, ‘stop_gained’, ‘frameshift_variant’, ‘stop_lost’, ‘initiator_ 
codon_variant’, ‘inframe_insertion’, ‘inframe_deletion’, ‘missense_variant’, 
‘transcript_amplification’, ‘splice_region_variant’, ‘incomplete_terminal_
codon_variant’, ‘mature_miRNA_variant’, ‘TFBS_ablation’, ‘TFBS_amplifica-
tion’, ‘TF_binding_site_variant’, ‘feature_elongation’ and ‘feature_truncation’ 
were kept for further analyses. We retained only those variants found in all 
affected cases of a single pedigree (to reduce the impact of systematic mapping 
errors). An identity-by-descent (IBD) analysis was performed to confirm that 
cases from different pedigrees within the study were not related.
Genes with cosegregating variants from the 28 pedigrees for which we had 
sequence data for 3 or more family members are shown in Supplementary 
Table 3 with their Gene Ontology (GO) terms. Variants in POT1 identified 
from this analysis were confirmed by capillary sequencing (Supplementary 
Fig. 1). Several low-penetrance variants in MC1R were also identified in the 
pedigrees with POT1 variants; all of these are common variants associated 
with freckling and sun sensitivity (Supplementary Table 8). We also iden-
tified a variant at the +6 intronic splice site of introns 17 and 18 of POT1 
(g.124467262A>C) in one melanoma pedigree, but our analyses suggested that 
this variant was unlikely to be deleterious (Supplementary Note), although 
the telomeres of the subject carrying this variant at +6 appeared longer than 
the telomeres of controls, suggesting some effect on telomere regulation 
(Supplementary Fig. 8).
MaxEntScan scoring of splice-site acceptor variant g.124465412C>T. We 
used the MaxEntScan algorithm9, which yielded scores of −3.22 for the mutated 
splice-acceptor site (g.124465412C>T) and 5.53 for the wild-type splice-site 
sequence. To put these values in context, we retrieved 10,000 splice-acceptor 
and splice-donor sites from random genes (choosing always the second exon) 
and obtained a distribution of their scores. The splice-acceptor variant low-
ered the score of the wild-type sequence from the 9.2 to the 0.57 percentile 
compared to the score distribution of real splice acceptors (Supplementary 
Fig. 2) and is thus predicted to be highly deleterious.
RT-PCR sequencing of the POT1 product in two individuals carrying 
the splice-acceptor variant g.124465412C>T. RNA extracted from the 
whole blood of two carriers of the splice-acceptor variant was converted to 
cDNA using SuperScript III Reverse Transcriptase (Invitrogen). RT-PCR 
was then performed to confirm that POT1 g.124465412C>T (c.1687–1G>A; 
ENST00000357628) was indeed disruptive to splicing. M13-tagged forward 
primer and reverse primer were designed to flank the spliced region (primer 
sequences available upon request). The product was visualized on a 3% NuSieve 
Agarose gel, and the sequence was verified using standard Sanger sequencing 
methods. Sequencing traces for one control and one carrier sample are shown 
in Supplementary Figure 1c.
Frequency of POT1 variants in a control data set. All exomes from the 
UK10K sequencing project (REL 14/03/12) cohorts UK10K_NEURO_MUIR, 
UK10K_NEURO_IOP_COLLIER and UK10K_NEURO_ABERDEEN (see 
URLs) were selected as controls because these exomes were captured with 
the same Agilent SureSelect exome probes as those used for the melanoma 
cases described above and were also sequenced on the Illumina HiSeq 2000 
platform (n = 546). One exome was discarded at random from each of three 
pairs of relatives within this set. UK10K exomes were aligned, filtered for 
duplicates, and recalibrated and realigned around indels as described above. 
Variants were then called and filtered for base quality with the same tools and 
parameters as the melanoma cohort. For 104 of 105 families, we had exome 
data for at least 1 individual in the pedigree; for 1 melanoma family, we used 
whole-genome sequence.
To ensure that the controls were matched by ancestry to the melanoma 
cohort, we performed a principal-component analysis (PCA) using 1,092 
individuals across 14 populations from the 1000 Genomes Project Phase 1 
data set31. A subset of high-quality variant positions (quality score >10, 
minimum mapping quality >10, strand bias P value >0.0001, end distance 
bias P value >0.0001) that were common to the melanoma cohort and the 
UK10K controls, as well as the 1000 Genomes Project data set, were taken 
forward for analysis. SNPs with a minor allele frequency of <0.05 or that were 
in linkage disequilibrium with another SNP (pairwise r2 > 0.1) in the 1000 
Genomes Project data set or that had a Hardy-Weinberg P value of <1 × 10−5 
in the UK10K controls were excluded. After filtering, 7,196 SNPs remained 
that were spread across all autosomes. The first ten principal components 
were estimated using the 1000 Genomes Project individuals and were then 
projected onto the melanoma cohort samples and UK10K controls using 
EIGENSTRAT34. Controls lying greater than 2 s.d. from the mean scores for 
principal component 1 or 2 (PC1 or PC2, respectively), calculated using only 
European individuals in the 1000 Genomes Project data set, were removed 
from subsequent analyses (n = 20). This analysis is shown in Supplementary 
Figure 4. An IBD analysis was performed to ensure that members of the 
UK10K cohort were not related. This analysis was performed using the 
PLINK toolset35 and the same set of variants that were used for PCA. For 
each pair of individuals with an estimated IBD of >0.2, 1 individual was 
removed at random (n = 3). This filtering left 520 exomes for comparison 
against the melanoma cohort.
Variants in this collection of 520 UK10K control exomes were then filtered 
as described above (keeping positions with exonic coordinates ±100 bp and 
removing all variants in Phase 1 of the 1000 Genomes Project October 2011 
release31, the dbSNP 138 release (see URLs) and a collection of 805 control 
exomes). Because we used an updated version of dbSNP for this step, we 
also checked that the POT1 variants found in this study passed this filter. 
Consequences were then predicted and filtered as described above. From this 
analysis, we identified 1 individual in 520 control exomes that carried a rare, 
potentially disruptive variant in POT1 (a missense variant located outside of 
the OB domains). We performed a two-tailed Fisher’s exact test comparing 
the 3 out of 104 families with melanoma, excluding a discovery pedigree, to 
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the 1 individual out of 520 controls carrying rare variants in POT1, yielding 
a P value of 0.016.
Genotyping in a population-based case-control series (TaqMan). The 
variants encoding p.Tyr89Cys, p.Gln94Glu and p.Arg273Leu and the splice-
acceptor variant were genotyped in 2,402 control samples belonging to the 
Leeds Melanoma Case-Control Study. This control set included 499 popula-
tion-matched control DNA samples, 370 family controls (family members of 
melanoma cases without a diagnosis of melanoma) and 1,533 DNA samples 
from the Wellcome Trust Case Control Consortium. All 2,402 samples 
were wild type for the POT1 variants. We also genotyped the correspond-
ing positions in 1,739 population-based melanoma cases that were recruited 
from across Yorkshire, UK, as part of the same study. One case, presenting 
with MPMs with early onset (48 years old), was found to be a carrier of the 
variant encoding p.Arg273Leu (Table 1 and Supplementary Tables 5 and 6). 
This variant was confirmed by PCR sequencing.
Protein alignment, structural modeling and characterization of POT1 
variants. The amino acid sequences of POT1 from evolutionarily diverse 
species were gathered from NCBI and aligned with Clustal Omega36. 
Alignments were displayed using Jalview v2.7 (ref. 37). To estimate the number 
of substitutions per site in this amino acid alignment, we used the ProtPars 
routine from PHYLIP38. This analysis showed higher conservation for the 
three altered amino acids (2, 2 and 0 substitutions at positions 89, 94 and 273, 
respectively) than the average for the OB domains (2.42 substitutions per site) 
and, in fact, the whole protein (3.49 substitutions per site) across ~450 million 
years of evolutionary history (since the divergence of the zebrafish and human 
lineages). If only sequences from eutherian organisms were taken into account, 
then no substitutions have occurred in any of the three residues, compared to 
0.8 substitutions per site in the OB domains and 1.39 substitutions per site in 
the whole protein. The OB domain regions were defined as amino acids 8–299 
in the human sequence, according to Ensembl superfamily domain annotation. 
The structure of the OB domains of POT1 (3KJO) was obtained from PDB and 
was rendered with PyMOL v0.99 (see URLs).
Analysis of nucleotide variants coding for the 24 key OB domain residues 
in close proximity (3.5 Å) to telomeric DNA. Ramsay et al.10 defined a list of 
24 residues that lie closer than 3.5 Å to telomeric DNA in the crystal structure 
of POT1 (PDB 3KJP): residues 31, 33, 36, 39–42, 48, 60, 62, 87, 89, 94, 159, 
161, 223, 224, 243, 245, 266, 267, 270, 271 and 273. To assess the statisti-
cal significance of finding amino acid substitutions affecting these residues, 
we searched 6,503 exomes that were part of the National Heart, Lung, and 
Blood Institute (NHLBI) Grand Opportunity (GO) Exome Sequencing Project 
(ESP)14 for substitutions at any of the bases that would cause a change in 
these amino acids. The genomic positions that encode these 24 residues are 
shown in Supplementary Table 7. In summary, a minimum of 6,498 exomes 
had all bases covered at a minimum average coverage of 59×. The variant 
encoding p.Asn224Asp was found at an overall allele frequency of 1 in 
13,005. No other amino acid–changing variants were found. We compared 
the number of variants found in the 24 key OB domain residues in controls 
(1 in 6,498) to the number of variants found in all analyzed pedigrees 
(3 in 105), obtaining a P value of 1.54 × 10−5 using a two-tailed Fisher’s exact 
test (Supplementary Table 6).
In vitro translation and G strand binding assays. We mutated human POT1 
in a T7 expression vector (Origene) by site-directed mutagenesis to generate 
cDNAs encoding the POT1 Tyr89Cys, Gln94Glu and Arg273Leu variants. 
Mutant and control T7 expression vectors were used in an in vitro translation 
reaction using the TNT coupled reticulocyte lysate kit (Promega) following 
the manufacturer’s instructions. Briefly, a 50-µl reaction mixture contain-
ing 1 µg of plasmid DNA, 2 µl of EasyTag 35S-labeled l-methionine (1,000 
Ci/mmol; PerkinElmer) and 25 µl of rabbit reticulocyte lysate was incubated 
at 30 °C for 90 min. A 5-µl fraction of each reaction was analyzed by SDS-
PAGE; proteins were visualized and relative amounts were quantified using 
the FLA 7000 phosphorimager system (Fujifilm) (Supplementary Fig. 5). 
DNA binding assays were performed as described previously with minor 
modifications39. In 20-µl reaction mixtures, 5 µl of each translation reaction 
was incubated with 10 nM telomeric oligonucleotide 5′ labeled with 32P 
(5′-GGTTAGGGTTAGGGTTAGGG-3′) and 1 µg of the nonspecific com-
petitor DNA poly(deoxyinosinic-deoxycytidylic) acid in binding buffer 
(25 mM HEPES-NaOH, pH 7.5, 100 mM NaCl, 1 mM EDTA and 5% glycerol). 
Reactions were incubated for 10 min at room temperature, and protein-
DNA complexes were analyzed by electrophoresis on a 6% polyacrylamide 
Tris-borate-EDTA gel run at 80 V for 3 h. Gels were visualized by exposure to 
a phosphorimager screen.
Analysis of telomere length from next-generation sequencing data. Telomere 
length was determined essentially as described15. The investigator who 
performed this analysis was blinded to the POT1 status of the 41 eligible 
samples (which were all sequenced at the Sanger Institute, as they were the 
only ones with enough data available; Supplementary Table 2).
After calculation of relative telomere length, the 38 samples without 
germline POT1 variants were adjusted for age at blood draw and sex using 
a linear model (Supplementary Fig. 6). The corresponding values for 
POT1 variant carriers were estimated on the basis of the same adjustment. 
A Wilcoxon rank-sum test comparing adjusted telomere lengths for non- 
carrier melanoma cases and the three members of pedigree UF20 (p.Tyr89Cys 
variant carriers) (P = 0.00019) supported the finding of increased telomere 
lengths for variant carriers. In Figure 2c, all values are shown relative to the 
largest sample measurement.
Analysis of telomere length (PCR). We measured telomere length in 
melanoma cases recruited from the Leeds Melanoma cohort who did not carry 
a POT1 variant, seven POT1 missense variant carriers (pedigrees UF20, UF31 
and UF23 and the carrier individual from the Leeds Melanoma cohort) and 
two non-carrier family controls (UF23, individual III-1 and UF20, individual 
III-1). The investigator who performed this analysis was blinded to the POT1 
status of all samples. Relative mean telomere length was ascertained by SYBR 
Green RT-PCR using a version of the published Q-PCR protocols40,41 that was 
modified as described previously42. In brief, genomic DNA was extracted from 
whole blood, and telomere length was ascertained by determining the ratio 
of detected fluorescence from the amplification of telomere repeat units 
(TEL) relative to fluorescence for a single-copy reference sequence from the 
HBB (β-globin) gene (CON). Telomere and control reactions were performed 
separately. For each assay, the PCR cycle at which each reaction crossed a 
predefined fluorescence threshold was determined (Ct value). The difference in 
the Ct values, ∆Ct = Ct TEL − Ct CON, was the measure of telomere length used 
in the analysis, as in other published data generated using this assay42,43.
For the analysis, samples with Ct CON < 18, Ct CON > 27 or Ct CON > 2 s.d. 
away from the mean were removed and considered to represent failed reactions. 
This filtering left 252 samples from the Leeds Melanoma cohort for further analy-
ses, with no missense variant carriers or non-carrier family controls removed. 
All samples had between two and eight technical replicates. Mean ∆Ct values 
for each sample were estimated from all replicates. The estimated mean values 
of ∆Ct obtained from melanoma cases without germline POT1 variants were 
adjusted for age at blood draw and sex using a linear model (Supplementary 
Fig. 7). The corresponding values for POT1 variant carriers were estimated 
on the basis of the same adjustment. Adjusted mean ∆Ct values are plotted 
(Fig. 2d), with the histogram showing the non-carrier melanoma cases 
compared to the missense variant carriers and the non-carrier family controls 
plotted above. A Wilcoxon rank-sum test comparing the adjusted mean ∆Ct 
values for the 252 non-carrier melanoma cases with those for the 7 missense 
variant carriers (P = 3.62 × 10−5) supported the finding of increased telomere 
lengths for variant carriers.
Analysis of POT1 mutations in cancer databases. Although mutations 
in POT1 have not been found at a high frequency in the cancer studies 
deposited in COSMIC18 and IntOGen19 (which integrates only whole-exome 
data from ICGC and TCGA as well as other studies), the mutations that have 
been reported show a tendency to be missense, alter residues that are predicted 
to interact with DNA and have a high functional impact bias.
To statistically assess the mutational patterns affecting POT1 in cancer, we 
compiled a list of all residues closer than 3.5 Å to the telomeric DNA in the 
crystal structure of POT1 (PDB 3KJP)10. We then mined COSMIC database 
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v66 for confirmed somatic mutations absent from the 1000 Genomes Project 
affecting the ORF of POT1 across 14 cancer types (breast, central nervous 
system, endometrium, hematopoietic and lymphoid tissue, kidney, large 
intestine, liver, lung, ovary, parathyroid, prostate, skin, urinary tract and not 
specified). This analysis yielded 35 somatic mutations, including 4 that were 
silent. We also compiled the total frequency of each reference/mutated base 
pair in the same COSMIC database. Finally, we performed a Monte Carlo 
simulation with 100,000 groups of 35 mutations at random locations in the 
POT1 ORF. The probability of a given mutation from a reference base (for 
example, A to G) was forced to equal the frequency for that pair in the whole 
COSMIC database.
Of the 100,000 simulations performed with this method, only 2,971 
contained 4 or fewer silent mutations. Therefore, the COSMIC database 
contains fewer silent mutations affecting POT1 than expected by chance 
(P < 0.03). To assess the clustering of mutations at sites encoding DNA- 
binding residues (Supplementary Table 7), we only considered missense 
mutations, as no selection would be expected for nonsense mutations. In 
the COSMIC database, we found 27 POT1 missense mutations, 4 of 
which affected telomere-binding residues. In the Monte Carlo experiment, 
9,244 simulations had exactly 27 missense mutations. In only 176 of these 
simulations were 4 or more residues identified that were classified as 
disrupting telomere binding. This result suggests that POT1 missense 
mutations affect DNA-binding residues at a higher than expected rate in the 
COSMIC database (P < 0.02).
To assess the functional impact bias of somatic mutations in POT1, we also 
looked at all mutations in POT1 that are present in the IntOGen database19. 
We chose this database because it integrates only samples that have been 
whole-exome sequenced and thus can provide a valid, non-biased estimate 
of the functional impact of mutations in POT1 when they are compared 
with mutations in the rest of the exome. The frequency of POT1 mutations 
in this data set is ~0.01 across 9 cancer sites (all of those available in the 
database, contained in the 14 sites listed above). P values for the three 
studies for which the gene passed set thresholds defined in the database19, 
calculated with Oncodrive-fm44, were combined to yield a P value of 
0.021, indicating that this gene is biased toward the accumulation of 
functional mutations.
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 Supplementary Figure 1. Capillary sequencing of POT1 variants detected by 
next-generation sequencing. One sample per variant is shown; variants are indicated 
with an arrow. (a) Sequencing showing the presence of the variant in an additional 
member of pedigree UF20 who was not exome-sequenced (individual III-2, Fig. 1a). 
(b) Sequencing of an affected individual of pedigree AF1; note that, in this case, the 
complementary strand is shown. (c) Sequencing of the POT1 product in a control with 
wild-type POT1 (top) and a carrier of the splice-acceptor variant (pedigree AF1, 
individual IV-1, Fig. 1a) (bottom). The boundary between exons 17 and 18 is marked 
with a dotted red line. The wild-type sequence, in nucleotides and in amino acids, is 
indicated in black, and the sequence the variant results in is indicated in red. The 
mutant sequence leads to the introduction of a premature stop codon 11 amino acids 
downstream of the exon 17-exon 18 boundary. (d) Sequencing of an affected member 
of pedigree UF31. (e) Sequencing of the carrier member of pedigree UF23. 
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Supplementary Figure 2. MaxEntScan scores for the splice-acceptor variant 
detected in a familial melanoma pedigree (AF1). The location of the scores for the 
wild-type (black) and mutated (red) sequences are shown against score distributions 
for real splice donors, real splice acceptors and random genomic sequences. 
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Supplementary Figure 3. Pedigrees with additional POT1 variants. (a) Pedigree 
of family UF31 carrying the p.Gln94Glu change. (b) Pedigree of family UF23 
carrying the p.Arg273Leu variant. Types of cancer are indicated under each symbol, 
and ages of onset are indicated in parentheses. Genotypes for all samples available for 
testing are shown in blue. All cancers were confirmed by histological analysis with 
the exception of one case (indicated by an asterisk). CMM, cutaneous malignant 
melanoma. Circles represent females; squares represent males; diamonds represent 
individuals of undisclosed sex. Half-filled symbols represent other cancers. The 
patients that were sequenced have a red outline.  
 
 
  
Nature Genetics: doi:10.1038/ng.2947
  
Supplementary Figure 4. Principal-component analysis showing that the 
melanoma cases and UK10K controls are ancestry matched. Plot showing the first 
and second principal components (PC1 and PC2, respectively). Ancestry was 
estimated using the 1000 Genomes individuals1 and then projected onto the melanoma 
(gray) and UK10K control (orange) cohorts. Note that controls lying greater than 2 
s.d. from the mean PC1 or PC2 scores, calculated using only European individuals in 
the 1000 Genomes Project data set, are not shown in this plot and were not considered 
in subsequent analyses. We did not depict three individuals from the QFMP cohort for 
whom we could not determine the zygosity of the called genotypes. 
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Supplementary Figure 5. 35S gel showing the in vitro translation products of 
wild-type POT1 and OB domain mutants. This gel confirms that each in vitro 
translation reaction successfully produced protein for the electrophoretic mobility 
shift assay shown in Figure 2b. The p.Tyr89Cys, p.Gln94Glu and p.Arg273Leu 
POT1 variants were identified by exome-sequencing familial melanoma cases. The 
p.Tyr223Cys variant was somatically acquired in CLL and has previously been shown 
to be unable to bind to telomeric DNA2. The DNA-protein complexes shown in 
Figure 2b were visualized by 32P labeling of (TTAGGG)3 single-stranded DNA 
(Online Methods).  
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Supplementary Figure 6. Linear model used to adjust bioinformatically 
calculated telomere lengths for age at blood draw and sex. Residuals were used as 
the adjusted relative telomere lengths. Dark circles represent male samples, and light 
circles represent females. The sex variable is coded as 0 = female, 1 = male. Note that 
only two dimensions (relative telomere length and age) are shown. 
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Supplementary Figure 7. Linear model used to adjust PCR mean ΔCt values for 
age at blood draw and sex. Residuals were used as the adjusted mean ΔCt values. 
Dark circles represent male samples, and light circles represent females. The sex 
variable is coded as 0 = female, 1 = male. Note that only two dimensions (mean ΔCt 
value and age) are shown. 
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Supplementary Figure 8. PCR-based estimate of telomere length showing the 
carrier of a POT1 intronic splice donor variant. The carrier of the intronic splice 
donor variant is shown in the fourth row, in green. The rest of the figure is identical to 
Figure 2d. 
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Supplementary Tables 
 
Supplementary Table 1. The number of pedigrees sequenced by Institute and 
sequencing centre. The number of pedigrees with POT1 variants is indicated in 
parentheses. 
Institutes Leeds (UK) Leiden 
(NL) 
QFMP 
(Australia) 
Total 
Sequencing centres Sanger BGI Sanger Macrogen 
Familial pedigrees 
5+ cases 8 (1) 0 1 25 (1) 34 (2) 
4 cases 11 1 2 5 19 
3 cases 2 12 0 3 17 
2 cases 0 18 (2) 0 2 20 (2) 
Total 21 (1) 31 (2) 3 35 (1) 90 (4) 
Single cases 
MPM* 0 4 0 0 4 
Early age of onset* (<40 yr) 0 10 0 0 10 
Different primaries 0 0 0 1† 1 
Total 0 14 0 1 15 
 
Total by Institute 66 (3) 3 36 (1) 105 (4) 
 
*These samples were selected from the Leeds Melanoma Case-Control study. All cases were chosen 
for an absence of phenotypic risk markers (self reported sun-sensitivity and/or low mole count). 
†This case was selected because they presented with three different primary cancers, one of which was 
melanoma. 
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Supplementary Table 2. Pedigrees sequenced as part of this study, with number of 
cases in pedigree and number of cases sequenced (exome or whole genomes) 
indicated* 
 
Family ID 
Origin 
(Sequencing 
centre) 
Number 
of 
melanoma 
cases in 
pedigree 
Total 
number of 
cases 
sequenced 
(exomes + 
genomes) 
Number 
of whole 
exomes 
Number of 
whole 
genomes 
Familial melanoma pedigrees 
 
UF1 Leeds (Sanger) 4 2 2 0 
 
UF2 Leeds (Sanger) 5 1 1 0 
 
UF3 Leeds (Sanger) 4 1 1 0 
 
UF4 Leeds (Sanger) 5 1 1 0 
 
UF5 Leeds (Sanger) 4 1 1 0 
 
UF6 Leeds (Sanger) 4 1 1 0 
 
UF7 Leeds (Sanger) 4 2 2 0 
 
UF8 Leeds (Sanger) 4 1 1 0 
 
UF9 Leeds (Sanger) 5 1 1 0 
 
UF10 Leeds (Sanger) 3 3 3 0 
 
UF11 Leeds (Sanger) 4 1 1 0 
 
UF12 Leeds (Sanger) 4 1 1 0 
 
UF13 Leeds (Sanger) 4 1 1 0 
 
UF14 Leeds (Sanger) 4 2 2 0 
 
UF15 Leeds (Sanger) 8 2 2 0 
 
UF16 Leeds (Sanger) 4 2 2 0 
 
UF17 Leeds (Sanger) 6 1 1 0 
 
UF18 Leeds (Sanger) 5 1 1 0 
 
UF19 Leeds (Sanger) 6 2 2 0 
 
UF20 Leeds (Sanger) 5 3 3 0 
 
UF21 Leeds (Sanger) 3 2 2 0 
 
UF22 Leeds (BGI) 2 1 1 0 
 
UF23 Leeds (BGI) 2 1 1 0 
 
UF24 Leeds (BGI) 4 1 1 0 
 
UF25 Leeds (BGI) 3 1 1 0 
 
UF26 Leeds (BGI) 3 1 1 0 
 
UF27 Leeds (BGI) 3 1 1 0 
 
UF28 Leeds (BGI) 3 1 1 0 
 
UF29 Leeds (BGI) 3 1 1 0 
 
UF30 Leeds (BGI) 3 1 1 0 
 
UF31 Leeds (BGI) 2 1 1 0 
 
UF32 Leeds (BGI) 2 1 1 0 
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UF33 Leeds (BGI) 3 1 1 0 
 
UF34 Leeds (BGI) 2 1 1 0 
 
UF35 Leeds (BGI) 3 1 1 0 
 
UF36 Leeds (BGI) 2 1 1 0 
 
UF37 Leeds (BGI) 3 1 1 0 
 
UF38 Leeds (BGI) 3 1 1 0 
 
UF39 Leeds (BGI) 2 1 1 0 
 
UF40 Leeds (BGI) 3 1 1 0 
 
UF41 Leeds (BGI) 2 1 1 0 
 
UF42 Leeds (BGI) 2 1 1 0 
 
UF43 Leeds (BGI) 2 1 1 0 
 
UF44 Leeds (BGI) 2 1 1 0 
 
UF45 Leeds (BGI) 3 1 1 0 
 
UF46 Leeds (BGI) 2 1 1 0 
 
UF47 Leeds (BGI) 2 1 1 0 
 
UF48 Leeds (BGI) 2 1 1 0 
 
UF49 Leeds (BGI) 2 1 1 0 
 
UF50 Leeds (BGI) 2 1 1 0 
 
UF51 Leeds (BGI) 2 1 1 0 
 
UF52 Leeds (BGI) 2 1 1 0 
 
NF1 Leiden (Sanger) 4 3 3 0 
 
NF2 Leiden (Sanger) 4 2 2 0 
 
NF3 Leiden (Sanger) 5 4 4 0 
 
AF1 QFMP (Macrogen) 6 3 3 0 
 
AF2 QFMP (Macrogen) 2 1 0 1 
 
AF3 QFMP (Macrogen) 5 3 2 1 
 
AF4 QFMP (Macrogen) 8 3 2 1 
 
AF5 QFMP (Macrogen) 8 3 2 1 
 
AF6 QFMP (Macrogen) 5 3 2 1 
 
AF7 QFMP (Macrogen) 3 3 2 1 
 
AF8 QFMP (Macrogen) 8 3 2 1 
 
AF9 QFMP (Macrogen) 4 2 1 1 
 
AF10 QFMP (Macrogen) 5 3 2 1 
 
AF11 QFMP (Macrogen) 6 4 3 1 
 
AF12 QFMP (Macrogen) 4 2 1 1 
 
AF13 QFMP (Macrogen) 11 2 1 1 
 
AF14 QFMP (Macrogen) 3 2 1 1 
 
AF15 QFMP (Macrogen) 5 3 2 1 
 
AF16 QFMP (Macrogen) 2 2 1 1 
 
AF17 QFMP (Macrogen) 9 3 3 0 
 
AF18 QFMP (Macrogen) 5 3 3 0 
 
AF19 QFMP (Macrogen) 5 3 3 0 
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AF20 QFMP (Macrogen) 5 3 3 0 
 
AF21 QFMP (Macrogen) 8 3 3 0 
 
AF22 QFMP (Macrogen) 6 3 3 0 
 
AF23 QFMP (Macrogen) 6 4 4 0 
 
AF24 QFMP (Macrogen) 4 1 1 0 
 
AF25 QFMP (Macrogen) 3 3 3 0 
 
AF26 QFMP (Macrogen) 9 4 4 0 
 
AF27 QFMP (Macrogen) 5 2 2 0 
 
AF28 QFMP (Macrogen) 5 3 3 0 
 
AF29 QFMP (Macrogen) 6 2 2 0 
 
AF30 QFMP (Macrogen) 4 2 2 0 
 
AF31 QFMP (Macrogen) 6 4 4 0 
 
AF32 QFMP (Macrogen) 6 4 4 0 
 
AF33 QFMP (Macrogen) 6 4 4 0 
 
AF34 QFMP (Macrogen) 4 1 1 0 
 
AF35 QFMP (Macrogen) 8 3 3 0 
 
Total 169 154 15 
Single cases 
 
UN1 Leeds (BGI) 1 1 1 0 
 
UN2 Leeds (BGI) 1 1 1 0 
 
UN3 Leeds (BGI) 1 1 1 0 
 
UN4 Leeds (BGI) 1 1 1 0 
 
UN5 Leeds (BGI) 1 1 1 0 
 
UN6 Leeds (BGI) 1 1 1 0 
 
UN7 Leeds (BGI) 1 1 1 0 
 
UN8 Leeds (BGI) 1 1 1 0 
 
UN9 Leeds (BGI) 1 1 1 0 
 
UN10 Leeds (BGI) 1 1 1 0 
 
UN11 Leeds (BGI) 1 1 1 0 
 
UN12 Leeds (BGI) 1 1 1 0 
 
UN13 Leeds (BGI) 1 1 1 0 
 
UN14 Leeds (BGI) 1 1 1 0 
 
AN1 QFMP (Macrogen) 1 1 0 1 
 
Total 15 14 1 
 Grand total 184 168 16 
*Whole genomes were only sequenced as part of the QFMP cohort. 
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Supplementary Table 4. Primers used for validating POT1 variants. 
 
 
 
 
 
  
Gene Variant Location Forward Primer Reverse Primer 
Amplicon 
Size 
POT1 7:124493077 TCTGGCAAGACCCTGATTCC GCCTTCATACCAAACTTCAATCAA 112 
POT1 7:124503684 GTGCGAGGTATGATAGGGGC GCCCTCTCTTAATTATGCTGGC 216 
POT1 7:124503670 GTGCGAGGTATGATAGGGGC GCCCTCTCTTAATTATGCTGGC 216 
POT1 7:124465412 TGGAGTTGAGACCAGCATTC ATCCCTGCCACTCTCTTCAT 436 
Nature Genetics: doi:10.1038/ng.2947
Supplementary Table 5: Details for pedigrees with POT1 variants identified in this 
study 
Pedigree Source Variant 
Number of 
melanoma 
cases in 
pedigree 
Study cohort Identification technique 
UF20 Sanger Tyr89Cys 5 UK Familial Melanoma Study 
Exome 
Sequencing 
AF1 Macrogen Splice acceptor 6 QFMP/Australia Exome Sequencing 
UF31 BGI Gln94Glu 2 UK Familial Melanoma Study 
Exome 
Sequencing 
UF23* BGI Arg273Leu 2 UK Familial Melanoma Study 
Exome 
Sequencing 
CT1663 Leeds Arg273Leu 1 Leeds Melanoma Case-Control study 
Candidate 
variant† 
 
*One patient with early onset disease and multiple primaries was sequenced and found to carry the 
Arg273Leu variant. A second case had a different clinical presentation (solitary melanoma in situ) in 
the 6th decade and did not carry the Arg273Leu variant.  
†Assessment of POT1 variants in the Leeds Melanoma Case-Control Study (details above). A TaqMan 
assay was used for this analysis. A case with MPM and an early age of onset (48 years old) was 
identified. This variant was validated by PCR-resequencing.  
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Supplementary Table 6. Controls used in this study 
 
Cohort Description No. samples Phase 
UK10K 
This project aims to sequence 10,000 
individuals with well-defined phenotypes 
(www.uk10k.org). All individuals from 
three cohorts with neurological phenotypes 
unrelated to cancer were chosen. 
520 
Frequency of POT1 
variants in an ancestry, 
technically matched 
population control 
Leeds Melanoma 
Case-Control 
Series / WTCCC 
Controls in this cohort are either part of the 
Leeds Melanoma Case Control Series (869), 
of which 499 are population-matched 
controls and 370 are unaffected individuals 
related to cases, or part of the Wellcome 
Trust Case Control Consortium (1,533). 
2,402 
Genotyping of the four 
variants found in 
familial melanoma 
families 
NHLBI GO ESP 
The NHLBI Grand Opportunity Exome 
Sequencing Project has sequenced and 
released 6,503 exomes from multiple 
cohorts with heart, lung and blood disorders 
(http://evs.gs.washington.edu/EVS/). 
6,498* 
Frequency of variants 
in residues in close 
proximity to DNA in a 
technically matched 
control 
*This was the minimum number of exomes with coverage in each of the 24 amino acids. 
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Supplementary Table 7. Genomic location of bases encoding the 24 key OB domain 
residues (GRCh37) 
Amino Acid Genomic position 
31 g.124532351-124532353 
33 g.124532345-124532347 
36 g.124532336-124532338 
39 g.124532327-124532329 
40 g.124532324-124532326 
41 g.124532321-124532323 
42 g.124532320 and g.124511094-124511095 
48 g.124511076-124511078 
60 g.124511040-124511042 
62 g.124511034-124511036 
87 g.124503689-124503691 
89 g.124503683-124503685 
94 g.124503668-124503670 
159 g.124503473-124503475 
161 g.124503467-124503469 
223 g.124499044-124499046 
224 g.124499041-124499043 
243 g.124493166-124493168 
245 g.124493160-124493162 
266 g.124493097-124493099 
267 g.124493094-124493096 
270 g.124493085-124493087 
271 g.124493082-124493084 
273 g.124493076-124493078 
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Supplementary Table 8. Variants in MC1R in POT1 pedigrees 
Pedigree Variants in known genes 
UF20 
One member carries chr. 16: g.89985844G>T (rs1805005, Val60Leu); two 
members carry g.89985940G>A (rs2228479, Val92Met).  
UF31 The sole member sequenced carries g.89985844G>T (rs1805005, Val60Leu) 
UF23 
The individual that was exome-sequenced carries g.89985940G>A 
(rs2228479, Val92Met) 
AF1 All three individuals carry g.89986117C>T (rs1805007, Arg151Cys) 
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Supplementary Note 
 
Analysis of a variant at the +6 intronic splice donor of POT1 in a familial melanoma 
pedigree (g.124467262A>C) 
Here we focused on the identification of familial melanoma cases with missense 
variants in the OB domains of POT1 and also deleterious variants throughout the 
gene. As part of our analysis we did, however, identify a variant at +6 in the 
consensus splice donor sequence of intron 17-18 in one of the families with one 
member sequenced. Transcriptome sequencing of lymphocyte RNA from this patient 
(deposited at the European Genome-phenome Archive, accession number 
EGAS00001000571) failed to reveal evidence of aberrant splice forms, although 
expression of POT1 appeared to be low, and MaxEntScan analysis of the splice site 
sequence (as described above) suggested that the variant was unlikely to be 
deleterious. We did note, however, that the telomeres of the case carrying this +6 
variant appeared longer than the telomeres of controls, suggesting some effect on 
telomere regulation (Supplementary Fig. 8). 
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Chapter 5 
Nonsense mutations in the shelterin complex genes ACD and TERF2IP 
in familial melanoma 
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5.1 Relevance to thesis aims 
 
Following the finding of inactivating germline mutations in POT1 in familial melanoma (Chapter 4) 
we searched for mutations in the other five shelterin components (ACD, TERF1, TERF2, TERF2IP 
and TINF2). We interrogated whole-genome, exome and targeted sequencing data for novel 
germline variants in 510 melanoma families from the QFMP and GenoMEL. We found novel 
nonsense mutations in ACD and TERF2IP which segregated with melanoma in a seven-case 
Queensland family and a three-case British family respectively. Additionally, novel missense 
mutations were found in these two genes in other probands, so that overall 10 families, from 
Australia, the UK, Sweden and Denmark, carried potentially deleterious ACD and TERF2IP 
mutations. Interestingly, these cases come from pedigrees enriched with other malignancies, 
suggesting these mutations may represent a general mechanism of tumour susceptibility. This study 
addressed Aims 2 to 4 of my thesis and adds to the growing support for telomere dysregulation as a 
key process associated with melanoma susceptibility.  
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The shelterin complex is responsible for all normal telomere functions, including the protection of 
telomeres from degradation, illegitimate recombination events and from being inappropriately 
processed by the DNA-repair pathway [132]. This is an important finding as it implicates other 
members of the shelterin protein complex in melanoma predisposition. Along with the findings 
from Chapter 4, we see three members of this complex implicated in melanoma predisposition in 
families from Australia, the UK, Sweden and Denmark. Importantly, mutations in ACD, TERF2IP 
and POT1 collectively account for approximately 9% of high-density melanoma families that lack 
mutations in the known familial melanoma genes (CDKN2A, CDK4, BAP1, MITF and the TERT 
promoter), making the shelterin complex the second most mutated pathway in familial melanoma. 
 
5.2 Contribution of candidate 
 
As with the POT1 study described in the previous chapter, this was a large collaborative effort 
between international research groups and therefore there are elements contained within this 
manuscript that were outside the scope of this thesis. I performed the analysis of the whole-genome 
and exome data from Australia, Sweden and Denmark as well as the validation of variants using 
Sanger sequencing methods. I performed the co-segregation analysis of mutations in the Australian, 
Swedish and Danish families. I was also responsible for the sample preparation for the Australian 
families including the extraction of DNA and RNA from whole blood and the co-segregation 
analysis. I wrote and edited the manuscript with Nicholas Hayward and Antonia Pritchard. I also 
compiled the majority of the tables and figures for the body of the manuscript and the supporting 
information. 
 
5.3 Contribution of other authors    
 
Nicholas K. Hayward, David J. Adams, Kevin M. Brown, Julia A. Newton Bishop, D. Timothy 
Bishop and Mark Harland designed the study. Samples were provided by Grant W. Montgomery, 
Nicholas G. Martin, Nicholas Hayward, Helen Snowden, Julia A. Newton Bishop, D. Timothy 
Bishop, Graham J. Mann, Anne-Marie Gerdes, Håkan Olsson, Christian Ingvar, Åke Borg, Remco 
van Doorn and Nelleke A. Gruis. I performed the whole-genome and exome data analysis and 
experiments for Australian samples in conjunction with Antonia L. Pritchard, Mitchell S. Stark 
Vanessa Bonazzi, Susan Woods, Ken Dutton-Regester and Michael G. Gartside. Carla Daniela 
Espinoza-Robles performed the NGS data-analysis for the UK families and the control samples. 
Xijun Zhang and Kristine Jones performed the Ion Torrent targeted sequencing while Jiyeon Choi 
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and Kevin M. Brown analysed the Ion Torrent data. Peter Johansson, Zhihao Ding and Thomas M. 
Keane provided bioinformatics support. Protein modelling was performed by Víctor Quesada, 
Andrew J. Ramsay and Carlos López-Otín. Karin Wadt recruited the Danish families and collected 
samples and clinical information. Jane M. Palmer, Judith Symmons, Elizabeth A. Holland and 
Helen Schmid contacted the families and collected the patient data and samples for the Australian 
cases. Nicholas Hayward and Antonia helped write the manuscript with the input of Carla Daniela 
Robles-Espinoza and David J. Adams. All authors read and approved the manuscript. 
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Abstract 
 
Background: The shelterin complex protects chromosomal ends by regulating how the telomerase 
complex interacts with telomeres. Following the recent finding in familial melanoma of inactivating 
germline mutations in POT1, encoding a member of the shelterin complex, we searched for 
mutations in the other five components of the shelterin complex in melanoma families.  
Methods: Next generation sequencing techniques were used to screen 510 melanoma families (with 
unknown genetic aetiology) and control cohorts, for mutations in shelterin complex encoding genes: 
ACD, TERF2IP, TERF1, TERF2 and TINF2.  
Results: Six families had mutations in ACD and four families carried TERF2IP variants, which 
included nonsense mutations in both genes (p.Q320X and p.R364X, respectively) and point 
mutations that co-segregated with melanoma. Of five distinct mutations in ACD, four clustered in 
the POT1 binding domain, including p.Q320X. This clustering of novel mutations in the POT1 
binding domain of ACD was statistically higher (p = 0.005) in melanoma probands compared to 
population controls (n = 6785), as were all novel and rare variants in both ACD (p = 0.040) and 
TERF2IP (p = 0.022). Families carrying ACD and TERF2IP mutations were also enriched with 
other cancer types, suggesting that these variants also predispose to a broader spectrum of cancers 
than just melanoma. Novel mutations were also observed in TERF1, TERF2 and TINF2, but these 
were not convincingly associated with melanoma. 
Conclusions: Our findings add to the growing support for telomere dysregulation as a key process 
associated with melanoma susceptibility. 
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Introduction 
Germline mutations in the high penetrance melanoma susceptibility genes CDKN2A and 
CDK4 account for cutaneous malignant melanoma (CMM) development in ~40% of multi-case 
families [1]. Additionally, rare mutations in BAP1 have been associated with uveal and cutaneous 
melanoma predisposition [2]. More recently, germline mutations in the promoter of TERT 
(telomerase reverse transcriptase) [3], as well as inactivating mutations in the shelterin component 
POT1 (protection of telomeres 1) [4, 5], implicate telomere dysregulation as a novel pathway 
underlying familial melanoma.  
Shelterin is a telomere-specific protein complex that protects the ends of chromosomes by 
mediating the interaction of telomerase with telomeres. It is made up of six family members, 
encoded by the genes POT1, ACD, (adrenocortical dysplasia protein homolog; also known as TPP1, 
TINT1, PIP1 and PTOP), TERF1 (telomeric repeat binding factor 1, also known as TRF1), TERF2 
(telomeric repeat binding factor 2, also known as TRF2), TERF2IP (telomeric repeat binding factor 
2 interacting protein; also known as RAP1 and DRIP5) and TINF2 (TERF1-interacting nuclear 
factor 2; also known as TIN2) (Supplementary Figure 1). The shelterin components are 
collectively necessary for all telomere functions, which include the protection of telomeres from 
degradation, aberrant recombination, from being inappropriately processed by the DNA-repair 
pathway, and also the facilitation of chromosome capping to mediate telomerase activity [6]. Thus, 
protein-altering variants located within this complex have recently been shown to have a great 
impact on diseases related to cellular lifespan, particularly cancer [4, 5, 7].  
Here, following on from recent reports of germline POT1 mutations in familial melanoma 
[4, 5], we establish a key role for other components of the shelterin complex in susceptibility to 
CMM.  
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Methods 
We screened for germline ACD, TERF2IP, TERF1, TERF2 and TINF2 variants in exome, whole-
genome, or targeted pulldown sequence data from 601 individuals belonging to 510 families with 
CMM.  
  
Samples used for whole-genome, exome or targeted sequence analysis 
All cases gave written informed consent for participation. Each was wild type for CDKN2A, BAP1, 
POT1, BRCA2, CDK4 and the TERT promoter. Samples were ascertained through the Queensland 
Familial Melanoma Project (QFMP) [8, 9], the Sydney Genetic Epidemiology of Melanoma study 
[10], the UK Familial Melanoma Study, the Leiden University Medical Centre; the Danish Project 
of Hereditary Malignant Melanoma and the Oncogenetic Clinic at Skåne University Hospital. 
Ethics approval was granted by the Committee of Biomedical Research Ethics of the Capital Region 
of Denmark, the UK Multicentre Research Ethics Committee, and the Human Research Ethics 
Committees of: the QIMR Berghofer Medical Research Institute, the Lund University, the 
University of Sydney, and the Leiden University Medical Centre.  
 
Next Generation Sequencing 
Whole-genome or exome sequencing was performed on 113 CMM families from Australia, UK, 
The Netherlands, Denmark and Sweden. Between 1 and 5 cases were sequenced from each family, 
totalling 204 individuals. Supplementary Table 1 details samples by centre. Supplementary Table 2 
summarises ages of CMM onset and other cancers in individuals sequenced. Sequencing was 
performed on the Illumina Hiseq 2000 platform with Agilent SureSelect Human All Exon 
V4+UTRs enrichment kits. Paired-end reads of 75-100 bp were generated, with mean coverage of 
60-96X. The Burrows-Wheeler Aligner was used to map reads to the UCSC hg19 [11]. UK and 
Leiden samples, were filtered for duplicate reads using Picard [12], recalibrated, and aligned using 
Genome Analysis Tool Kit [13]. SNPs and indels were annotated using bcftools and SAMtools 
mpileup with disabled BAQ computation [14]. Data were filtered using: quality score > 40, 
alternate reads > 2, and alternate reads  ≥ 20% of total reads. Variants in dbSNP135, or the 1000 
Genomes Project (April 2012) were removed.  
Targeted sequencing of the shelterin genes was carried out in 397 QFMP probands  (Supplementary 
Table 3) using two Ampliseq panels. The first panel (105 amplicons; 10202 bp) included the coding 
regions and had 100% coverage except TERF1 (96%). The second panel (68 amplicons; 7723 bp) 
comprised of UTRs, promoters, and alternative exons. Libraries were barcoded and run on an Ion 
PGM using 318 chips, with minimum 30X coverage. Sequence reads were processed by the Ion 
114 
 
Torrent Suite (Life Technologies, CA, USA) with alignment and variants called as above. Variants 
were filtered to exclude those listed in dbSNP, the 1000 Genomes Project, Kaviar and synonymous 
changes. Variants had to have a quality score ≥ 30 and ≥ 10 alternate reads.  
 
Sanger sequencing 
Sanger sequencing was used to confirm variants found by next-generation sequencing. Primers are 
listed in Supplementary Table 4.  
 
Sequenom iPLEX 
Seven variants (ACD: p.N249S, p.A200T, p.Q320X, p.I322F; TERF2IP: p.M5I, p.D10H, p.R364X) 
were genotyped in an Australian case-control sample. Cases (n = 1669) were derived from the 
QFMP [8, 15] and the controls (n = 1590) were parents of twins ascertained in the Brisbane Twin 
Naevus Study (BTNS) [16]. The controls self-reported their melanoma history and had not 
developed CMM at the time of sample collection. The Sequenom iPLEX gold system (Sequenom 
Bioscience, CA, USA) was used to genotype the variants; primers were designed using Assay 
Design Suite (Supplementary Table 4).  
 
Analysis of novel variants in shelterin genes in control exomes 
Publicly available exome data from 1965 Danish individuals [17], or a subset of exomes from the 
UK10K sequencing project (http://www.uk10k.org), or the European-American samples lodged in 
the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP) database 
(http://evs.gs.washington.edu/EVS/) were also used as controls. 
 
Statistical Analyses 
 
Maximum likelihood analysis 
The age of the founder mutation was estimated using a statistical model described by Neuhausen 
and colleagues [18]. Assuming 1 cM equals 1 Mb and a de novo mutation rate of 1.2 x 10-8 per 
generation [19], a joint likelihood of the genotype data was calculated taking into account ancestral 
haplotype, number of generations, G, since the ancestor, and allele frequencies of the SNPs among 
the European population. An estimate of G was calculated that maximized the likelihood. A 
confidence interval was calculated by finding the range of values of G that yielded a likelihood of at 
least one tenth of the maximum likelihood. 
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LOD score analysis 
An autosomal dominant model was used to generate the LOD score for families carrying the ACD 
p.N249S variant. Parametric linkage analysis was done using the Genehunter MOD score 
algorithm. Penetrance was specified as 5%, 95% and 95% for the three genotype classes, with allele 
frequency at the disease and marker locus specified as 0.001.  
 
Mutation clustering 
Chi-squared tests were used to determine whether mutations were significantly enriched in 
melanoma cases versus controls and whether they clustered more often in the POT1 binding domain 
of ACD. Fisher’s Exact test was used where any value was < 5. A p-value of < 0.05 was considered 
statistically significant (one-tailed with Yates’ correction).  
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Results 
 
Novel germline ACD and TERF2IP mutations in melanoma 
Segregating nonsense mutations in ACD and TERF2IP were found in a five-case and a four-case 
family, respectively. The p.Q320X mutation in ACD, in family AUS1, was present in all four cases 
available for genotyping (Figure 1) and results in a truncated protein, disrupting the POT1 binding 
domain and eliminating the TINF2 binding domain downstream (Figure 2A). Three CMM cases in 
family UK1 were carriers of a p.R364X nonsense mutation in TERF2IP (Figure 1). This results in 
truncation of the protein 36 amino acids from the C-terminus, disrupting the TERF2 binding 
domain (Figure 2A).  
In addition, we found novel (not in dbSNP135, or the 1000 Genomes Project data at the time of 
analysis) missense mutations in ACD and TERF2IP that co-segregated in all available invasive 
CMM cases in four other families (Table 1, Figure 1). This included a p.N249S mutation in ACD in 
two separate families, which like the p.Q320X mutation, also occurs in the POT1 binding domain 
(Figure 2A). This mutation segregated in all seven available cases of AUS2, with eight confirmed 
and four unconfirmed cases of CMM. Danish family, DK1, which harboured the same mutation 
(Figure 1), presented with five confirmed cases and one unconfirmed case of melanoma. Of the 
individuals available for analysis, three invasive CMM cases were found to harbour this mutation; a 
person diagnosed with a melanoma in situ was not a carrier. A second novel mutation, which co-
segregated with all three melanoma cases in family AUS3, was identified in the POT1 binding 
domain of ACD (p.V272M). Unfortunately, as the crystal structure of the POT1 binding domain of 
ACD, containing the p.N249 and the p.V272 residues, has not been resolved, there is insufficient 
information for in silico modelling of the effects of these variants. Another completely co-
segregating mutation we discovered was in the MyB domain of TERF2IP (p.Q191R) in a two-case 
melanoma family (Table 1, Figure 1). 
Additionally, four novel variants were observed in ACD or TERF2IP, which did not fully segregate 
with all melanoma cases in the respective families (Supplementary Figure 2A). These included a 
p.A200T substitution within the OB domain of ACD, a p.I322F substitution within the POT1 
binding domain of ACD, as well as p.M5I and p.D10H substitutions, both of which lie in the BRCT 
domain of TERF2IP (Figure 1 and Supplementary Figure 2A). All of these co-segregating missense 
mutations in ACD and TERF2IP occur at highly evolutionarily conserved sites across species 
(Figure 2, B and C).  
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Prevalence, linkage and haplotype analysis of the ACD p.N249S mutation 
The ACD p.N249S variant was the only novel mutation at that time of initial analysis of our exome 
data that was subsequently observed in the ESP database, albeit exceedingly rarely (3/8600 
European-American chromosomes). We therefore additionally screened an Australian population-
based case-control panel for this variant, and did not see it in any of 1669 cases or 1590 controls; it 
has also not been seen in the 1000 Genomes Project data, or in the exomes from ~1000 Danish 
diabetes cases and ~1000 metabolically healthy controls [17]. 
Linkage analysis of the two families segregating the ACD p.N249S variant gave a combined LOD 
score of 1.14, which equates to a p-value of 0.011. Analysis of a possible common founder in these 
families was carried out using whole-genome SNP arrays. Each of the carriers tested shared an 
allele for 112 SNPs, stretching from rs12918121 (chr16:67187795) to rs16957597 
(chr16:67946356), a region 758561 bp long, spanning ACD (Supplementary Table 5). The data are 
thus consistent with all affected individuals sharing the same haplotype. Estimates of when the 
mutation arose gave a maximum likelihood for 129 generations ago (with a 90% confidence interval 
of 28-362 generations).  
 
ACD and TERF2IP variants in controls 
To further assess the association between ACD and TERF2IP variants and familial melanoma 
susceptibility, we screened 6785 publicly available control exomes for rare (variant allele frequency 
(VAF) < 0.001) variants in these genes. Controls included the ESP cohort (n = 4300), Danish 
controls (n = 1965) [17] and the UK10K sequencing project (http://www.uk10k.org; n = 520). ACD 
and TERF2IP variants in these control cohorts are listed in Supplementary Tables 6 – 8 and the 
relative positions with respect to protein domains given in Supplementary Figure 3. Taking all ACD 
variants with a VAF < 0.001, we found significant enrichment in melanoma cases versus controls 
(6/510 melanoma probands versus 33/6785 controls; p = 0.040). Moreover, if only novel ACD 
variants were considered the association with melanoma was stronger (6/510 melanoma probands 
versus 8/2485 controls (note ESP controls were not included since by definition variants in the ESP 
were not considered novel); p = 0.013). The most significant association was found when we only 
considered variants with a VAF < 0.001 that occurred in the POT1 binding domain; 5/510 CMM 
probands versus 16/6785 controls (p = 0.005).  
No novel or rare variants were observed in TERF2IP in the 520 UK10K samples or the 1965 
Danish controls. There were 8 variants (12 individuals) listed amongst the 4300 European-
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American ESP controls. Thus there was significant enrichment (p = 0.022) of novel plus rare (VAF 
< 0.001) TERF2IP variants in melanoma probands (4/510) versus controls (12/6785).   
Lastly, to assess the potential contribution of ACD and TERF2IP to sporadic melanoma we 
conducted a case-control analysis for a total of six variants (other than ACD p.N249S reported 
above) in these two genes (ACD: p.A200T, p.Q320X, p.I322F; TERF2IP: p.M5I, p.D10H, 
p.R364X) and did not observe any other individual that carried one of these variants amongst 1669 
QFMP cases and 1590 BTNS controls. 
 
Germline variants in other shelterin genes 
Novel variants were also observed in TERF1, TERF2 and TINF2 (Supplementary Table 9), but 
these were not convincingly associated with melanoma (see Supplementary Results). 
Supplementary Table 10 lists incidences of all cancers in families carrying shelterin mutations. 
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Discussion 
 
The aim of this study was to screen individuals with strong personal or family histories of CMM 
that do not carry a mutation in one of the known high penetrance melanoma risk genes, for germline 
mutations in ACD, TERF1, TERF2, TERF2IP and TINF2. We identified ten mutations in 
ACD/TERF2IP, including two fully segregating nonsense mutations and four novel co-segregating 
missense mutations. 
ACD, in a subunit with POT1, mediates the interaction between shelterin and TERT through its 
oligonucleotide/oligosaccharide-binding folds (OB-folds); Figure 2A [20]. When the ACD/POT1 
subunit is inhibited, the telomerase complex increases telomere length, indicating that this sub-
complex is required to inhibit the elongation of chromosome ends [21-25]. Additionally, within the 
shelterin complex, ACD links POT1 to other members (Supplementary Figure 1) and increases 
the affinity of POT1 for telomeric single stranded DNA [26]. We identified a nonsense mutation in 
ACD, p.Q320X, which disrupts the POT1 binding domain and abolishes the TINF2 binding 
domain, so would therefore be predicted to result in an unformed shelterin complex. Individuals in 
this family presented with early onset melanoma at: 23, 25, 29, 39 and 56 years (Figure 1). The 
p.N249S mutation in ACD was identified in 2 families, from Australia and Denmark, which shared 
a large founder haplotype across the ACD locus. A co-segregating ACD p.V272M mutation was 
identified in a lower density melanoma family (Figure 1). Two ACD mutations were identified that 
did not fully-segregate with all CMM cases in the family; p.A200T was found in four of seven cases 
that could be tested from an eight -case family and p.I322F was found in three of four available 
cases from a six-case family (Supplementary Figure 2A). Missense mutations p.A200T, p.V272M 
and p.I322F were predicted to be damaging or possibly damaging by the Polyphen2 and SIFT 
prediction programs (Table 1). Overall, of the five distinct mutations in ACD, four clustered in 
highly conserved residues in the POT1 binding domain (Figure 2A) and are enriched for 
occurrence in melanoma cases compared to controls (p = 0.005), indicating this domain plays an 
important role in melanoma susceptibility.  
TERF2IP, associates with the shelterin complex via its C-terminus to a central region of TERF2, 
forming a stable 1:1 complex. TERF2IP, as part of the shelterin complex, is vital for the repression 
of homology-directed repair of double strand chromosomal break at the telomere [27]. TERF2IP 
p.R364X results in premature truncation of the protein 36 amino acids from the C-terminus, 
resulting in disruption of the TERF2 binding domain and is therefore predicted to result in a loss of 
binding to the shelterin complex. Of the three novel missense variants observed in TERF2IP, 
p.Q191R was found in the two cases in family AUS6, who both developed CMM at an early age 
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(15 and 24 years) and p.D10H was predicted to be damaging/probably damaging by Polyphen2 and 
SIFT (Table 1); all three missense mutations occur at highly conserved amino acid residues (Figure 
2, B and C).  
Many families harboring mutations in ACD/TERF2IP included members with multiple primary 
melanomas (MPM) and other cancer types (Figure 1; Supplementary Figure 2A). The TERF2IP 
nonsense mutation, in family UK1, was found in an individual without CMM, but who developed 
breast cancer at age 85. Family AUS2, harboring the ACD p.N249S mutation, included six 
individuals with MPM and/or early onset melanoma (15, 26 and 35 years), four CMM cases also 
developed other cancers (three lung and one breast) and a mutation carrier without CMM developed 
breast cancer aged 50. In family DK1, harboring ACD p.N249S, two mutation carriers developed 
MPM, one of whom also developed B-cell lymphoma aged 82. The ACD p.V272M mutation 
occurred in a family (AUS3) with three cases of CMM, all of whom developed other cancers; two 
mutation carriers developed three different primary cancers: CMM, colon and lung; or CMM, 
bowel and leukemia. The two TERF2IP p.Q191R carriers in family AUS6 had both CMM and 
cervical cancer. The p.M5I missense mutation occurred in a sporadic melanoma case, with bilateral 
ovarian cancer at 77 years, and meningioma aged 78. Two ACD p.A200T carriers had CMM and 
prostate cancer and two other carriers had MPM. Finally, a carrier of the ACD p.I322F mutation in 
family AUS5 had MPM. Taken together, these data are strongly suggestive that mutations in ACD 
and TERF2IP are associated with early onset CMM, and MPM, and may predispose to a broader 
spectrum of cancers than just melanoma. Limitations of this study are that numbers of these other 
tumour types are too low to determine whether they are robustly associated with germline mutations 
in ACD and TERF2IP and that tumour blocks were not available on these cancers, or melanomas, to 
determine whether loss of heterozygosity is required for tumorigenesis. 
In summary, the loss-of-function mutations we report here in ACD and TERF2IP, along with those 
previously published in POT1, suggest that multiple components of the shelterin complex play a 
role in melanoma predisposition. Collectively, mutations in ACD, TERF2IP and POT1 account for 
~9% (12/132) of high-density melanoma families (≥ 3 CMM cases) lacking mutations in CDKN2A, 
CDK4, TERT and BAP1. Given that the shelterin complex directly interacts with the product of 
TERT, a recently reported melanoma predisposition gene, the evidence we document here indicates 
that dysregulated telomere maintenance is a key pathway controlling melanoma development. 
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Table 1: Germline mutations in the ACD and TERF2IP genes identified in melanoma families by exome sequencing 
Family 
ID Chr Start§ Gene 
cDNA 
change mRNA refSeq 
Protein 
change 
cases 
in 
family 
Genotyped 
cases who 
are 
carriers^ 
VAF 
ESP6500~ 
Polyphen2 
prediction† 
SIFT 
prediction† GERP++ 
AUS1 16 67692665 ACD c.958C>T NM_001082486 p.Q320X 5 4/4 0 (truncating) (truncating) 2.28 
AUS2 16 67693137 ACD c.746A>G NM_001082486 p.N249S 5 7/7 3/8597 benign tolerated -9.69 
DK1 16 67693137 ACD c.746A>G NM_001082486 p.N249S 4 3/4 3/8597 benign tolerated -9.69 
AUS3 16 67692920 ACD c.814G>A NM_001082486 p.V272M 3 2/2 0 probably damaging damaging 3.44 
AUS4 16 67693513 ACD c.598G>A NM_001082486 p.A200T 6 4/6 0 probably damaging damaging 3.4 
AUS5 16 67692659 ACD c.964A>T NM_001082486 p.I322F 5 3/4 0 possibly damaging damaging 0.87 
UK1 16 75690399 TERF2IP c.1090C>T NM_018975 p.R364X 4 3/3 0 (truncating) (truncating) 4.88 
AUS6 16 75682352 TERF2IP c.572A>G NM_018975 p.Q191R 2 2/2 0 benign tolerated 4.62 
SE1 16 75681808 TERF2IP c.28G>C NM_018975 p.D10H 5 1/3 0 probably damaging damaging 5.75 
AUS7 16 75681795 TERF2IP c.15G>A NM_018975 p.M5I 1 1/1 0 benign damaging 2.55 
 
§ genome build GRCh37, hg19 
^ includes obligate carriers 
~European American population 
†effect of nonsense mutations not predicted by either Polyphen2 or SIFT are annotated as truncating 
GERP++ is an estimate of the constrained elements in the human genome 
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Figure 1: Mutations in ACD and TERF2IP that segregate with melanoma. The age at first diagnosis of cutaneous malignant melanoma (CMM) is 
indicated in brackets. If the individual has had more than one primary melanoma the first age at onset is annotated and the total number of CMM is 
given. A line through a symbol indicates the individual is deceased. Individuals carrying a mutation are indicated by ‘M’, while family members that 
are wild-type for the indicated variant are annotated ‘WT’. ‘(M)’ indicates as individual is an obligate carrier. Square symbols indicate males and 
circles females. Black symbols represent confirmed CMM cases and grey symbols unconfirmed cases. Symbols with a central black circle represent 
individuals with a confirmed cancer other than CMM. Those family members with other unconfirmed cancers are indicated by symbols containing a 
central grey circle. Unaffected siblings are indicated by a diamond with the number of siblings shown in the centre of the symbol. 
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Figure 2: Relative location of germline variants in melanoma cases with respect to ACD and TERF2IP protein domains (a) and conservation 
of ACD and TERF2IP variants in melanoma families across placental mammals (b) and spanning species clades (c). 
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Supplementary results 
 
Novel mutations were also observed in TERF1, TERF2 and TINF2, encoding the three other 
members of the shelterin complex studied here (Supplementary Table 8). The main role of TERF1, 
telomeric repeat-binding factor 1 (also known as TRF1), and TERF2, telomeric repeat-binding 
factor 2 (also known as TRF2), is to bind telomeric double-stranded DNA (dsDNA) and thus 
mediate recruitment of different factors to telomeres1,2. These subunits directly recognise the 
telomeric repeat motif and bind using a DNA-binding Myb domain3-5. Each of these proteins also 
contains a TRFH domain (Supplementary Fig. 4) that allows homodimerization6. A TERF1 variant 
(p.A105P) was found in the only individual available for testing from a three-case family; this 
individual presented with MPM and thyroid cancer (Supplementary Fig. 2b). Two mutations were 
discovered in TERF2. A p.S119C substitution occurred in the TRFH domain in both affected 
members of a two-case family (Supplementary Fig. 2b). A p.S379C variant was observed in three of 
five confirmed cases in an Australian family. One individual had MPM and a second CMM case 
had lung and unconfirmed cervical cancer (Supplementary Fig. 2b). This mutation in TERF2 occurs 
at a highly conserved amino acid residue across species (Supplementary Fig. 5a,b) and is predicted 
to be damaging/probably damaging by Polyphen2 and SIFT analysis (Supplementary Table 8). Two 
variants could be mapped on a known protein structure: TERF1 p.A105P and TERF2 p.S119C 
(Supplementary Fig. 6a). Both mutations are predicted to destabilize the protein structure with 
putative disruption of binding sites. Specifically, p.A105P occurs in an alpha helix, the variant 
residue being unfavoured for this structural motif7. Importantly, alpha helix 2 (p.A105P) is one of 
the three critical alpha helices that constitute the binding interface for homodimerisation6. 
Therefore, this model suggests that the variant impairs the homodimerization of the protein. 
Furthermore the variant p.S119C in TERF2 affects the putative binding interface of this molecule 
with TINF28
Finally, a single novel variant was found in TINF2 (p.V22L) in one member of a two-case family 
(Supplementary Fig. 2b). TINF2, 
. As shown in Supplementary Fig. 6b, this residue interacts with two tightly packed 
water molecules which are important in the structure of the TINF2-binding loop. A mutation of this 
residue to cysteine, while being conservative, is expected to disrupt this arrangement for sterical 
reasons. This geometrical constrainment suggests that the binding interface would be disrupted. 
TERF1-interacting nuclear factor 2 (also known as TIN2), 
interacts with the TERF1-TERF2 dsDNA binding complex. TINF2 is at the centre of the complex, 
tethering the ACD-POT1 partnership to TERF1 and TERF2. It is crucial for the assembly of the 
shelterin complex as it is the only mechanism available for TERF1 to interact with TERF29-13. 
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To further assess the association between TERF1, TERF2 and TINF2 gene variants and familial 
melanoma susceptibility we searched for variants in these genes in exome data from a similar 
population of control individuals in the UK10K sequencing project (http://www.uk10k.org). After 
filtering for such variants in data from 520 exomes in a similar manner to that used for the CMM 
families (see Online Methods) we identified a total of six non-synonymous variants in these three 
genes (Supplementary Table 6). Two novel variants occurred each in TERF1 and TERF2, one of 
which (TERF2 p.S119C) was identical to a variant found in a CMM family (Supplementary Table 
8). Additionally, two rare variants were found in TINF2: p.G25A and p.S208P, which have been 
seen in 1/4133 and 15/4144 individuals of European descent in the ESP database, respectively.  
Similar analysis of these three genes in sequence data from 2000 Danish control exomes revealed a 
total of 17 rare (N=7) or novel (N=10) variants (summarized in Supplementary Table 7).  
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Supplementary Table 1: Total number of families exome or genome sequenced, broken down by 
research centre and the number of cases sequenced in each centre. 
 
Origin of family Number of families sequenced 
Number of 
melanoma cases 
sequenced 
Brisbane 33 96 
Copenhagen 7 13 
Leeds 62 70 
Leiden 3 9 
Lund 4 9 
Sydney 4 7 
Total: 113 204 
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Supplementary Table 2: Summary information for individual’s exome or genome sequenced. 
Family 
ID 
CMM 
cases in 
family # 
N cases 
sequenced 
in family 
Sample 
ID 
Exome 
or 
genome 
Ages of onset of CMM 
(years) Other cancers (age in years) 
AUS7 1 1 001 genome 62 bilateral ovary (77), meningioma (78) 
AUS12 6 3 007 exome 29, 29  
AUS12 6 3 009 genome 53, 63, 64, 64, 66, 66, 68  
AUS12 6 3 010 exome 30, 32, 34, 38, 38  
AUS13 9 3 002 exome 54, 54, 60  
AUS13 9 3 007 exome 55, 65, 67, 73, 73, 73 prostate (79), bowel (83) 
AUS13 9 3 058 exome 68, 77, 83, 83  
AUS14 5 3 006 exome 30  
AUS14 5 3 008 exome 22  
AUS14 5 3 010 exome 47  
AUS15 8 3 001 exome 55, 56, 62  
AUS15 8 3 003 genome* 61, 64, 69, 76, 76, 76, 76  
AUS15 8 3 004 exome 22  
AUS16 8 3 006 genome* 23, 45  
AUS16 8 3 011 exome 30, 33  
AUS16 8 3 015 exome 44  
AUS1 5 3 002 exome 39, 57  
AUS1 5 3 005 exome 29  
AUS1 5 3 006 exome 25  
AUS10 5 3 002 exome 78, 79  
AUS10 5 3 007 exome 65  
AUS10 5 3 010 exome 53 lung (60) 
AUS17 8 4 002 exome 57, 75  
AUS17 8 4 007 exome 59, 60  
AUS17 8 4 009 exome 34  
AUS18 6 3 001 exome 47, 59, 61, 64, 74, 77  
AUS18 6 3 003 exome 34  
AUS18 6 3 004 exome 20  
AUS4 6 4 001 exome 34  
AUS4 6 4 004 exome 14  
AUS4 6 4 005 exome 74, 74  
AUS4 6 4 016 exome 59 prostate (69) 
AUS19 4 1 007 exome 27, 27, 27, 27, 28, 28, 30  
AUS20 5 3 001 exome 50, 52, 58, 66, 68, 74, 76, 77, 77 prostate (71) 
AUS20 5 3 003 genome* 55, 55 bladder (58), leukaemia (76), lung (77) 
AUS20 5 3 004 exome 45, 45, 60, 71 prostate (69) 
AUS21 8 3 001 exome 47  
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AUS21 8 3 009 exome 
41, 42, 44, 47, 50, 50, 
53, 54, 58, 61, 63, 65, 
66, 66, 66, 66, 67, 67, 
68, 68, 68 
 
AUS21 8 3 015 exome 42, 42, 57, 62, 62, 62, 64, 64, 65, 65, 65  
AUS22 3 3 002 exome 59  
AUS22 3 3 004 exome 51, 51, 55, 60, 67, 69, 71, 72  
AUS22 3 3 005 exome 18, 47, 71, 71, 71, 71, 71, 71, 76, 76, 76  
AUS23 3 3 002 exome 53  
AUS23 3 3 003 genome 61 lymphoma (70), prostate (71), bowel (81) 
AUS23 3 3 012 exome 37  
AUS24 9 4 001 exome 41, 69  
AUS24 9 4 003 exome 29  
AUS24 9 4 007 exome 14  
AUS24 9 4 016 exome 58  
AUS25 5 2 002 exome 43  
AUS25 5 2 007 exome 46, 69  
AUS26 5 3 001 exome 27, 31  
AUS26 5 3 003 exome 62, 74  
AUS26 5 3 005 exome 14, 14  
AUS27 6 2 002 exome 16  
AUS27 6 2 004 exome 60  
AUS28 8 3 002 exome 37, 55  
AUS28 8 3 003 genome 46, 36  
AUS28 8 3 020 exome 38,  38  
AUS29 4 2 005 exome 73 kidney, bladder 
AUS29 4 2 006 exome 76 colon (71) 
AUS30 6 4 004 exome 32  
AUS30 6 4 007 exome 55  
AUS30 6 4 008 exome 48 cervix (46) 
AUS30 6 4 016 exome 17  
AUS31 6 4 001 exome 65  
AUS31 6 4 004 exome 79, 79  
AUS31 6 4 008 exome 49  
AUS31 6 4 009 exome 41  
AUS32 4 2 001 genome 
54, 60, 71, 73, 73, 73, 74 
(+22 others before 
compulsory records) 
prostate (74) 
AUS32 4 2 004 exome 84  
AUS2 5 3 001 genome 58, 59  
AUS2 5 3 005 exome 35 lung (68) 
AUS2 5 3 009 exome 26  
AUS33 6 4 001 exome 47 breast (46) 
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AUS33 6 4 004 exome 57  
AUS33 6 4 006 exome 54  
AUS33 6 4 013 exome 43  
AUS34 6 4 001 genome 31, 31 breast (58) 
AUS34 6 4 002 exome 19, 33, 37, 47, 48, 53 bilateral breast (51) 
AUS34 6 4 003 exome 36  
AUS34 6 4 004 exome 19, 26, 26, 44, 44  
AUS35 4 2 001 genome 61 breast (79), lung (79) 
AUS35 4 2 002 exome 58  
AUS36 11 2 003 exome 26, 27  
AUS36 11 2 014 genome 79, 79 kidney (70), bladder (80) 
AUS37 3 2 002 exome 70 lung (75) 
AUS37 3 2 003 genome 69 prostate (79), oesophagus (89) 
AUS5 5 3 001 genome 57, 59, 61, 77  
AUS5 5 3 002 exome 30  
AUS5 5 3 013 exome 46  
AUS38 17 5 001 exome 23, 33, 48, 52, 52  
AUS38 17 5 007 exome 24  
AUS38 17 5 008 exome 34  
AUS38 17 5 011 exome 23  
AUS38 17 5 022 exome 38  
SE1 5 3 564 exome 77  
SE1 5 3 615 exome 52  
SE1 5 3 648 exome 31  
SE2 3 2 396 exome 47  
SE2 3 2 641 exome 29  
SE3 3 2 638 exome 78  
SE3 3 2 700 exome 72 (multiple)  
SE4 3 2 56 exome <35  
SE4 3 2 64 exome <30  
DK2 3 2 110736 exome 53 cervical CIS (38), uterus (75) 
DK2 3 2 210949 exome 40  
DK3 3 1 200564 exome 28  
DK4 3 2 070650 exome 56  
DK4 3 2 090146 exome 63  
DK5 3 2 020946 exome 60  
DK5 3 2 160655 exome 53  
DK6 4 2 270550 exome 53, 55  
DK6 4 2 280944 exome 55  
DK1 3 2 020830 exome 76,80 large diffuse B cell lymphoma (82) 
DK1 3 2 221143 exome 42,52,59  
DK7 4 2 130948 exome 55  
DK7 4 2 200450 exome 54  
AUS39 8 1 1067 genome* 58, 79, 88, 89 Wilms' tumour (53) 
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AUS40 3 1 2835 exome 20  
AUS41 8 3 2669 genome* 57  
AUS41 8 3 2673 exome 25  
AUS41 8 3 2680 exome 41  
AUS42 5 3 1762 exome 24  
AUS42 5 3 1764 genome* 28  
NL1 4 3 3 exome 41  
NL1 4 3 10 exome 44  
NL1 4 3 8 exome 24  
NL2 4 2 1 exome 61  
NL2 4 2 8 exome 45  
NL3 5 4 1 exome 71 breast (66) 
NL3 5 4 3 exome 56 brain (53) 
NL3 5 4 5 exome 71  
NL3 5 4 12 exome 24  
UK2 3 3 2024F exome 68  
UK2 3 3 4353F exome 62, 62, 63  
UK2 3 3 4354F exome 35  
UK3 4 1 2033F exome 18  
UK4 4 1 2114F exome 44 cervix (26) 
UK5 4 1 2141F exome 42  
UK6 4 2 2177F exome 36  
UK6 4 2 2176F exome 36  
UK7 8 2 18646F exome 54  
UK7 8 2 2213F exome 21  
UK8 4 2 2453F exome 72  
UK8 4 2 2388F exome 49  
UK9 6 1 973F exome 47, 48  
UK10 5 1 324F exome 21  
UK11 6 2 1778F exome 31 bladder (46) 
UK11 6 2 1771F exome 27  
UK12 5 1 2506F exome 57  
UK13 3 2 1795F exome 80, 81  
UK13 3 2 1792F exome 41  
UK14 2 1 1326F exome** 28, 32  
UK15 4 1 1814F exome** 39, 52  
UK16 3 1 1952F exome** 30  
UK17 3 1 2140F exome** 35, 44  
UK18 3 1 2172F exome** 9, 41  
UK19 3 1 2191F exome** 41  
UK20 3 1 2143F exome** 45, 45  
UK1 4 1 65F exome 43  
UK21 3 1 2314F exome** 37, 38, 38  
UK22 2 1 2289F exome** 24, 34, 34  
137 
 
UK23 3 1 2304F exome** 17  
UK24 2 1 2394F exome** 59, 69, 72, 74  
UK25 3 1 2417F exome** 32, 54, 54  
UK26 2 1 2402F exome** 41, 42, 50, 51, 53  
UK27 3 1 2406F exome** 50  
UK28 3 1 2507F exome** 47  
UK29 2 1 2330F exome** 45, 68, 68, 68 breast (71) 
UK30 5 1 1485F exome 34, 34, 34, 38  
UK31 3 1 99F exome** 55, 56, 56, 70  
UK32 2 1 1290F exome** 49, 58, 58, 58  
UK33 2 1 788F exome** 45, 45, 45  
UK34 2 1 986F exome** 23, 30, 44  
UK35 2 1 1476F exome** 44, 50, 51, 64, 64, 65  
UK36 3 1 1561F exome** 59, 66 prostate (67) 
UK37 2 1 1687F exome** 39, 46, 50  
UK38 4 1 1819F exome 50, 54 breast (52) 
UK39 4 1 1823F exome 42  
UK40 4 2 1892F exome 36  
UK40 4 2 1893F exome 38  
UK41 4 1 1894F exome 34  
UK42 5 1 2029F exome 57  
UK43 1 1 CT0024 exome** 39  
UK44 1 1 CT0177 exome** 40  
UK45 1 1 CT1241 exome** 75, 80  
UK46 1 1 CT1406 exome** 31  
UK47 1 1 CT1746 exome** 38  
UK48 1 1 CT1912 exome** 40  
UK49 1 1 CT3775 exome** 65, 67  
UK50 1 1 CT3761 exome** 63, 74  
UK51 1 1 CT0155 exome** 38  
UK52 1 1 CT4128 exome** 58, 58  
UK53 1 1 CT0673 exome** 38  
UK54 1 1 CT0861 exome** 33  
UK55 1 1 CT1036 exome** 40  
UK56 2 1 CT1643 exome** 28  
UK57 2 1 CT1163 exome** 57  
UK58 2 1 CT1204 exome** 68  
UK59 2 1 CT1927 exome** 45  
UK60 2 1 CT2996 exome** 67  
UK61 2 1 CT0598 exome** 34  
UK62 1 1 CT1687 exome** 33  
 
#confirmed cases only; *done by Complete Genomics; **done by Beijing Genomics Institute  
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Supplementary Table 3: Summary information for targeted pull down samples. 
Proband ID CMM cases in family # Ages of onset of CMM (years) 
000045 2 39 
000085 2 57 
000121 2 36 
000122 2 56 
000147 2 36 
000178 2 46, 62 
000246 1 50 
000336 2 38 
000371 2 57 
000461 2 65, 67, 67, 75 
000578 2 29 
000602 2 20 
000786 2 53 
000906 2 21 
000970 2 59 
000971 2 53, 70 
001032 2 26, 28, 41 
001077 2 62 
001093 2 41 
001142 2 56 
001285 2 58 
001375 2 68, 76 
001399 2 36 
001458 2 63 
001599 2 48 
001669 2 55 
001746 2 52 
001872 2 55 
001891 2 44 
001918 2 46 
001968 3 36 
001971 2 33 
002012 2 48 
002135 2 46 
002145 2 32 
002214 2 66, 71 
002274 2 37 
002295 3 41 
002458 2 41 
002527 2 68 
002591 2 68, 73 
002676 2 58 
002703 2 66, 72 
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002771 2 35 
002810 2 40 
002832 3 63 
002860 2 57, 59, 61, 77 
002869 2 38, 53 
002918 2 66 
002948 2 65 
002967 2 61, 70, 83, 84 
003055 2 26 
003057 2 64, 70, 79, 81 
003091 2 55 
003153 2 53, 74 
003167 2 17 
003173 2 61 
003190 2 55 
003254 2 58, 76, 82 
003267 2 28 
003402 2 63 
003412 2 59 
003451 2 26, 38 
003611 2 44, 56 
003655 2 51 
003723 3 54 
003741 2 40 
003754 2 39 
003771 2 31 
004169 2 29, 32 
004278 2 48 
004279 2 47, 48, 57 
004288 2 65 
004307 3 52 
004359 2 33 
004497 2 45, 48 
004604 2 64, 68 
004874 2 54 
004963 2 30 
004966 2 19 
004970 2 75, 85, 85, 85, 89 
004974 2 54, 59, 63, 67, 69, 70 
005036 2 56 
005048 2 56, 57 
005055 2 35 
005116 2 25 
005177 2 69, 87 
005223 2 34 
005247 2 50 
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005429 2 28 
005510 2 71, 78, 87 
005577 2 52 
005638 2 69 
005651 2 64 
005711 2 24 
005814 2 73, 73 
005851 2 55 
005899 2 35, 54 
005910 2 33 
005921 2 54 
005929 2 62 
005939 2 46 
006096 2 61 
006120 2 51, 55 
006122 2 33, 37 
006126 2 61, 65, 65 
006128 2 71 
006180 2 36 
006190 2 64 
006202 2 31 
006270 2 35 
006281 2 24 
006349 1 27 
006416 3 56 
006487 3 62, 76 
006648 2 66 
006649 3 50, 63, 66 
006686 2 69 
006713 2 48 
006865 2 50 
006915 2 75 
006945 2 57 
007005 2 34 
007099 2 56, 66 
007137 2 51 
007178 2 74 
007303 2 40 
007311 2 23 
007319 2 40, 41 
007321 1 63 
007325 2 63 
007346 2 56 
007356 2 41 
007373 2 36 
007376 2 49 
141 
 
007415 2 52 
007444 2 64 
007579 2 59 
008047 2 75 
008136 2 50, 53 
008191 2 38 
008224 2 61 
008245 2 42 
008290 2 49 
008654 2 48, 55, 64 
008779 4 38 
008856 2 19 
008876 2 24 
008891 2 64 
008972 2 73 
009005 2 53, 62, 63 
009161 2 61 
009171 3 14 
009198 2 41 
009237 2 65 
009254 2 14 
009341 2 37 
009386 2 50 
009494 2 50 
009522 2 35 
009537 2 18, 32 
009547 2 48 
009626 2 57 
009644 2 67 
009650 2 29 
009760 2 28 
009782 2 52 
009787 2 63 
009811 3 57 
009815 2 74, 75, 87, 87 
009818 2 27 
009828 2 62 
009864 2 24 
009909 2 64 
009912 3 38 
009965 1 43 
010069 2 62, 78 
010129 1 18 
010133 4 12 
010156 2 45, 45, 59 
010187 2 38 
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010213 2 58 
010274 2 66 
010284 2 12 
010335 3 48, 58 
010357 3 65, 65, 83 
010373 2 55, 72 
010408 2 60 
010441 2 27 
010448 2 54 
010471 3 29, 42 
010482 3 54 
010587 2 51, 58 
010709 2 53 
010867 2 82, 82, 87 
011093 2 67 
011115 2 46, 47 
011132 2 35 
011321 2 25 
011351 2 50 
011428 2 76 
011437 1 44 
011453 2 36 
011488 2 32 
011571 2 46 
011630 2 76 
011661 2 19, 30 
011692 2 49, 54, 55, 56, 65 
011734 2 41, 48 
011746 2 34, 46 
011751 2 63 
011756 2 69, 78, 80, 83 
011802 2 59 
011809 2 34 
011848 2 46 
011880 2 67 
011893 2 66 
011905 2 27 
011954 2 36 
011971 2 61 
012081 2 34 
012086 2 32 
012150 2 62 
012152 2 32 
012182 2 50 
012283 2 58 
012319 2 56 
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012324 2 40 
012592 2 68 
012617 2 53 
012681 2 46 
012698 2 60 
012811 2 42 
012812 2 45, 49 
012828 2 50 
012878 2 43 
012883 2 44 
012982 2 60 
013014 2 51 
013023 2 76 
013049 2 44 
013148 2 43, 44 
013304 2 61 
013341 2 70, 70 
013362 2 39 
013398 2 42 
013434 2 39 
013438 3 37 
013447 2 67, 78 
013477 2 31 
013538 2 21 
013546 2 44 
013650 2 36, 40 
013674 2 26 
013685 2 40 
013698 2 52 
013809 2 28 
013811 2 53, 57, 61, 61, 62 
013829 2 53, 55 
013868 2 46, 46 
013900 2 48 
013910 2 33 
013917 2 63 
013921 2 55, 65 
013999 2 58 
014008 2 45 
014254 2 39 
014296 2 40 
014354 2 53, 53, 60, 60 
014359 2 65, 66 
014392 2 46 
014401 2 43 
014438 2 29 
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014465 2 34 
027982 3 53 
030713 3 66 
032327 3 72 
033751  2 19  
050193 2 41 
050251 2 56 
050261 2 52 
050280 2 58 
050314 2 57 
050339 2 24 
050383 2 39 
050400 2 61, 63 
050413 2 51 
050427 2 46 
050443 2 46 
050492 2 64 
050497 2 41 
050519 2 43 
050520 2 65 
050611 2 64 
050657 2 58 
050695 2 71, 75, 79, 83 
050731 2 45, 46 
050744 2 66 
050764 2 57 
050795 3 51 
050826 2 43 
050837 2 68 
050872 2 71 
050885 2 34 
050904 2 64 
050971 2 63, 64 
051009 2 39 
051016 3 50 
051047 2 65 
051061 2 35 
051101 2 31, 36 
051121 2 65 
051146 2 66 
051177 2 49 
051226 2 33 
051269 2 20 
051362 2 26, 26 
051412 2 40 
051457 2 53, 58, 63, 67 
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051484 2 62 
051502 2 71 
051506 2 49 
051522 2 54 
051538 2 66 
051550 2 34 
051594 2 60 
051600 2 66 
051656 2 64 
051662 2 53 
051680 2 62 
051802 2 55 
051820 2 45 
051824 2 40 
051836 2 68, 77, 80, 81, 82 
051839 2 34 
052037 2 68, 70, 79, 81, 82, 83 
052094 2 44 
052101 2 46, 46 
052104 2 45 
052116 2 50 
052193 2 30 
052242 2 26 
052260 2 38 
052280 2 47 
052313 2 69 
052364 2 41 
052447 2 70 
052448 2 46 
052465 2 44 
052499 2 67 
052507 2 62 
052708 3 16 
052730 2 59 
052749 2 52, 63 
052793 2 46 
052809 2 41 
052810 2 42 
052833 2 72 
AUS43-006 2 51 
AUS44-001 2 60 
AUS45-001 2 52 
AUS46-002 1 57 
AUS47-002 4 48 
AUS48-001 1 20 
AUS49-001 2 71 
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AUS50-001 2 76 
AUS51-001 2 62 
AUS52-001 1 45 
AUS53-001 1 61 
AUS54-008 3 29 
AUS55-001 2 43 
AUS56-001 2 67 
AUS57-001 1 47 
AUS58-001 2 57 
AUS59-002 2 68 
AUS60-001 2 43 
AUS70-001 2 54 
AUS71-001 1 44, 48, 48, 49, 49, 50, 50, 51, 52, 54, 54, 56 
AUS72-001 1 23, 25, 25, 25 
AUS73-001 2 61 
AUS74-001 2 53, 53, 60, 60, 60, 60 
AUS75-001 5 66, 69, 70, 70, 81 
AUS76-005 4 18, 47 
AUS77-001 6 51, 51 
AUS78-002 2 49 
AUS79-702 3 59, 59, 59 
AUS80-002 3 43, 45, 59 
AUS81-001 4 25 
AUS82-001 1 55 
AUS83-005 1 53 
AUS84-001 2 44 
AUS85-003 5 40 
AUS86-001 3 43 
AUS87-001 5 46, 47, 50, 52, 55, 55, 57, 58, 58, 64 
AUS88-001 4 44, 52, 67, 67 
AUS89-001 4 36 
AUS90-003 4 73, 74, 74 
 
 
#confirmed cases only
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Supplementary Table 4: Primers used in the Sanger sequencing and Sequenom MassArray genotyping. 
 
 Variant Forward primer Reverse primer Extension primer 
Sanger 
sequencing 
ACD A200T gtaaaacgacggccagtcttgttgcagggaggagaag attggacgaggtggactctg  
ACD N249S gtaaaacgacggccagtgcccccattaactaccctta ccaactcctcaccctgacat  
ACD I322F gtaaaacgacggccagtatgtcagggtgaggagttgg tgaggaactgggtgaggaag  
ACD V272M gtaaaacgacggccagtgcccccattaactaccctta ccaactcctcaccctgacat  
ACD Q320X gtaaaacgacggccagtatgtcagggtgaggagttgg tgaggaactgggtgaggaag  
TERF1 S119C gtaaaacgacggccagttgtcagtttcttgccactcg caatctctccccattgctgt  
TERF2 S379C gtaaaacgacggccagtccagccctcaaaaacaagag ctttccattcccactcatgc  
TERF2IP M5I gtaaaacgacggccagtcgacccaaaagtaaggagga gggcattttccttcacgtag  
TERF2IP D10H gtaaaacgacggccagtcgacccaaaagtaaggagga gggcattttccttcacgtag  
TERF2IP Q191R gtaaaacgacggccagtggacgacgtagccatcctta cagctacttgggaggctgaa  
TERF2IP R364X acttggatctatcaacagttacaca ttgaccaatgcctctctggt  
 TINF2 V22L gtaaaacgacggccagtttaaagctgagcgacccagt tgattcagggctttcaggac  
MassArray ACD N249S acgttggatgtctcttcctgtagggagcac acgttggatggatcactggtcaagctctac acctttcagagtccacctcgtcca 
LOH 
ACD A200T acgttggatgctcttcgtgacgattctgag acgttggatgaagcggtccacctggagata ccgaactcctccagccc 
ACD N249S acgttggatggttaggatcactggtcaagc acgttggatgtctcttcctgtagggagcac agagtccacctcgtcca 
ACD I322F acgttggatgctcaatgctgtgcatctctg acgttggatgaacctctccagtccccctta gcctagagagctcagaa 
ACD Q320X acgttggatgctcaatgctgtgcatctctg acgttggatgaacctctccagtccccctta tgcatctctgagaatgac 
TERF2 S379C acgttggatgaagcagattggtcttggagg acgttggatgatggtggcgctgaagcggc cagcgcaggcctcaact 
TERF2IP M5I acgttggatgttctagtagtgctcggcgtc acgttggatgacgaacagagtcgaggaatg gacatggcggaggcgat 
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Supplementary Table 5: ACD haplotype analysis. The table shows 112 markers detected in the region of ACD. The SNPs listed are consistent with a 
shared haplotype.  
rsID Position 41202-001 41202-007 41202-009 41202-021 221143 20830 100132 Shared haplotype 
Reference 
allele freq. 
rs12918121 67187795 GG GG GG GG GG GG GG G 0.980 
rs13312727 67188443 AA AA AA AA AA AA AC A 0.970 
rs13312723 67191696 GG GG GG GG GG GG GG G 0.970 
rs11642409 67203777 CC CC CC CC CC CC CC C 0.990 
rs2233456 67207962 GG GG GG GG GG GG -- G 0.990 
rs8057598 67209255 AA AA AA AA AA AA AG A 0.940 
rs13339140 67213923 GG GG GG GG GG GG GG G 0.940 
rs868213 67220457 AA AA AA AA AA AA AG A 0.940 
rs2346676 67223803 AA AA AA AA AA AA AG A 0.940 
rs3729639 67225501 GG GG GG GG GG GG AG G 0.940 
rs3730393 67226405 GG GG GG GG GG GG GG G 0.970 
rs3730397 67228128 GG GG GG GG GG GG GG G 0.980 
rs3730403 67229486 AA AA AA AA AA AA AA A 0.980 
rs3730406 67230422 AG GG GG GG GG GG GG G 0.930 
rs11700 67232684 AA AA AA AA AA AA AG A 0.940 
rs12923138 67233266 AC AA AC AA AA AA AC A 0.550 
rs8058861 67234134 AA AA AA AA AA AA AG A 0.940 
rs12051247 67241282 GG GG GG GG GG GG AG G 0.940 
rs13338846 67247444 AA AA AA AA AA AA AA A 0.980 
rs13338688 67248831 GG GG GG GG GG GG AG G 0.940 
rs8049470 67250226 GG GG GG GG GG GG GG G 0.990 
rs7193713 67254419 AA AA AA AA AA AA AG A 0.940 
rs7196793 67259567 CC CC CC CC CC CC AC C 0.960 
rs6499118 67265360 CC CC CC CC CC CC AC C 0.940 
rs28730536 67266617 GG GG GG GG GG GG AG G 0.960 
rs13330273 67271106 AA AA AA AA AA AA AG A 0.960 
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rs16957265 67272377 AA AA AA AA AA AA AA A 0.970 
rs12922483 67282234 AA AA AA AA AA AA AA A 0.960 
rs12447443 67295020 GG GG GG GG GG GG GG G 0.990 
rs1061356 67304915 AA AA AA AA AA AA AG A 0.960 
rs7186310 67305513 AA AA AA AA AA AA AC A 0.890 
rs8050745 67311767 GG GG GG GG GG GG AG G 0.930 
rs11860295 67316234 GG GG GG GG GG GG AG G 0.930 
rs7200919 67316600 AG GG AG GG GG GG AG G 0.560 
rs8044843 67318242 AA AA AA AA AA AA AG A 0.900 
rs3868142 67320223 GG GG GG GG GG GG AG G 0.930 
rs785029 67320920 GG GG GG GG GG GG GG G 0.940 
rs9922130 67323664 AA AA AA AA AA AA AG A 0.960 
rs16957304 67334969 AA AA AA AA AA AA AA A 0.960 
rs10852437 67338497 AA AA AA AA AA AA AG A 0.960 
rs4783754 67358816 GG GG GG GG GG GG GG G 0.910 
rs16942883 67387817 AA AA AA AA AA AA AA A 0.960 
rs11859352 67390448 AA AA AA AA AA AA AG A 0.900 
rs10500541 67392027 AA AA AA AA AA AA AG A 0.960 
rs16957358 67394541 AA AA AA AA AA AA AA A 0.960 
rs8052655 67409180 GG GG GG GG GG GG GG G 0.960 
rs6499127 67417003 AA AA AA AA AA AA AA A 0.960 
rs16957407 67418598 AA AA AA AA AA AA AA A 0.960 
rs8058996 67418860 GG GG GG GG GG GG GG G 0.999 
rs16957415 67418957 AA AA AA AA AA AA AA A 0.960 
rs8059226 67419025 CC CC CC CC CC CC CC C 0.999 
rs12920590 67420603 AG AG AG AA AA AA AA A 0.610 
rs2242140 67421798 AA AA AA AA AA AA AA A 0.970 
rs1053612 67423939 AA AA AA AA AA AA AG A 0.920 
rs11552319 67424122 GG GG GG GG GG GG GG G 0.960 
rs3785095 67426869 GG GG GG GG GG GG GG G 0.997 
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rs5479 67469733 CC CC CC CC CC CC CC C 0.960 
rs2279023 67478251 GG GG GG GG GG GG GG G 0.970 
rs9922624 67478976 GG GG GG GG GG GG GG G 0.930 
rs3892816 67499714 AA AA AA AA AA AA AA A 0.960 
rs8044652 67506247 GG GG GG GG GG GG GG G 0.950 
rs34702968 67509400 GG GG GG GG GG GG GG G 0.990 
rs13338993 67515312 AA AA AA AA AA AA AA A 0.930 
rs35079605 67517538 GG GG GG GG GG GG GG G 0.996 
rs13334182 67524024 GG GG GG GG GG GG GG G 0.950 
rs7196853 67560613 AA AA AA AA AA AA AG A 0.900 
rs1210978 67578396 GG GG GG GG GG GG GG G 0.960 
rs8054369 67587281 GG GG GG GG GG -- GG G 0.999 
rs9940960 67598274 AA AA AA AA AA AA AA A 0.999 
rs34523198 67607987 AA AA AA AA AA AA AA A 0.960 
rs28711261 67617186 AA AG AA AA AA AA AG A 0.870 
rs6499135 67625872 AC AC AC AC AA -- AC A 0.520 
rs17686899 67627635 CC AC CC CC CC CC CC C 0.950 
rs16957489 67651879 GG AG GG GG GG GG AG G 0.870 
rs7191281 67655133 AA AG AA AA AA AA AG A 0.870 
rs6499137 67671804 AA AC AA AA AA AA AC A 0.910 
rs34012739 67675969 AA AG AA AA AA AA AG A 0.840 
rs9972635 67682580 AA AA AA AA AA AA AA A 0.950 
rs14920 67691515 CC CC CC AC CC CC CC C 0.940 
ACD p.N249S 67693137          
rs35356834 67696365 GG GG GG GG GG GG GG G 0.960 
rs9927609 67699257 AA AA AA AA AA AA AA A 0.996 
rs7185559 67699734 GG GG GG GG GG GG GG G 0.996 
rs7187476 67699948 AA AG AA AA AA AA AG A 0.840 
rs12449157 67708897 AA AG AA AA AA AA AA A 0.840 
rs34895002 67709262 AG GG GG GG GG GG GG G 0.970 
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rs12927959 67727069 AG AA AG AG AA AA AA A 0.660 
rs4474673 67758778 GG AG GG GG GG GG GG G 0.880 
rs8051587 67796315 AA AC AA AA AA AA AA A 0.840 
rs6499141 67797134 AA AA AA AA AA AA AA A 0.960 
rs13335252 67808212 GG GG GG GG GG GG GG G 0.996 
rs8057184 67827247 GG GG GG GG AG AG GG G 0.820 
rs17619927 67834585 GG GG GG GG GG GG GG G 0.960 
rs12325430 67853425 AG AG AG AG AA AA AA A 0.510 
rs34693072 67861501 AA AA AA AA AA AA AA A 0.950 
rs3743733 67863451 AG AG AG AG AA AA AA A 0.510 
rs11558533 67865937 AA AA AA AA AA AA AA A 0.990 
rs11558534 67867739 CC CC CC CC CC CC CC C 0.960 
rs6499143 67874264 AA AG AA AA AA AA AA A 0.830 
rs3809630 67879400 GG AG GG GG GG GG GG G 0.870 
rs1113232 67879827 CC CC CC CC CC CC CC C 0.960 
rs28679372 67882932 AA AA AA AA AA AA AA A 0.960 
rs12930280 67891074 AA AA AA AA AA AA AA A 0.970 
rs1124324 67897487 GG AG GG GG GG GG GG G 0.870 
rs2271293 67902070 GG AG GG GG GG GG GG G 0.870 
rs34132524 67909150 GG GG GG GG GG GG GG G 0.920 
rs8060686 67911517 AA AG AA AA AA AA AA A 0.820 
rs12447425 67919535 GG GG GG GG GG GG GG G 0.990 
rs10468274 67922342 GG AG GG GG GG GG GG G 0.830 
rs7196789 67927124 GG AG GG GG GG GG GG G 0.830 
rs34298659 67927697 GG GG GG GG GG GG GG G 0.970 
rs16942887 67928042 GG AG GG GG GG GG GG G 0.870 
rs16957597 67946356 CC CC CC CC CC CC CC C 0.997 
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Supplementary Table 6: Rare (VAF < 0.01) germline variants in the shelterin complex identified in UK10K control exomes. 
Sample Chr Position Gene cDNA change mRNA refSeq 
Protein 
change 
VAF 
ESP6500~ 
dbSNP 
138 Polyphen2 SIFT GERP 
MUIR 
1523795 16 67694167 ACD c.215G>T NM_001082486 p.A72E 0 0 probably damaging damaging 1.04 
MUIR 
1523826 16 69391449 TERF2 c.1316T>C NM_005652* p.D439G 0 0 benign tolerated 5.29 
COLLIER 
5120586 16 69418607 TERF2 c.356G>C NM_005652* p.S119C 0 0 probably damaging damaging 5.52 
ABDN 
5050486 8 73921375 TERF1 c.254C>G NM_017489 p.S85C 0 0 probably damaging tolerated 4.08 
COLLIER 
5120685 8 73951369 TERF1 c.1058A>T NM_017489 p.E353V 0 0 benign tolerated -0.77 
MUIR 
1523793 14 24710064 TINF2 c.622A>G NM_001099274.1 p.S208P 1/8267 rs377436580 probably damaging damaging 4.02 
MUIR 
1523853 14 24711465 TINF2 c.74C>G NM_001099274.1 p.G25A 15/8303 rs202093758 benign tolerated 2.64 
 
*refers to canonical protein isoform Q15554-1 
~ European American population 
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Supplementary Table 7: Rare (VAF < 0.01) germline variants in the shelterin complex identified in 2000 Danish control exomes. 
Chr Position Gene cDNA change mRNA refSeq 
Protein 
change dbsnp137 
VAF 
ESP6500
~ 
VAF 1000 
Genomes 
VAF 
Danish PolyPhen2  Sift  GERP 
16 67691750 ACD c.1471C>A NM_001082486 p.P491T rs201441120 2/8598  0.001018 damaging damaging 3.27 
16 67691947 ACD c.1406G>A NM_001082486 p.R469Q rs200293827 1/8598  0.000509 benign tolerated -7.84 
16 67692017 ACD c.1336G>A NM_001082486 p.A446T    0.000509 
probably 
damaging tolerated 1.6 
16 67692121 ACD c.1232C>A NM_001082486 p.T411N    0.001272 benign tolerated 1.99 
16 67692631 ACD c.992G>A NM_001082486 p.R331K    0.000255 benign damaging 1.15 
16 67692863 ACD c.871A>G NM_001082486 p.T291A rs139438549 11/8589  0.000763 damaging damaging 4.61 
16 67693939 ACD c.367G>A NM_001082486 p.D123N rs142662151 6/8554  0.000255 
probably 
damaging tolerated 4.27 
16 67694044 ACD c.338G>A NM_001082486 p.R113Q rs142507451 14/8574 0.0005 0.001527 probably damaging tolerated -3.55 
16 67694102 ACD c.280G>A NM_001082486 p.V94I rs149365469 6/8584 0.0014 0.000255 probably damaging tolerated 2.64 
16 67694254 ACD c.128G>A NM_001082486 p.R43Q    0.000509 
probably 
damaging damaging -2.44 
16 67694333 ACD c.49G>A NM_001082486 p.A17T    0.001018 benign damaging 1.57 
16 67692855 ACD c.879G>A NM_001082486 p.W293X    0.000255 na na 4.61 
16 67693131 ACD c.751+1G>T NM_001082486     0.000255 na na  
8 73934512 TERF1 c.599T>C NM_017489 p.I200T    0.000255 
probably 
damaging damaging 4.29 
8 73944309 TERF1 c.980A>G NM_017489 p.Q327R    0.000255 benign tolerated 1.78 
8 73951417 TERF1 c.1106C>T NM_017489 p.P369L rs148824563 6/8592  0.000255 damaging tolerated -1.76 
16 69390938 TERF2 c.1492G>A NM_005652* p.E498K rs150757154 18/8582 0.0005 0.00229 probably damaging tolerated 5.26 
16 69395328 TERF2 c.1405G>A NM_005652* p.D469N    0.000255 
probably 
damaging tolerated 4.1 
16 69400902 TERF2 c.1148C>T NM_005652* p.P383L    0.000255 
probably 
damaging tolerated 4.53 
16 69401069 TERF2 c.981G>A NM_005652* p.M327I rs141046852 1/8599  0.000255 benign tolerated -0.479 
16 69404453 TERF2 c.773C>A NM_005652* p.T258N    0.000255 
probably 
damaging tolerated 0.697 
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14 24709052 TINF2 c.1307C>T NM_001099274 p.A436V rs369249473 1/8247  0.000255 benign tolerated -0.37 
14 24709502 TINF2 c.1096C>A NM_001099274 p.L366I    0.000255 
probably 
damaging tolerated -0.796 
14 24709724 TINF2 c.962G>C NM_001099274 p.R321T    0.000509 damaging damaging -0.995 
14 24709952 TINF2 c.734C>A NM_001099274 p.S245Y rs142777869 4/8304 0.0005 0.000255 benign damaging 0.481 
14 24710007 TINF2 c.679C>T NM_001099274 p.L227F    0.000255 benign tolerated -0.456 
14 24710064 TINF2 c.622T>C NM_001099274 p.S208P rs377436580 1/8267  0.000255 damaging damaging 3.94 
14 24711177 TINF2 c.216G>T NM_001099274 p.Q72H    0.000255 damaging damaging -2.44 
14 24711465 TINF2 c.74G>C NM_001099274 p.G25A rs202093758 15/8303  0.003053 
probably 
damaging tolerated 0.443 
14 24711179 TINF2 c.214C>T NM_001099274 p.Q72X    0.000255 na na 2.46 
 
*refers to canonical protein isoform Q15554-1 
~ European American population 
GERP++ is an estimate of the constrained elements in the human genome 
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Supplementary Table 8: Germline mutations in the TERF, TERF2 and TINF2 genes identified in melanoma families by exome sequencing.  
Family 
ID Chr Start§ Gene 
cDNA 
change 
mRNA 
refSeq 
Protein 
change 
Cases 
in 
family 
Genotyped 
cases who are 
carriers^ 
VAF 
ESP650
0 ~ 
Polyphen2 
† SIFT † GERP++ 
AUS8 8 73921434 TERF1 c.313G>C NM_017489 p.A105P 3 1/1 0 
probably 
damaging damaging 4.85 
AUS9 16 69418607 TERF2 c.356G>C NM_005652* p.S119C 2 2/2 0 
probably 
damaging damaging 5.52 
AUS10 16 69400788 TERF2 c.1136C>G NM_005652* p.S379C 5 3/5 0 
probably 
damaging damaging 5.09 
AUS11 14 24711475 TINF2 c.64C>G NM_001099274 p.V22L 2 1/2 0 
possibly 
damaging damaging 5.41 
 
§ genome build GRCh37, hg19 
* refers to canonical protein isoform Q15554-1 
^ includes obligate carriers 
~European American population 
†effect of nonsense mutations not predicted by either Polyphen2 or SIFT are annotated as truncating 
GERP++ is an estimate of the constrained elements in the human genome 
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Supplementary Table 9:  Histology of confirmed cancers in shelterin mutation-positive families  
Family 
ID ID carrier 
Year 
of 
birth 
Tumour 
verification 
Year of 
diagnosis 
CMM 
type CMM site 
Clark 
level 
Breslow 
Depth 
(mm) 
Other cancer Other cancer site 
AUS1 001 yes 1904 cancer registry 1994     myeloid leukemia, NOS bone marrow 
AUS1 002 yes 1926 histology of primary 1983 SSM right scapular I    
AUS1 002 yes 1926 histology of primary 1966 NOS upper arm II    
AUS1 003 yes 1928 histology of primary 1984 SSM face II 0.25   
AUS1 005 yes 1959 histology of primary 1989 NOS upper right arm II 0.51   
AUS1 006 yes 1969 histology of primary 1994 SSM upper right arm II 0.38   
AUS1 011 na 1955 histology of metastatic disease 1982 NOS 
right axillary 
lymph node na    
AUS1 703 na 1960 histology of primary 1972     gemistocytic astrocytoma frontal lobe 
AUS2 001 yes 1942 histology of primary 1999     
intraductal carcinoma 
noninfiltrating, NOS right breast 
AUS2 001 yes 1942 histology of primary 2000 NOS left lower leg I 0.3   
AUS2 005 yes 1940 histology of primary 2008     small cell carcinoma, NOS right lung 
AUS2 005 yes 1940 histology of metastatic disease 1975 
unknown 
primary NOS na    
AUS2 007 yes 1938 histology of primary 2002     non-small cell carcinoma left lung 
AUS2 007 yes 1938 histology of primary 2000 in situ back I    
AUS2 007 yes 1938 histology of primary 1993 NOS back II 0.3   
AUS2 009 yes 1959 histology of primary 1985 SSM leg III 0.56   
AUS2 010 na 1966 histology of primary 1997 NOS forehead II 0.5   
AUS2 010 na 1966 cancer registry 1987 NOS left scapular na    
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AUS2 010 na 1966 cancer registry 1987 NOS leg na    
AUS2 015 yes 1943 histology of primary 1994     
mucin-producing 
adenocarcinoma breast 
AUS2 021 yes 1971 histology of primary 2007 nodular right elbow II 0.5   
AUS2 804 na 1923 death certificate 1923     neoplasm lung 
AUS2 901 na 1894 death certificate 1961     malignant epithelial tumour prostate 
AUS3 001 yes 1925 histology of primary 1984 SSM back II 0.5   
AUS3 001 yes 1925 histology of primary 1995     adenocarcinoma colon 
AUS3 001 yes 1925 death certificate 1997     leukemia  
AUS3 002 yes 1923 clinical record 1979 SSM left forearm     
AUS3 002 yes 1923 histology of primary 1982     adenocarcinoma colon 
AUS3 701 na 1948 death certificate 1990     acute lymphoid leukemia  
AUS3 804 na 1927 histology of primary 1994 SSM 
right 
preauricular IIII 4   
AUS4 001 yes 1931 histology of primary 2003     adenocarcinoma,NOS prostate 
AUS4 001 yes 1931 histology of primary 1966 SSM right shoulder na    
AUS4 003 yes 1932 histology of primary 1968 NOS upper left arm III    
AUS4 003 yes 1932 histology of primary 2002 SSM upper left arm I    
AUS4 004 no 1967 histology of primary 1982 SSM left calf I    
AUS4 005 yes 1906 histology of primary 1994 
spindle 
cell right ankle IV 2.8   
AUS4 005 yes 1906 histology of primary 1991 NOS right calf III 1.65   
AUS4 006 no 1937 histology of primary 1988 SSM right scapular I    
AUS4 012 yes 1956 histology of primary 2012     B-cell lymphoma lymph node 
AUS4 016 yes 1932 histology of primary 2001     adenocarcinoma,NOS prostate 
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AUS4 016 yes 1932 histology of primary 1991 NOS left calf II 0.54   
AUS4 039 no 1935 histology of primary 2010 SSM 
upper back of 
left arm II 0.55   
AUS4 804 na 1903 death certificate 1980     neoplasm colon 
AUS5 001 yes 1926 histology of primary 2004 SSM forehead II 0.3   
AUS5 001 yes 1926 histology of primary 1986 SSM upper right arm II 0.4   
AUS5 001 yes 1926 histology of primary 1984 SSM left thigh II 0.74   
AUS5 001 yes 1926 histology of primary 1987 SSM right knee II 0.29   
AUS5 002 yes 1951 clinical record 1981 SSM NOS     
AUS5 007 yes 1939 histology of primary 1995 SSM right scapular I    
AUS5 010 na 1929 histology of primary 1996     fibroxanthoma ear 
AUS5 013 no 1957 histology of primary 2003 SSM left cheek III 1   
AUS5 020 na 1938 histology of primary 1982     adenocarcinoma rectum 
AUS5 020 na 1938 histology of primary 2012     adenocarcinoma prostate 
AUS5 601 na 1949 death certificate 2006     Burkitt lymphoma, NOS lymph node 
AUS5 602 na 1969 death certificate 2001     acute myeloid leukemia  
AUS5 701 na 1919 histology of metastatic disease 1992 SSM unknown     
AUS6 006281 yes 1961 
histology of 
primary 1985 SSM NOS III 0.2   
AUS6 006281 yes 1961 
histology of 
primary 2012     adenocarcinoma, in situ cervix 
AUS6 005682 yes 1969 
histology of 
primary 1984 SSM NOS III 0.3   
AUS6 005682 yes 1969 
histology of 
primary 1999     
squamous intraepithelial 
neoplasia grade III cervix 
AUS7 001 yes 1924 histology of primary 2005     transitional meningioma 
meninges, 
arachnoid 
AUS7 001 yes 1924 histology of primary 2001     
serous surface papillary 
carcinoma ovary 
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AUS7 001 yes 1924 histology of primary 1987 SSM left thigh III 0.35   
AUS8 006126 yes 1924 
histology of 
primary 1985 nodular face III 1.6   
AUS8 006126 yes 1924 
histology of 
primary 1989 LMM face II 0.42   
AUS8 006126 yes 1924 
histology of 
primary 1989 in situ back I 0   
AUS8 006126 yes 1924 
histology of 
primary 2003 LMM face II 0.9   
AUS8 006126 yes 1924 
histology of 
primary 2004     papillary adenocarcinoma thyroid 
AUS8 023818 no 1942 
histology of 
primary 2010 in situ anterior chest I    
AUS8 023818 no 1942 
histology of 
primary 1997     carcinoma, NOS left breast 
AUS8 023819 na 1944 
histology of 
primary 2008 LMM neck II 0.26   
AUS8 052712 na 1948 
histology of 
primary 1980 SSM lower limb II 0.25   
AUS8 052712 na 1948 
histology of 
primary 1980 SSM lower limb IIII 2.6   
AUS9 009262 yes 1918 
histology of 
primary 1987 SSM right ankle IIII 0.7   
AUS9 011115 yes 1942 
histology of 
primary 1988 SSM  III 1.8   
AUS9 029671 yes 1944 
histology of 
primary 2004     intraepithelial neoplasm prostate 
AUS10 001 yes 1900 histology of primary 1984 nodular left foot V 6.4   
AUS10 002 yes 1922 histology of primary 2001 in situ nose I    
AUS10 002 yes 1922 histology of primary 2001 SSM left leg I    
AUS10 003 yes 1927 histology of primary 2001     
infiltrating duct carcinoma, 
NOS right breast 
AUS10 007 no 1937 histology of primary 2003 LMM left shoulder II 0.73   
AUS10 010 yes 1951 histology of primary 2004 SSM left shoulder I    
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AUS10 010 yes 1951 histology of primary 2013     adenocarcinoma,NOS lung 
AUS10 701 no 1916 histology of primary 1982 SSM right calf IV 1   
AUS10 704 na 1936 histology of primary 1993     adenocarcinoma,NOS stomach 
AUS10 704 na 1936 histology of primary 1991     
infiltrating duct and lobular 
carcinoma left breast 
AUS10 704 na 1936 histology of primary 1987     
intraductal carcinoma 
noninfiltrating left breast 
AUS10 808 na 1911 death certificate 1993     carcinoma, metastaic, NOS pancreas 
AUS11 001 yes 1953 histology of primary 1984 SSM back III 0.55   
AUS11 001 yes 1953 histology of primary 2006     adenocarcinoma,NOS large bowel 
AUS11 002 no 1944 histology of primary 1989 nodular left forearm II 0.74   
UK1 65F yes 1947 statistics office 1990 SSM leg na na   
UK1 193F yes 1915 statistics office/ death certificate 1952 NOS na na na   
SE1 564 no 1920 histology of primary 1997       
SE1 614 no 1945 histology of primary 1985       
SE1 648 Yes 1954 histology of primary 1997       
DK1 1 yes 1943 histology of primary 1986 SSM left shoulder II    
DK1 1 yes 1943 histology of primary 2003 SSM knee II 0.34   
DK1 2 yes 1932 histology of primary 1992 SSM arm I    
DK1 3 yes 1930 histology of primary 2006 SSM knee     
DK1 3 yes 1930 histology of primary 2010 SSM calf II 0.33   
DK1 3 yes 1930 histology 2012     B-cell lymphoma, diffuse 
lumbal bone 
marrow 
DK1 4 no 1964 histology of primary 2013 in situ anterior chest I    
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DK1 5 na 1903 death certificate 1980     adenocarcinoma colon 
DK1 6 na 1938 histology of primary 2009     
adenocarcinoma and 
squamous carcinoma lung 
 
na is not available 
NOS is not otherwise specified 
SSM is superficial spreading melanoma 
LMM is lentigo maligna melanoma  
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Supplementary Figure 1: The shelterin complex. Telomeres consist of variable numbers of 
TTAGGG repeats with a single stranded telomeric 3’-tail. This 3’ tail has two key functions: 1) 
binding of the shelterin complex telomere specific proteins, which cap chromosome ends, 
promoting genome stability; 2) providing the primer for telomere extension by the telomerase 
complex. The shelterin complex consists of six proteins: TERF1 and TERF2, which form 
homodimers and anchor the complex to the double stranded DNA (dsDNA) telomere. POT1 
contains a single DNA binding domain, which is highly specific to the single stranded telomeric 3’-
tail and has the recognition sequence 5’-(T)TAGGGTTAG-3’. In the presence of the telomerase 
complex POT1 does not bind to the single stranded DNA overhang, resulting in telomere 
lengthening. TERF2IP binds exclusively to TERF2, augmenting its dsDNA binding capacity. 
TINF2 has a critical role in the shelterin complex, binding to dsDNA-interacting TERF1 and 
TERF2 homodimers and recruiting ACD to the complex. ACD binds to POT1.
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Supplementary Figure 2: Variants identified in ACD and TERF2IP that incompletely segregate with melanoma (A), and segregation analysis of 
variants identified in TINF2, TERF1 and TERF2 (B). Legend as for Figure 1.  
 
 
 
 
165 
 
 
 
 
 
 
Supplementary Figure 3: Relative location of germline variants in NHLBI Exome Sequencing Project, UK10K and Danish controls with respect to 
ACD and TERF2IP protein domains.  
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Supplementary Figure 4: Relative location of germline variants in melanoma families with respect to TERF1, TERF2 and TINF2 protein domains. 
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Supplementary Figure 5: Conservation of TERF1, TERF2 and TINF2 variants in melanoma families across placental mammals (A) and spanning 
species clades (B). 
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Supplementary Figure 6: Protein structural modelling. (a) Model structure from TERF1 bound to TINF2 (PDB id 3BU8) showing the predicted 
location of new variants. The model structure is shown in green, except for the TINF2-interacting loop, in blue. Variant residues are shown in grey. 
TINF2 is shown in orange. Two water molecules located in the interface between both proteins are displayed as red spheres. (b) Closer view of the 
interaction between TERF1 and TINF2 showing the Ser119 residue. 
A B 
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6.1 Relevance to thesis aims 
 
This chapter addresses Aim 1 of this thesis by detailing the prevalence of BAP1 mutation in an 
Australian population-based sample of uveal melanoma cases. To date, BAP1 is the only known 
UMM predisposition gene. The aim of the study was to determine the contribution of germline 
BAP1 mutation to an unselected sample of individuals with UMM. A group of 66 blood samples 
from UMM cases was genotyped for BAP1 mutation using Sanger sequencing methods. The project 
revealed that 2 out of 66 individuals harboured novel germline mutations in BAP1. The findings 
were published as a letter to the editor in Pigment Cell & Melanoma Research. This was the first 
published study to look at BAP1 in a sporadic sample of UMM cases to estimate its contribution to 
disease development. Germline BAP1 mutations are estimated to occur in 3% of population-based 
UMM cases. 
 
6.2 Contribution of candidate 
 
I was involved in the initial concept and study design which was carried out in conjunction with 
Nicholas Hayward. I performed all laboratory experiments including the primer design for the 17 
exons of BAP1, PCR, Sanger sequencing and analysis of chromatograms. I wrote the manuscript 
under the supervision of Nicholas Hayward. 
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6.3 Contribution of other authors 
 
The samples for this study were collected by Claire M. Vajdic, Anne Kricker, and Bruce 
Armstrong. These samples were originally collected as part of a study to better characterise UMM 
occurrence in Australia [132].  Nicholas Hayward contributed to the study concept and design and 
helped write and edit the manuscript. All authors read and approved of the manuscript. 
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Dear Editor,
In a seminal study by Harbour et al. (2010), somatic
mutations of BAP1 (BRCA-1 associated protein 1) were
found to occur in 84% of metastasizing uveal melanomas.
Additionally, this study reported one germline mutation.
Subsequent studies have shown that germline mutations
of BAP1 predispose to uveal and cutaneous melanoma as
well as mesothelioma and a range of other tumour types
(Abdel-Rahman et al., 2011; Testa et al., 2011; Wadt
et al., 2012). To date, there have been no studies
assessing the contribution of BAP1 mutation to a popu-
lation-based sample of uveal melanoma (UMM) cases,
although Tsao and co-workers have shown that BAP1
contributes to a small proportion of selected UMM cases
from a clinic-based sample (Njauw et al., 2012). Here, we
sought to determine the prevalence of germline BAP1
mutations in a population-based sample of Australian
UMM cases to gain a better understanding of the relative
contribution of BAP1 mutation to UMM susceptibility.
We examined 66 UMM cases unselected for family
history of UMM sampled from New South Wales, Austra-
lia. Individuals were eligible for inclusion in the study if they
were diagnosed with primary UMM at the age of 50 or
younger or if theywere diagnosedwith bilateral UMM. This
sample comprises 51 individualswith choroidalmelanoma,
five with melanoma of the ciliary body, seven that
presented with melanoma of the iris and three samples
of unknown site. UMM that presented on the conjunctiva
were excluded from the current study. Previous published
work showed that none of these individuals carries a
deleterious mutation of CDKN2A (Vajdic et al., 2003).
Sanger sequencing was used to interrogate the 17
exons of BAP1 for disease causing mutations. For
information detailing DNA extraction, PCR and Sanger
sequencing methods please refer to Supporting Informa-
tion Appendix S1 and Table S1. Sequencing results
showed that 2/66 sporadic UMM DNA samples har-
boured protein altering BAP1 mutations (see Figure S1).
One resulted in a frameshift in exon 13, p.D494fs, caused
by a two base pair deletion at c.1480_1481delGA. This
occurred in an individual with a primary tumour of the
ciliary body. The second mutation occurred in exon 14 at
c.1806g>c and resulted in a p.E602D substitution. The
individual harbouring this mutation had a tumour of the
choroid. SNPs have been reported in dbSNP occurring at
the same location as this variant. This however is a novel
protein change that has not been previously reported.
Although this is a conservative amino acid change and not
likely to truncate the protein through a cryptic exonic
splice site, it is located in the BRCA1 binding domain,
which may be functionally relevant and deleterious to
protein activity despite the fact that the amino acid
substitution seems conservative. A synonymous variant,
L334L (rs28997577), was found in the individual carrying
the E602D mutation. This occurs at low frequency in the
general population and is unlikely to be associated with
UMM risk in this person. Aside from variants found in the
coding region, there were also several other known SNPs
that were identified in intronic regions of the gene as well
as other unreported variants in intronic regions (see Table
S2). These were excluded from further consideration as
the reported SNPs occur in the general population, and
the other mutations are unlikely to be disease causing.
The overall outcome of our screening revealed that 2/
66 (3%) unselected UMM cases had novel mutations in
BAP1 that may have contributed to their disease risk. The
findings of our study are consistent with the data
published by Njauw et al. (2012), who found germline
BAP1 mutations in approximately 4% of the sporadic
UMM cohort screened in their study. These two studies
show remarkably consistent rates of BAP1 mutation in
sporadic UMM cases but also suggest that other genes
must be involved in the development of UMM because
BAP1 mutation accounts for susceptibility in only a very
small proportion of UMM cases. Further research into
identifying genes responsible for UMM predisposition is
needed.
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Figure S1: Novel germline BAP1 mutations 
In figure S1a, the top left panel shows the c.1480_1481delga (P494fs) and the bottom left shows the wild 
type trace. The top right panel of 1a shows the C.1806g>c mutation with the wild type trace directly below it. 
Figure 1b shows the truncating and missense mutations in relation to BAP1 protein domains. The figure is 
not drawn to scale. 
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A BAP1 mutation in a Danish family predisposes to uveal melanoma 
and other cancers 
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7.1 Relevance to thesis aims 
 
This chapter describes a Danish family with predominantly uveal melanoma but also a range of 
other tumour types, including lung, neuroendocrine, stomach and breast cancer, as well as 
pigmented skin lesions. There are a total of 7 UMM cases and one CMM case in the family 
presented. This study addresses Aims 2 and 3 of my thesis by determining the contribution of novel 
melanoma risk genes to UMM development in a high-risk UMM family.  
An exome sequencing approach identified a BAP1 splice mutation located at c.581-2A>G, which 
leads to a premature truncation of the protein in an individual with uveal melanoma. This mutation 
was carried by several other family members with UMM, CMM, breast cancer and lung cancer. The 
role of BAP1 as a tumour suppressor was also supported by LOH experiments which showed loss of 
the wild type allele in a carrier with UMM. This finding is consistent with other published reports 
of frameshift aberrations in mutation carriers. The finding expands on the growing profile of BAP1 
as an important uveal and cutaneous melanoma tumour suppressor gene and suggests its 
involvement in the development of lung, and stomach cancer. The literature describes germline 
mutations in BAP1 in relation to several forms of cancer including: UMM, CMM, mesothelioma 
and renal cell carcinoma, as well as benign melanocytic tumours [103-105, 107-111, 133, 134]. 
This report suggests the phenotype for germline BAP1 mutation carriers may extended even further 
into other cancer types.  
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Additionally, this study looked at the BAP1 splice variant in a case-control cohort to assess the 
possibility that this could contribute to predisposition in the general population (Aim 5). The results 
showed that this mutation is likely to be ‘private’ to the discovery family as it was not seen in the 
1,655 cases from the QFMP or the 1,596 controls genotyped. Overall, this study expands the role of 
BAP1 in cancer development and further describes its role as a high-risk predisposition gene for 
UMM development. 
 
7.2 Contribution of candidate 
 
I performed the exome data analysis and the Sanger sequencing validation of the variant. I also 
performed co-segregation analysis to determine whether the variant segregated with disease and 
whether it would be seen in family members with other cancer types. I genotyped the case-control 
sample using iPLEX chemistry to determine whether this variant occurred in any other probands. I 
wrote the manuscript with the guidance of Nicholas Hayward. 
 
7.3 Contribution of other authors 
 
Clinical data on the Danish family was collected by Karin Wadt. Samples were contributed by 
Anders Bojesen, Dorthe Crüger and Åke Borg. Göran Jönsson performed the RT-PCR, LOH 
analysis and contributed to the study design. Kevin M. Brown and Jeffrey M. Trent also contributed 
to the study design. Nicholas Hayward contributed to the concept and design of the study and 
helped write and edit the manuscript. All authors read and approved of the manuscript. 
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Abstract
Truncating germline mutations in the tumor suppressor gene BRCA-1 associated protein-1 (BAP1) have been reported in
families predisposed to developing a wide range of different cancer types including uveal melanoma and cutaneous
melanoma. There has also been an association between amelanotic tumor development and germline BAP1 mutation
suggesting a possible phenotypic characteristic of BAP1 mutation carriers. Though there have been many types of cancer
associated with germline BAP1 mutation, the full spectrum of disease association is yet to be ascertained. Here we describe
a Danish family with predominantly uveal melanoma but also a range of other tumor types including lung, neuroendocrine,
stomach, and breast cancer; as well as pigmented skin lesions. Whole-exome sequencing identified a BAP1 splice mutation
located at c.581-2A.G, which leads to a premature truncation of BAP1 in an individual with uveal melanoma. This mutation
was carried by several other family members with melanoma or various cancers. The finding expands on the growing profile
of BAP1 as an important uveal and cutaneous melanoma tumor suppressor gene and implicates its involvement in the
development of lung, and stomach cancer.
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Introduction
BRCA-1 associated protein-1 (BAP1) is a tumor suppressor gene
located on chromosome 3, a region that has been linked to uveal
melanoma (UMM). In the first report to make an association
between BAP1 and UMM Harbour and colleagues used a next-
generation sequencing approach to exome-sequence two tumors
from patients with metastatic UMM [1]. BAP1 was found to be the
only gene that was mutated on chromosome 3 in each of these
samples and both mutations led to truncation of the protein. They
next interrogated 57 UMM tumors using Sanger sequencing and
found that BAP1 mutations occurred predominantly in tumors that
had metastasized. Overall, 26/31 of the metastasizing (high risk)
tumors had inactivating BAP1 somatic mutations compared to
only 1/26 of the low risk (non-metastatic) group. For the 20
samples with a matched normal DNA sample, almost all BAP1
mutations were found to be acquired somatically, the exception
being a single case with a matching germline frameshift mutation.
This mutation introduced the possibility that BAP1 defects could
predispose to UMM. Leading on from the study by Harbour et.
al., several groups have looked at the risk of disease conferred by
germline BAP1 mutation. Testa and colleagues investigated BAP1
mutations in two American families presenting with mesothelioma
and who had no contact with any of the known environmental risk
factors for this disease [2]. They found two different frameshift
mutations in BAP1 responsible for the elevated risk of mesothe-
lioma in these individuals. Interestingly, these families also
presented with a range of cancers that included UMM and
cutaneous melanoma (CMM). A second study also supported these
findings by interrogating germline DNA from a family that
presented with mesothelioma, meningioma and UMM [3]. In this
family a nonsense mutation caused premature truncation of the
BAP1 protein in carriers. A report by Wiesner showed BAP1
mutations in two families that had an autosomal dominant
syndrome characterized by UMM, CMM and atypical benign
melanocytic nevi [4]. The two families presented with unique
frameshift mutations that co-segregated with the disease pheno-
type. In a follow up report, Wiesner and colleagues identified a
third family with a BAP1 mutation that co-segregated with
mesothelioma and also showed evidence of a melanocytic lesion
in a mutation carrier [5]. Other groups have also described BAP1
mutations in individuals presenting with atypical intradermal
tumors, proposing that these lesions may be a phenotypic
characteristic of BAP1 mutation carriers [6,7]. A recent study of
Portuguese siblings with a rare subtype of epithelioid mesotheli-
oma uncovered a germline BAP1 mutation as the possible cause of
the only known familial clustering of well-differentiated papillary
mesothelioma. Notably one of the siblings also developed UMM
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[8]. Recently a cryptic splice mutation in BAP1 was found to co-
segregate in a Danish family with UMM, paraganglioma and
atypical CMM [9]. BAP1 mutation has also been implicated in the
development of renal cell carcinoma and some of the relatives of
these cases have had UMM or CMM also [10]. As evidenced by
the literature, there is a large tumor spectrum that appears to
accompany BAP1 germline mutation.
In this paper we report a Danish family predisposed to
developing UMM predominantly but also presents with a wide
range of seemingly unrelated tumors. There are 7 family members
that have had UMM, with the youngest age of onset being 20.
One developed UMM at the age of 30 and later went on to
develop breast cancer at age 45. There is an individual with lung
cancer who had two children that developed melanoma, one
UMM and the other CMM. Another individual developed UMM
at the age of 69 and has two children that were diagnosed with
UMM at ages 27 and 41. There is a single instance of diffuse
infiltrating gastric cancer and this individual also had a child with
UMM, diagnosed at age 57. Finally, another case of UMM was
diagnosed at age 56. Refer to Figure 1 for a family pedigree which
identifies the cancer history of each individual.
Aside from the striking incidence of cancer, this family presents
with other clinical features that have become indications of BAP1
mutation. Four of the five individuals with UMM died of liver
metastasis derived from the UMM. Individual III:6, who was
diagnosed with UMM at age 20, had an isolated iris melanoma
and later developed three basal cell carcinomas. She is currently
61 years old and well. Individual III:8, with CMM diagnosed at 35
had a tumor localized in the occipital region, which most likely was
a primary CMM but metastasis could not be excluded. She died at
39 years of age with disseminated CMM.
Methods
Ethics Statement
Ethics approval for this project was granted by the Human
Research Ethics Committees of the Queensland Institute of
Medical Research and Lund University. Written consent was
obtained for each individual.
Samples
Whole blood was collected from disease affected individuals in
dense uveal melanoma families. Genomic DNA was extracted
using standard methods. DNA samples were then used for exome
and Sanger sequencing experiments.
Whole-Exome Sequencing
In order to find disease-associated variants, whole-exome
sequencing was carried out on key individuals representative of
the tumor burden in this family. Two UMM cases that were three
meioses apart (III:14 and III:17, Figure 1) were selected and
sequencing was carried out using an Illumina Hiseq 2000 and an
Illumina TruSeq Exome Enrichment Kit. The reads that were
generated were mapped to reference genome UCSC hg19 using
the BWA alignment algorithm [11]. SAMTOOLS was then used
to detect the SNPs and indels [12]. This process generates large
volumes of data and in order to sculpt the long list of resulting
variants into a manageable panel of variants several filtering
criteria were applied to the data set. Firstly, any variants that were
Figure 1. Co-segregation analysis of a BAP1 splice mutation in a Danish family. In the pedigree individuals that have uveal melanoma
(UMM) are represented by black circles (female) or boxes (male) and individuals with cutaneous melanoma (CMM) are indicated by grey circles or
boxes. The age of diagnosis of each melanoma is indicated in brackets. A line through a symbol indicates that the person is now deceased. If a person
carries the BAP1 splice mutation it is indicated by an ‘M’ and if they are wild type for this variant it is indicated with a ‘WT’. Where the mutation status
is indicated in brackets, the person is a presumed obligate carrier, ‘(M)’. Other cancer types are also indicated in the pedigree with the age of
diagnosis in brackets. Asterisks indicate the two individuals that were exome sequenced. Unaffected siblings are represented by diamonds, with the
number in the centre indicating the number of people.
doi:10.1371/journal.pone.0072144.g001
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seen in dbSNP (build 132) or reported by the 1000 Genomes
Project (February 2012) were filtered out, leaving only novel
variants for consideration. Secondly, synonymous changes were
removed, leaving only the protein-altering variants. A cut off of 40
was then applied to the quality score returned for each variant in
order to limit the false positive rate amongst the called variants. A
20% cut off was also applied to the number of alternate reads, that
is, if a variant did not have a high enough percentage of reads for
the alternate allele then it was removed from consideration. What
remained after this filtering process were 140 novel variants for
individual III:14 and 145 novel variants for individual III:17.
Exome data from these individuals may be made available for
research purposes upon request to the authors.
Exome-sequencing uncovered a BAP1 splice mutation, which
results in the premature truncation of the protein, in one (III:17) of
the two individuals and was seen as a likely candidate responsible
for UMM susceptibility due to the supporting literature. The result
was verified in the individual using Sanger sequencing (refer to
Figure 2). Following this, co-segregation analysis was carried out to
determine how well the variant segregated with disease in the
family and whether it was present in individuals with different
cancer types. Every available blood DNA sample from this family
was screened for the variant. For individual II:11 DNA was
obtained from tumor tissue. Additionally, a new blood sample was
obtained from individual III:14 since the initial sample did not
show presence of a germline BAP1 mutation. The second blood
sample was screened for the specific mutation in BAP1 using
Sanger sequencing.
RT-PCR
RT-PCR was performed on cDNA from one carrier (III:6) to
verify that the BAP1 mutation was indeed a splicing variant. RNA
was converted to cDNA using Superscript II (Life technologies)
and primers flanking the exons affected by the putative splice site
were designed. Subsequently, PCR products were run on an
acrylamide gel (refer to Figure 3).
Case-Control Genotyping
To more fully understand the role that this variant could play in
melanoma risk an Australian case-control sample was genotyped
for this novel variant. A Sequenom iPLEX was run on 1655
affected probands from families that had either CMM, UMM or a
combination of both, and 1596 controls. The sample set included
a wide cross-section of cases with varied histories of melanoma.
Some of the probands are from dense melanoma families while
others are sporadic cases. This cohort also includes cases with a
wide spectrum of ages of onset, which range from childhood
disease to late onset melanoma.
Results
Whole-exome-sequencing identified a BAP1 splice mutation
(c.581-2A.G) in an individual with UMM from a Danish family
predisposed to developing UMM as well as a host of other cancers.
Co-segregation analysis showed that three out of the four UMM
cases with DNA available for research purposes were carriers of
this mutation, which causes premature truncation of BAP1.
Additionally, there were four other individuals with different
cancer types that also carried the mutation. These cancers were
Figure 2. Sanger sequencing trace and amino acid alignment showing the truncated BAP1 protein. (A) The left panel shows the wild
type chromatogram while the right panel shows that of the BAP1 splice mutation. (B) Wild type nucleotide and amino acid sequences are shown in
the upper panel while the lower panel shows part of the truncated BAP1 protein resulting from the loss of exon 8.
doi:10.1371/journal.pone.0072144.g002
Figure 3. RT-PCR showing the aberrantly spliced BAP1 tran-
script. From the left, the first lane shows a size marker, the next two
lanes show wild type BAP1 RT-PCR products, and the last two lanes
show the aberrantly spliced product resulting from the c.581-2A.G
mutation.
doi:10.1371/journal.pone.0072144.g003
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CMM, lung cancer and stomach cancer. To confirm that
individual III:14 was wildtype for the BAP1 mutation a newly
obtained blood sample was screened. Indeed, the analysis
confirmed the absence of BAP1 mutation suggesting that this case
is a phenocopy. Loss of heterozygosity (LOH) of the BAP1
mutation was also observed in DNA from tumor tissue from II:11.
Consistent with data from the 1000 Genomes Project,
genotyping results showed that this variant was only present in
the current family, that is only 1/1655 melanoma probands
carried the variant and 0/1596 controls. Data from the NHLBI
GO Exome Sequencing Project (ESP) also reflects this finding as
this splicing variant is not found in any of the 6500 individuals
sequenced from the USA [13]. Exome data from 200 healthy
Danish controls was also examined for BAP1 mutation and no
protein altering variant was seen [14]. This suggests that the
individuals described here most likely carry a mutation ‘private’ to
this family.
Discussion
There have been several cancer types associated with BAP1
germline mutations but the full spectrum of tumor susceptibility is
still to be ascertained. We report here a Danish family with UMM
and pigmented skin lesions, as well as lung, neuroendocrine,
stomach, and breast cancers. Whole-exome sequencing of a UMM
case identified a BAP1 splice mutation (c.581-2A.G), which leads
to premature truncation of BAP1. This frameshift aberration is
consistent with published germline mutations seen in other families
predisposed to UMM. In keeping with other Scandinavian
germline BAP1 carriers, we also observe a younger age at
diagnosis of UMM (Table 1). In the present and the previously
published Scandinavian families, the mean age at diagnosis of
UMM was 42 years for the nine affected individuals, compared to
53 years for UMM carriers in non-Scandinavian families (Table 1
and references therein). This compares to a median age at
diagnosis for UMM of between 58-62 years in population-based
sporadic cases in Scandinavia [15] and the United States [16]. The
role of BAP1 as a tumor suppressor gene was further supported by
LOH of the wild type allele in UMM tumor tissue of II:11. The
wild type individual that is affected with UMM shows that in dense
families it is possible to observe phenocopies even with a tumor
type as rare as UMM. The exome sequence data of the person
with UMM and wild type BAP1 did not reveal mutations in other
known cancer predisposition genes.
In summary, this finding expands on the growing profile of
BAP1 as an important uveal and cutaneous melanoma suppressor
gene. The family described here also had a variety of other cancer
types, some of which have been implicated with BAP1 mutation
(lung) and some that have not (stomach, neuroendocrine). To
assess the possible involvement of BAP1 in predisposition to these
non-melanoma cancers and to more fully understand the spectrum
of disease associated with such mutations, large population-based
studies are required.
Supporting Information
Methods S1 Addition information on whole-exome
sequencing, Sanger sequencing and Sequenom iPLEX
methods.
(DOCX)
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Supplementary Information 
 
Methods 
 
Whole-exome Sequencing 
Whole-exome sequencing was carried out on two members of a Danish family predisposed to uveal 
melanoma. Both individuals were affected with UMM and had a family history of disease that is not 
limited to UMM but also includes several other cancer types. The sequencing was performed on the 
Illumina HiSeq 2000 using the Illumina TruSeq Exome Enrichment Kit. The sequencing was 
outsourced to Axeq Technologies in Seoul, South Korea. The sequencing was paired-end and had a 
median coverage of 100x. Sequence data were mapped to the Human Genome build 19 (hg19). Any 
variant that was found in dbSNP or the 1000 Genomes project was filtered out leaving only the 
novel mutations. By applying cut offs to the quality score and the rate of mutant calls for each 
variant, we were left with novel 140 variants in III:14 and 145 novel variants in III:17 for follow up. 
 
Sanger Sequencing 
Sanger sequencing was used to validate the BAP1 splice mutation (c.581-2A>G) identified through 
whole-exome sequencing. A PCR reaction was run using 0.5 units of Qiagen HotStarTaq, 2ul of 
10x PCR Buffer, 4ul of 5x Q-Solution, 1.6ul of 2.5mM dNTP mix, 1mM each of the forward and 
reverse primers (CCTGGCTCAACTGCTCTTCT and GCCCAGGCAGGAAATAAGAC 
respectively) and 15ng of genomic DNA, made up to a final reaction volume of 20ul.  
The PCR was run on a Biorad Thermocycler according to Qiagen PCR protocol. It is initiated with 
a 5 minute activation step at a temperature of 95oC, followed by a 3-step cycling process which is 
repeated 35 times. The cycle starts with a denaturation step at a temperature of 94oC for 45 seconds 
followed by an annealing step at 65oC for 45 seconds and then an extension step at 72oC for 45 
seconds. This 3-step process is repeated with a 65oC annealing temperature for two cycles and then 
steps down in 2oC increments until it reaches 57oC where the temperature remains until the full 35 
cycles are complete. A final 10 minute extension at 72o
The crude PCR product was sent to Functional Biosciences, Wisconsin, USA, to be cleaned up and 
run on a sequencer. The AB1 files were analysed using an online chromatogram comparison tool, 
Multiple SeqDoC (http://research.imb.uq.edu.au/seqdoc/multi.html) which is curated by the 
University of Queensland. The traces were also analysed using chromatogram viewer, Chromas 
(version 1.45).  
C finalises the PCR run.  
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Sequenom iPLEX 
The BAP1 c.581-2A>G splice variant was multiplexed using the Sequenom iPLEX gold system 
which allows up to 36 variants to be genotyped concurrently using 10 ng of genomic DNA. The 
iPLEX Gold PCR amplification reactions were carried out in 384-well plates according to supplier 
protocol and then transferred onto SpectroCHIP arrays using a MassARRAY Nanodispenser. The 
chips were then transferred to a Sequenom mass spectrometer where the data were generated.  The 
results were analysed using Typer Analyzer software 4.0.   
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Chapter 8 
General discussion and future direction 
 
 
In this thesis, a next-generation sequencing (NGS) approach has been used to identify novel 
pathogenic mutations in high-density melanoma families from Australia, the UK, Denmark and 
Sweden. Using a combination of whole-genome and exome-sequencing we identified three genes in 
the telomere-associated complex, shelterin, which confer a highly elevated risk of melanoma when 
mutated. NGS technology has revolutionised our ability to identify cancer predisposition genes and 
has been particularly valuable in instances where mutations are rare, occurring in only a small 
fraction of families. By looking at mutations that segregate within specific families and then 
extending this to a large collection of families, we were able to pinpoint significant genes that 
contribute to CMM predisposition.  
Over the course of this project, a novel mutation occurring in the promoter region of the telomerase 
reverse transcriptase gene (TERT) was found to be associated with familial CMM by Horn and 
colleagues [130]. The mutation, located -57 bp from the ATG translation start site, was found to 
segregate with disease in a 14-case family from Germany. Functionally, it created a new binding 
motif for Ets transcription factors and ternary complex factors (TCF), which resulted in a two-fold 
increase in transcription of TERT (Figure 7). Similar to what was observed in families with shelterin 
mutations, some carriers of the TERT promoter mutation developed multiple cancer types. One 
individual developed ovarian cancer (at 27 years) and CMM (at 30 years), while another family 
member developed CMM (at 20 years) followed by ovarian, renal cell, bladder, breast and 
bronchial carcinoma. Following the identification of the TERT mutation in this family, Horn and 
colleagues analysed tumours derived from sporadic CMM cases and found that 85% of metastatic 
tumours and 33% of primary tumours carried somatic mutations in the promoter region of TERT, 
with the majority of these mutations occurring at two hotspots (-124 bp and -146 bp; Figure 7). This 
finding represents the first documentation of a novel high-risk melanoma predisposition gene since 
CDK4 in 1996 [6], and despite the huge sequencing efforts of several international research groups, 
it has taken over 15 years for this breakthrough to occur. This mutation in TERT also points to a 
new pathway responsible for familial melanoma.  
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Figure 7: TERT promoter mutations in melanoma. Mutations creating Ets/TCF binding motifs 
occurred in affected family members at -57 bp (next to the transcription start site). This also 
occurred in sporadic cases at -124 to -149 bp. Asterisks indicate sites at which Ets2 binding was 
reported. Adapted from Horn et al., 2013. 
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This thesis shows mutations in genes POT1, ACD and TERF2IP confer a high risk of melanoma in 
carriers. These genes encode members of shelterin, the telomere-specific protein complex that 
mediates the interaction between telomeres and telomerase (which includes TERT). Shelterin is 
made up of 6 components, encoded by the genes ACD, POT1, TERF1, TERF2, TERF2IP and 
TINF2. Collectively, they are necessary for all telomere functions, which include the protection of 
telomeres from degradation or aberrant recombination, as well as from being inappropriately 
processed by the DNA-repair pathway [135].  
Telomeres are characterised by (TTAGGG)n nucleotide repeats, typically between 50 bp and 300 
bp in length at each 3’ single-stranded overhang [136]. The length of telomeric DNA is variable 
between chromosomes and also between individuals, with the range of total telomere length in 
humans being 0.5 kb to 15 kb depending on age and tissue type [137]. Telomerase is the reverse 
transcriptase that elongates telomeres by adding telomeric repeats [138]. Shelterin binds to 
telomeres and mediates telomere length by restructuring the terminal domain through the generation 
of t-loops in order to protect chromosomes from unwarranted cleavage (Figure 8) [135]. These t-
loops are also able to physically block telomerase from elongating the telomeres to facilitate 
continued cell proliferation [139, 140]. Without this t-loop mediation it is feasible that cells will not 
enter a natural state of senescence and therefore avoid normal regulation through the cell cycle.  
POT1 is the most conserved of the shelterin complex genes and in conjunction with ACD, enables 
the formation of t-loops [141]. POT1 specifically binds to telomeric single-stranded DNA (ssDNA) 
through two OB (oligonucleotide/oligosaccharide-binding) domains in order to mediate the access 
of telomerase [142]. It has been shown that the ACD-POT1 sub-complex also has a higher binding 
affinity to ssDNA than POT1 does on its own [143]. Literature shows that if the function of POT1 
is inhibited the length of telomeres is increased through telomerase activity, indicating that this sub-
complex is able to regulate the elongation of chromosome ends [144-148]. In our study, we show 
that missense mutations in the OB-domains of POT1 result in an elongation of telomeres in carriers. 
This was measured in both exome data and through qPCR. In a separate study, Bataille and 
colleagues report that a large naevus count is positively correlated with longer telomere length in 
women of Caucasian descent by measuring the telomere length of white blood cells. They have also 
shown that individuals (N=1,897) with naevi larger than 5 mm in diameter had an average telomere 
length that was 150 bp longer than their age-matched controls [149]. High naevus count and naevus 
diameter has been shown to be a strong predictive marker of melanoma risk with members of 
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Figure 8: The shelterin complex. The top panel depicts the formation of the t-loop, blocking the 
interaction with telomerase. The lower frame shows the shelterin complex in the open position, 
allowing telomerase access to telomeres.  
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large melanoma families often having large naevus counts [150, 151]. The research supports the 
association between telomere length and naevus development. A future avenue of research will be 
to investigate whether aberrant function of the shelterin complex gives rise to irregular naevi and a 
higher risk of CMM development. 
The main role of TERF1 and TERF2 (telomeric repeat-binding factor 1 and telomeric repeat-
binding factor 2) is to bind telomeric double-stranded DNA (dsDNA) and mediate recruitment of 
different factors to telomeres [152-156]. TINF2 (TERF1-interacting nuclear factor 2) 
Unlike the mutations we have reported in POT1, mutations in ACD and TERF2IP do not appear to 
alter the length of telomeres. Quantitative PCR data showed no observable difference in the length 
of telomeres between mutation carriers and their wild type relatives. The data suggests that these 
mutations are most likely disrupting the complex and destabilising chromosomes, in carriers rather 
than specifically altering their telomere length. More comprehensive functional experiments will be 
needed to deduce the exact mechanism through which mutations in ACD and TERF2IP confer 
elevated risk of CMM development in the families we describe. 
interacts with 
the TERF1-TERF2 dsDNA binding complex. TINF2 is at the centre of the complex, tethering the 
ACD-POT1 partnership to the TERF1-TERF2 partnership. It is crucial for the assembly of the 
shelterin complex. TERF2IP (TERF2-interacting telomeric protein 1) binds to a central region of 
TERF2 via its C-terminus and is necessary for the repression of homology-directed repair of double 
strand chromosomal break at the telomere [157].  
The initial association between mutations in the shelterin complex and cancer were first published 
in 2013 by Ramsey et al [129]. Exome sequencing data showed that a recurrent somatic mutation in 
POT1 occurred in approximately 3.5% of chronic lymphocytic leukaemia (CLL) patients, with 
these mutations occurring at a frequency of 9% when considering only the more aggressive disease 
subtype. The authors showed that CLL cells with mutated POT1 acquired numerous chromosomal 
abnormalities in comparison to POT1 wild type controls. Interestingly, the majority of the 
mutations detected in these cases lie within the OB-domains of POT1, similarly to what we report 
in the germline (Chapter 4). This indicates that POT1 plays an important role in cancer biology, 
specifically in CLL and CMM. The functional consequences of the POT1 mutations in CLL lends 
to the hypothesis that mutations may also lead to destabilisation of chromosomes in CMM and that 
this may be an important mechanism driving tumour development in families. Further functional 
analysis is required to test this theory in CMM development. 
Currently, the only other disease to report germline mutations in the shelterin complex is 
dyskeratosis congenita (DKC). It is a rare congenital disorder with phenotypic characteristics 
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resembling premature aging. Its clinical features include abnormal skin pigmentation with cases 
presenting with hyper or hypo skin pigmentation, nail dystrophy, oral leukoplakia and bone marrow 
failure [158]. Cases also have an elevated risk of malignancy with an over representation of basal 
cell carcinoma, Hodgkin lymphoma, gastrointestinal cancers and bronchial cancers. One type of 
DKC is caused by germline mutations in exon 6 of TINF2 [158-162]. It is of note that the mutation 
we report in Chapter 5, Supplementary methods, occurs outside of this region (in exon 1). In the 
first report linking TINF2 mutations to DKC, the authors described shortened telomeres leading to 
destabilisation of telomeres in carriers [160]. This is the opposite of what we have seen, as CMM 
cases with POT1 mutations are shown to have increased telomere length. Overall, this indicates that 
both very short and very long telomeres are pathogenic and can lead to different malignancies; 
clearly the role of shelterin is multifaceted and we are yet to fully understand its biological 
complexities. It would be valuable to determine the functional mechanism through which ACD and 
TERF2IP mutations are leading to CMM development. Obvious experiments (protein modelling; 
qPCR length assay; protein-protein interaction through octet; exome data analysis) have not been 
able to pinpoint the biological mechanism that causes these variants to be pathogenic in our 
families.  
When looking collectively at the families with shelterin mutations in conjunction with the family 
carrying the TERT promoter mutation [130], we see an enrichment of cancers in mutation carriers. 
This may be an indication that this pathway is important in general tumour suppression and that 
mutations in these genes may lead to a cancer phenotype that extends beyond CMM. It is possible 
that, like BAP1, mutations in these genes cause a predisposition to a host of malignancies. This 
would be a valuable follow-up to the body of work presented in Chapters 4 and 5. Looking at CMM 
families that also present with CLL may be a good starting point for association to a general cancer 
phenotype.  
We have identified shelterin mutations in cases that lack mutation in any of the known melanoma 
predisposition genes (CDKN2A and CDK4). Collectively, with the identification of the TERT 
promoter mutation [130], the findings of this thesis have uncovered a novel pathway that leads to 
CMM development in the familial setting. It would be valuable to more thoroughly interrogate the 
role of the remaining three shelterin members in melanoma predisposition as well as other genes in 
this pathway as it is becoming clear that telomere dysregulation is a major contributor to melanoma 
development in some high-density families. 
An alternative method of gene discovery presented in this thesis was the candidate gene approach, 
whereby a literature-based search was used to identify genes of interest in melanoma susceptibility. 
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The protein-coding regions of the chosen genes were Sanger sequenced to identify novel variants in 
probands from melanoma families for mutations in PALB2, SOX10 and MITF (Chapter 3). This 
method did not prove overly successful in identifying causative mutations amongst high-risk CMM 
families. Though the literature is suggestive of a role of SOX10 in melanomagenesis, no evidence of 
it was found in the familial setting. There was also a lack of evidence for further MITF variants in 
melanoma predisposition. This consolidates the notion that a more high-throughput approach to 
sequencing entire exonic/genomic regions in cases is a more time-effective method for gene 
discovery in cancer, particularly seeing as the costs associated with NGS have dropped dramatically 
over the past two years. 
Over the course of my PhD, BRCA-1 associated protein-1 (BAP1) was identified as a melanoma 
risk gene in the familial setting. The initial association was made with UMM predisposition but 
since its discovery the disease profile has extended far beyond this phenotype [103]. In this thesis, I 
sought to determine the contribution of BAP1 to both CMM and UMM population-based samples 
from Australia (Chapter 2 and Chapter 7). This was achieved through a combination of high-
throughput, targeted pull-down of the selected genes using the Ion Torrent PGM, and also SNP 
analysis using Sequenom mass spectrometry. We also estimated the contribution of known 
melanoma risk genes CDKN2A, CDK4 and BAP1 to melanoma in a Queensland population-based 
sample (N=1,109). We showed that CDKN2A accounts for around 1.31% of Queensland melanoma 
cases, BAP1 accounts for around 0.63%, and CDK4 mutations are extremely rare, not being found 
in the Queensland-based sample. This is the best estimate of the contribution of CDKN2A and 
CDK4 to CMM in the Queensland population reported to date. It is also the only reported estimate 
of BAP1 contribution to CMM and UMM in any population. 
In the familial setting, BAP1 has become the first (and currently the only) predisposition gene for 
UMM. We have shown that a mutation of this gene is present in a high-density UMM family from 
Denmark. Interestingly, this family presented with a host of other cancer types which support BAP1 
as a general tumour suppressor that predisposes to a range of cancers that includes both UMM and 
CMM. In terms of risk genes that are associated with UMM, there is still a great deal that is 
unknown. In comparison to CMM, the discovery rate of UMM predisposition genes has been slow, 
with only a single gene attributed to predisposition in 2011. This may be in part due to the smaller 
availability of samples. Given that UMM affects only 5.6 people per million in the USA, the 
collection of samples for this type of study is much more difficult. In the data that we have 
examined to date, it is likely that the mutations driving UMM in families are going to be rare; 
therefore we will need to sequence larger numbers of families to see the recurrence of genes being 
mutated in families. It is feasible that like CMM, mutations in particular pathways will predispose 
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to UMM and therefore we may need to interrogate families of genes to identify the causative 
pathways rather than stand-alone genes. 
 In Australian clinics, it is not yet routine for sporadic UMM cases to be screened for mutations in 
BAP1. As families with UMM are rare, there may be only a few individuals that present with a 
family history. A better guide for determining whether or not a person may have a causative 
germline mutation in BAP1 would be to look at the extended cancer history of the family. Since 
there have been such a broad range of cancer implicated with germline BAP1 mutations (see 
Chapter 1 and Chapter 7) it is likely that these families will present with a more complex cancer 
history than just UMM. In the future, clinicians could benefit from comprehensive guidelines for 
identifying a BAP1 mutation phenotype so these families can be better identified. This will lead to 
earlier detection and better management of cancers arising by germline mutations in this gene. If we 
can identify individuals carrying germline BAP1 mutations in the clinical setting we can improve 
the diagnosis and prognosis of cancer in their family members. 
Overall, this project has made a major contribution to the field of familial melanoma genetics. 
Firstly, we have analysed the population-based frequency of melanoma risk genes CDKN2A, CDK4 
and BAP1 in a CMM sample from Queensland, Australia. We have also determined the fraction of 
UMM cases that can be attributed to BAP1 mutation in a population-based sample from New South 
Wales, Australia. Following on from this, we described a Danish family with a germline BAP1 
mutation responsible for the development of UMM and a host of other cancers. Finally, we have 
described novel truncating mutations in three members of the shelterin complex in CMM families, 
which collectively accounts for 9% of families lacking mutations in previously known risk genes. In 
combination with a reported finding of a mutation in the TERT promoter, the research presented in 
this thesis has led to the identification of a novel pathway related to melanoma predisposition and 
thus a significant advance in the field of familial melanoma genetics.  
The findings of this thesis could be translated to positive outcome in the clinical setting. Currently, 
genetic counselling clinics in Australia only screen CMM families for mutations in CDKN2A and 
CDK4. In the future, the hope is that individuals presenting with a strong family history of CMM 
will be able to be tested for mutations in POT1, ACD and TERF2IP as well. By identifying those 
individuals with the greatest risk of CMM development, dermatologists can monitor them and their 
family members more rigorously for changes to their skin. Furthermore these families could benefit 
from education that allows them to better monitor changes to their own skin. As melanoma is quite 
curable when detected in the early stages, the key for the future will be identifying the families that 
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carry these high-risk germline mutations so they can be thoroughly monitored to improve CMM 
prognosis.  
Next-generation sequencing techniques have been an invaluable tool in melanoma predisposition 
gene discovery. Understanding the genetic mutations behind melanoma development provides an 
insight into the disease mechanism and, in the future, will aid early detection and inform more 
effective prevention strategies. Ultimately, the identification of these genes will lead to more 
therapeutic options for patients with melanoma. This is of particular importance to a population like 
Queensland’s where the burden of melanoma is so great. 
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A novel recurrent mutation inMITF predisposes to
familial and sporadic melanoma
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So far, two genes associated with familial melanoma have been iden-
tified, accounting for a minority of genetic risk in families.
Mutations in CDKN2A account for approximately 40% of familial
cases1, and predisposingmutations in CDK4 have been reported in a
very small number of melanoma kindreds2. Here we report the
whole-genome sequencing of probands from several melanoma
families, which we performed in order to identify other genes asso-
ciatedwith familialmelanoma.We identify one individual carrying a
novel germline variant (coding DNA sequence c.G1075A; protein
sequence p.E318K; rs149617956) in the melanoma-lineage-specific
oncogene microphthalmia-associated transcription factor (MITF).
Although the variant co-segregated with melanoma in some but
not all cases in the family, linkage analysisof31 families subsequently
identified to carry the variant generated a log of odds (lod) score
of 2.7 under a dominant model, indicating E318K as a possible
intermediate risk variant. Consistent with this, the E318K variant
was significantly associated with melanoma in a large Australian
case–control sample. Likewise, it was similarly associated in an
independent case–control sample from the United Kingdom. In
the Australian sample, the variant allele was significantly over-
represented in cases with a family history of melanoma, multiple
primary melanomas, or both. The variant allele was also associated
with increased naevus count and non-blue eye colour. Functional
analysis of E318K showed that MITF encoded by the variant
allele had impaired sumoylation and differentially regulated several
MITF targets. These data indicate that MITF is a melanoma-
predisposition gene and highlight the utility of whole-genome
sequencing to identify novel rare variants associated with disease
susceptibility.
Cutaneous malignant melanoma is predominantly a disease of fair-
skinned individuals. Aetiology is complex, with environmental
(mainly ultraviolet radiation exposure) and genetic factors affecting
disease risk. Phenotypic risk factors, which are largely heritable,
include pigmentation (fair skin, blue or green eyes, blonde or red hair),
sun sensitivity, an inability to tan3–6, high number of melanocytic
naevi7,8, or the presence of clinically atypical naevi7. Candidate-gene
studies and genome-wide association studies (GWAS) for melanoma
and these melanoma-associated phenotypes have identified several
variants associated with melanoma risk in the general population9–13.
Family studies, on the other hand, have identified only two high-
penetrance melanoma genes, CDKN2A (ref. 1) and CDK4 (ref. 2),
accounting for a minority of genetic risk in melanoma families.
As part of a larger sequencing effort to identify novelmelanoma risk
genes, we sequenced the genome of an affected individual from an
eight-case melanoma family negative for alterations in CDKN2A or
CDK4 (Fig. 1, FAM1) using a nanoarray-based short-read sequencing-
by-ligation strategy14. From among the 410 novel variants predicted to
affect protein structure, we prioritized for follow-up a single nucleotide
polymorphism (SNP) resulting in a glutamic acid to lysine substitution
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Figure 1 | Co-segregation analysis of the MITF E318K variant in the family
in which it was identified. The pedigree shows individuals that have had
melanoma (shaded circles or boxes), with the age of first melanoma diagnosis
indicated in brackets and the number of melanomas that have occurred in the
individual so far (for example, 3 2 indicates two primary melanomas). If the
number of melanomas is not stated, the individual has had a single melanoma.
A diagonal line through the symbol indicates that the person is deceased. The
genotype for theMITF E318K variant for individuals with an available DNA
sample for testing is annotated ‘E318K’ if a carrier or wild type ‘WT’. Other
cancer types are also indicated with the age of first diagnosis indicated in
brackets if known. Br, breast; Mes, mesothelioma; MM, melanoma; Oes,
oesophagus. The individual circled in Family 1 (FAM1) is themelanoma case in
which theMITF E318K variant was discovered through whole-genome
sequencing. See Supplementary Fig. 3 for pedigrees of all other families
identified as carrying E318K.
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in MITF (E318K, codon numbering based on the melanocyte-specific
MITF-M isoform; c.G1075A, NCBI accession NM_000248.3;
p.E318K, NCBI accession NP_000239.1; rs149617956). Although
linkage15 andGWAS studies9,10 have not provided evidence implicating
MITF in either predisposition to melanoma or the melanoma-
associated phenotypes of pigmentation and naevogenesis11,12,16–19,
MITF is known to regulate a broad repertoire of genes whose functions
in melanocytes range from development, differentiation, survival,
cell-cycle regulation and pigment production. MITF is somatically
amplified20,21 ormutated22 in a subset ofmelanomas, and strongly over-
expressed in others20, making it an attractive candidate despite the lack
of prior evidence for involvement in germline risk.
We evaluatedwhetherMITFE318K is a high-penetrancemelanoma
susceptibility variant in Family 1 by genotyping the remaining affected
individuals available for study. The MITF variant allele was found in
3/7 melanoma cases assessed in this family (Fig. 1), consistent with it
being a medium-penetrance melanoma risk variant. To assess further
this possibility, we genotyped two large Australian melanoma case–
control samples forMITF E318K. The variant was found in 14/1,953
controls (carrier frequency5 0.0072) and thus represents a rare popu-
lation variant (Table 1). We observed a significantly higher frequency
(34/2,059) in cases (carrier frequency5 0.0165) than controls (Fisher
exact P5 0.008, odds ratio (OR) 2.33, 95% confidence interval (CI)
1.21–4.70), indicating that the variant correlates with increased
melanoma risk in the general population. The effect size for E318K
is larger than those reported for variants from melanoma GWAS9,10
and similar to that observed for red-hair-colour-associated variants of
the melanocortin 1 receptor (MC1R) gene (OR for most populations
,2.4)23. Among cases, theMITF E318K variant was enriched in those
with multiple primary melanomas (OR 4.22, 95% CI 1.52–10.91), a
family history of melanoma (OR 2.95, 95%CI 1.23–6.92), or both (OR
8.37, 95% CI 2.58–23.80), but not in cases with earlier age of onset
(comparing diagnosis before age 40 versus after 40 years) (Table 2).
We replicated these findings in two independent population-based
case–control samples from the United Kingdom. In the combined UK
sample, the variant allele frequency was also significantly higher in
cases (carrier frequency5 0.0176) than controls (carrier frequency5
0.0085, P5 0.012, OR 2.09, 95% CI 1.14–3.94, Table 1). The asso-
ciation with melanoma in the pooled UK and Australian data was
highly significant (combined P5 0.0003, OR 2.19, 95% CI 1.41–
3.45). In the UK cases there were also trends towards family history,
earlier age of onset, and the occurrence of more than one primary
melanoma in variant carriers (Table 2).
To extend assessment of the MITF variant in melanoma-prone
families, we screened for E318K in 182 UK families with at least two
melanoma cases and 88 Australian families with at least three cases, all
of which are negative for mutations in CDKN2A or CDK4. Six families
(2.2%)were found to carry the variant. In theUK, E318Kwas enriched
in the more melanoma-dense families; 4/54 (7.4%) families with at
least three melanoma cases versus 1/128 (0.8%) families with two
melanoma cases (Fisher’s exactP5 0.013).We subsequently evaluated
whetherMITF E318K co-segregatedwithmelanoma in these as well as
additional multiple-case families identified from the case–control
sample. In total, we identified 31 unrelated cases carrying MITF
E318K from Australia and the UK with at least one first- or second-
degree relative diagnosed with melanoma (listed in Supplementary
Table 1; Supplementary Fig. 3), 22 of which had DNA available from
additional affected family members for genotyping. In 9/31 families
(five three-case and four two-case families) the variant was found in all
affected individuals (Supplementary Fig. 3a; non-segregating families
shown in Supplementary Fig. 3b), whereas in 12 additional families,
the variant co-segregated with melanoma in the available cases, but
DNA from all cases was not available for screening (Supplementary
Fig. 3c). To test more formally for linkage of melanoma with MITF
E318K in these families, we calculated a lod score of 2.7 under a
dominant model, again consistent with an incompletely penetrant
medium risk variant.
To assess whether theMITF variant is related to knownmelanoma-
associated risk phenotypes of pigmentation and naevus count, we
tested for association both in cases and controls from the Australian
and British populations. TheMITF variant allele is significantly asso-
ciated with increased naevus count (combined P5 0.002, OR 2.54,
95% CI 1.42–4.55; Supplementary Table 2) and non-blue eye colour
(combined P5 0.018, OR 2.01, 95% CI 1.11–3.81; Supplementary
Table 3). It was not associated with skin colour, hair colour, or freck-
ling (Supplementary Table 4). Reassessing the case–control analysis
accounting for naevus count and eye colour gave a slightly reduced
effect size for association of the variant with melanoma (OR 1.82, 95%
CI 0.85–3.92), suggesting that the risk of melanoma attributable to
MITF E318K may be mediated at least in part via one or both of these
phenotypes, but that there is a substantial residual risk conferred by the
variant through an as yet undetermined mechanism.
Wenext sought to evaluatewhether theE318Kmutation altersMITF
function. The E318K variant is located within one of two IKXE con-
sensus sites onMITFpreviously shown to be post-translationallymodi-
fied by the addition of the small ubiquitin-like-modifier SUMO24.
Table 1 | MITF E318K association with melanoma
Population Group No. of individuals
with variant
No. of individuals
without variant
Variant carrier
frequency
OR 95% CI One-sided
exact P
Two-sided
exact P
Australia Cases 34 2,025 0.0165 2.33 1.21–4.70 0.0045 0.0083
Controls 14 1,939 0.0072
UK Cases 34 1,895 0.0176 2.09 1.14–3.94 0.0074 0.0115
Controls 18 2,097 0.0085
Australia 1 UK Cases 68 3,920 0.0171 2.19 1.41–3.45 0.0001 0.0003
Controls 32 4,036 0.0079
It should be noted that the reported allele frequencies forMITF E318K in the population-based samples are without removing individuals with CDKN2A or CDK4mutations, as screening for these genes was not
routinely performed.
Table 2 | Association ofMITF E318K with melanoma-associated variables
Australia UK
Case set Carrier
frequency
Carrier counts
(carrier/wild type)
OR vs Aus
controls
95% CI Carrier
frequency
Carrier counts
(carrier/wild type)
OR vs UK
controls
95% CI
All cases 0.0165 34/2,025 2.33 1.21–4.70 0.0176 34/1,895 2.09 1.14–3.94
Age of onset ,40 years 0.0139 14/996 1.95 0.86–4.42 0.0174 5/283 2.10 0.60–5.91
Family history of melanoma 0.0209 12/563 2.95 1.23–6.92 0.0273 3/107 3.36 0.62–11.77
Multiple primary melanomas 0.0296 8/262 4.22 1.52–10.91 0.0225 2/87 2.74 0.30–11.74
Multiple melanomas and family
history
0.0571 6/99 8.37 2.58–23.80 0.0000 0/10 - -
Aus, Australia.
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Mutation of the residue to which SUMO is covalently attached in this
motif (K316R) has previously been shown to abrogateMITF sumoyla-
tion and significantly increase MITF transcriptional activity in
vitro24,25. We thus hypothesized that E318K would similarly alter
sumoylation and transcriptional activity of MITF. To test this we con-
structed a cDNA encoding His-tagged MITF carrying the E318K
mutation. We evaluated the effects of E318K on sumoylation in com-
parison to the wild type and previously characterized synthetic muta-
tions of the twoknownMITF sumoylation sites (K316RandK182R)by
co-transfecting with haemagglutinin (HA)-tagged SUMO1 in COS-7
cells (Fig. 2a). Wild-type MITF shows two SUMO1-modified forms,
whereasMITFmutants K182RorK316R each show only onemodified
form (Fig. 2a). Similar to the synthetic K316R and K182R mutants,
E318K abrogates sumoylation, resulting in complete loss of the doubly
sumoylated form of MITF and reducing the mono-sumoylated form.
When the second site is mutated (K182R) simultaneously with E318K,
MITF sumoylation is completely abolished. Immunoprecipitation
of endogenously expressed MITF E318K from melanoma cells
homozygous for E318K (NAE)when transfectedwith SUMOsimilarly
revealed only bands corresponding to mono- and non-sumoylated
isoforms of MITF on western blot (Fig. 2b).
We then looked for differences between mutant and wild-type
MITF transcriptional activity using a reporter construct containing
the MITF-responsive TRPM1 promoter25. At two concentrations
tested, the E318K mutant exhibited 1.34–1.40 fold induction of the
TRPM1 luciferase reporter relative to wild-type MITF (Fig. 2c). This
fold induction is similar to that observed previously onmultiple MITF
target promoters using single or double artificial sumoylation-site
MITF mutants24,25 and suggests that the E318K variant found in
melanoma changes the transcriptional potency ofMITF. To study this
in greater detail, we determined the effect of the E318K mutation on
global MITF target gene transcription. We developed a tetracycline-
inducible system for expression of wild-type MITF or the E318K vari-
ant in melanoma cell lines with constitutively low or undetectable
levels of endogenous MITF (HT144 and C32, respectively26, Fig. 2d).
At the phenotypic level, induction of wild-type or E318KMITF led to
increased proliferation compared to uninduced controls for each of the
cell lines, although there was no significant difference in growth rate
between the cells expressing the different isoforms (data not shown).
We examined whole-genome expression profiles in these cells follow-
ing induction of either wild-type or E318K MITF for 48 h. Of the 37
genes commonly regulated by wild-type and E318KMITF in both cell
lines (Supplementary Fig. 1a, b; see Methods for analysis details), 28
(76%) had previously been identified as MITF target genes (Sup-
plementary Table 5)27,28, and 17 showed$1.25-fold differences in
expression between the wild-type and E318K isoforms (Supplemen-
tary Fig. 1b). We also identified two gene products that were uniquely
differentially regulated compared to uninduced cells by the induction
of wild-type MITF but not MITF E318K in both parental cell lines,
and 16 gene products after induction of MITF E318K but not wild-
typeMITF (Supplementary Table 6). Of these, 61% (11/18) have previ-
ously been reported as MITF targets (Supplementary Table 6)27,28.
Collectively, these data indicate that the MITF E318Kmutant exhibits
differential transcriptional activity against some, although not all,
target genes. In agreement with the reporter assays (Fig. 2c), we iden-
tified transcriptional differences in gene products known to be
involved in pigmentation (DCT, MLANA), in which the differences
were more marked with expression of the E318K variant in com-
parison to wild-type MITF. These were validated by quantitative
polymerase chain reaction with reverse transcription (qRT–PCR) in
the cell lines used for microarray analysis (Fig. 2e), as well as in an
additional melanoma cell line constitutively expressing wild-type or
E318K mutant MITF (Fig. 2f and Supplementary Fig. 2). In keeping
with the increase in expression of these pigmentation genes, we
detected a 22% increase inmelanin content inHT-144melanoma cells
72 h after induction of MITF E318K compared to wild-type MITF
(data not shown). This is also consistent with our observation that
carriers are more likely to have darker (that is, non-blue) eye colour
(Supplementary Table 3) but, notably, these data contrast with other
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Figure 2 | E318K prevents MITF sumoylation and results in differential
expression of MITF target genes. a, His-tagged wild-type MITF or the
indicated single or double point mutants were co-transfected with HA–
SUMO1 in COS-7 cells or b, HA–SUMO was transfected alone into
homozygous mutant E318KMITFmelanoma cells (NAE). Single- and double-
sumoylated forms of MITF are indicated by a dagger and double dagger,
respectively. The doublet bands are caused by MAPK-mediated
phosphorylation at serine 73 (ref. 30). c, UACC62 humanmelanoma cells were
transfected with TRPM1-promoter constructs with indicated amounts of
expression vector encodingwild-type ormutant forms ofMITF. Fold induction
is shown as the ratio to the average of no MITF transfection (0 ng). Data are
mean6 s.d. of at least four independent experiments. d, Expression ofMITF in
two melanoma cell lines (HT144 and C32) engineered to inducibly express
wild-type (WT) or mutant (E318K) MITF after treatment with tetracycline for
48 h (48), as determined by qRT–PCR. Performed in triplicate, error bars depict
s.d. e, Expression of MITF target genesDCT (top left),MLANA (top right) and
THBS1 (bottom left) determined by qRT–PCR inmelanoma cell lines 48 h after
induction of wild-type or E318K MITF. Gene expression is normalized to
GAPDH and shown as fold change compared to uninduced cells. Performed in
triplicate, error bars denote s.d. f, qRT–PCR analysis of total RNA isolated from
UACC62 human melanoma cells, which were transfected with expression
vector encoding wild-type or mutant forms of MITF. The expression level of
each target gene was normalized toMITF mRNA. Fold induction is shown as
the ratio to each mRNA expression with wild-typeMITF. Data aremean6 s.d.
of at least three independent experiments. *P, 0.05, **P, 0.01.
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previously reported ‘fair-skin-associated’ melanoma risk variants,
such as those inMC1R or TYR. It is uncertain whether the enhanced
expression of pigment genes may contribute to melanomagenesis,
perhaps by increasing oxidative stress and an increase in oxidative
DNA damage29, or alternatively may simply reflect increased MITF
activity, which (separately) promotes tumorigenesis, as MITF is a
previously recognized amplified melanoma oncogene20.
We adopted the approach of whole-genome sequencing of patients
from melanoma families and identified a novel germline mutation of
MITF. This mutation was found to be present in numerous melanoma
families, as well as the general population, in which its association with
melanoma has an effect size similar to red-hair-causing variants of
MC1R23. The melanoma susceptibility genes discovered through
GWAS so far account for only a minority of inherited disease risk. A
proportion of this ‘missing heritability’ may be due to rare sequence
variants, which are poorly detected by GWAS using SNP arrays. The
new MITF variant reported here shows reasonably strong linkage to
melanoma (lod score 2.7) but crucially not a high enough signal to be
clearly visible in previous genome-wide linkage scans.We also provide
in vitro data supporting a functional mechanism by which this muta-
tion may mediate melanoma risk, specifically abrogation of MITF
sumoylation and differential transcription of select MITF target genes.
Although the individual changes in transcription induced by the
mutant E318K MITF in comparison to wild-type MITF are modest,
the orchestrated change in the levels of multiple MITF target genes is
likely to be biologically important, especially over the lifetime of a
person. This study offers a rare glimpse of a complex functionality
whereby a risk-conferring SNP affects the post-translational proces-
sing of a crucial lineage-specific survival and differentiation gene. This
study demonstrates the utility of performing whole-genome and
exome resequencing in appropriate affected individuals to identify
such novel rare disease-specific variants and functionally characterize
variants associated with complex disease not otherwise detectable via
GWAS or linkage approaches.
METHODS SUMMARY
The collection of the Australian melanoma families used for the study, as well as
the Queensland and AMFS case–control sets are described elsewhere and in
Methods. Likewise the UK studies from Leeds and Cambridge as well as the panel
of melanoma cell lines. Whole-genome sequencing, assembly and variant calling
were performed by Complete Genomics, as described previously14. Genotyping of
MITF E318K was performed using the SequenomMassArray system (Australian
studies) or a custom TaqMan assay (UK studies), with DNA from the affected
family member in which E318K was identified included multiple times as a
positive control. Statistical analyses are described in detail in Methods. Co-
segregation analyses were performed inmelanoma families via Sanger sequencing
using the primers: forward, 59-CAGGCTCGAGCTCATGGA-39; reverse,
59-TGGGGACACTATAGGCTTGG-39. MITF sumoylation andTRPM1 reporter
assays were performed as previously described25.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
Received 17 March; accepted 13 October 2011.
Published online 13 November 2011.
1. Goldstein, A. M. et al. Features associated with germline CDKN2A mutations: a
GenoMEL study ofmelanoma-prone families from three continents. J. Med. Genet.
44, 99–106 (2007).
2. Zuo, L. et al. Germline mutations in the p16INK4a binding domain of CDK4 in
familial melanoma. Nature Genet. 12, 97–99 (1996).
3. Naldi, L. et al. Cutaneous malignant melanoma in women. Phenotypic
characteristics, sun exposure, and hormonal factors: a case–control study from
Italy. Ann. Epidemiol. 15, 545–550 (2005).
4. Titus-Ernstoff, L. et al. Pigmentary characteristics and moles in relation to
melanoma risk. Int. J. Cancer 116, 144–149 (2005).
5. Holly, E. A., Aston, D. A., Cress, R. D., Ahn, D. K. & Kristiansen, J. J. Cutaneous
melanoma in women. I. Exposure to sunlight, ability to tan, and other risk factors
related to ultraviolet light. Am. J. Epidemiol. 141, 923–933 (1995).
6. Holly, E. A., Aston, D. A., Cress, R. D., Ahn, D. K. & Kristiansen, J. J. Cutaneous
melanoma inwomen. II. Phenotypic characteristics andother host-related factors.
Am. J. Epidemiol. 141, 934–942 (1995).
7. Bataille, V. et al.Risk of cutaneousmelanoma in relation to the numbers, types and
sites of naevi: a case–control study. Br. J. Cancer 73, 1605–1611 (1996).
8. Chang, Y.M.et al.Apooledanalysis ofmelanocytic nevusphenotypeand the riskof
cutaneous melanoma at different latitudes. Int. J. Cancer 124, 420–428 (2009).
9. Bishop, D. T. et al. Genome-wide association study identifies three loci associated
with melanoma risk. Nature Genet. 41, 920–925 (2009).
10. Brown, K. M. et al. Common sequence variants on 20q11.22 confer melanoma
susceptibility. Nature Genet. 40, 838–840 (2008).
11. Duffy, D. L. et al. IRF4 variants have age-specific effects on nevus count and
predispose to melanoma. Am. J. Hum. Genet. 87, 6–16 (2010).
12. Falchi, M. et al. Genome-wide association study identifies variants at 9p21 and
22q13 associated with development of cutaneous nevi. Nature Genet. 41,
915–919 (2009).
13. Gudbjartsson, D. F. et al. ASIP and TYR pigmentation variants associate with
cutaneousmelanomaandbasal cell carcinoma.NatureGenet.40,886–891(2008).
14. Drmanac, R. et al. Human genome sequencing using unchained base reads on
self-assembling DNA nanoarrays. Science 327, 78–81 (2010).
15. Gillanders, E. et al. Localization of a novel melanoma susceptibility locus to 1p22.
Am. J. Hum. Genet. 73, 301–313 (2003).
16. Han, J. et al. A genome-wide association study identifies novel alleles associated
with hair color and skin pigmentation. PLoS Genet. 4, e1000074 (2008).
17. Nan,H.et al.Genome-wideassociation studyof tanningphenotype inapopulation
of European ancestry. J. Invest. Dermatol. 129, 2250–2257 (2009).
18. Sulem, P. et al. Genetic determinants of hair, eye and skin pigmentation in
Europeans. Nature Genet. 39, 1443–1452 (2007).
19. Zhu, G. et al. A genome-wide scan for naevus count: linkage to CDKN2A and to
other chromosome regions. Eur. J. Hum. Genet. 15, 94–102 (2007).
20. Garraway, L. A. et al. Integrative genomic analyses identifyMITF as a lineage
survival oncogene amplified in malignant melanoma. Nature 436, 117–122
(2005).
21. Stark, M. & Hayward, N. Genome-wide loss of heterozygosity and copy number
analysis inmelanomausing high-density single-nucleotide polymorphismarrays.
Cancer Res. 67, 2632–2642 (2007).
22. Cronin, J. C. et al. Frequentmutations in theMITF pathway inmelanoma. Pigment
Cell Melanoma Res. 22, 435–444 (2009).
23. Williams, P. F., Olsen, C. M., Hayward, N. K. & Whiteman, D. C. Melanocortin 1
receptor and risk of cutaneous melanoma: a meta-analysis and estimates of
population burden. Int. J. Cancer 129, 1730–1740 (2010).
24. Murakami, H. & Arnheiter, H. Sumoylation modulates transcriptional activity of
MITF in a promoter-specific manner. Pigment Cell Res. 18, 265–277 (2005).
25. Miller, A. J., Levy, C., Davis, I. J., Razin, E. & Fisher, D. E. Sumoylation of MITF and its
related family members TFE3 and TFEB. J. Biol. Chem. 280, 146–155 (2005).
26. Boyle,G.M.et al.Melanomacell invasiveness is regulatedbymiR-211suppression
of theBRN2transcription factor.PigmentCellMelanomaRes.24,525–537 (2011).
27. Strub, T. et al. Essential role of microphthalmia transcription factor for DNA
replication,mitosis andgenomicstability inmelanoma.Oncogene30,2319–2332
(2011).
28. Hoek, K. S. et al. Novel MITF targets identified using a two-step DNA microarray
strategy. Pigment Cell Melanoma Res. 21, 665–676 (2008).
29. Smit, N. P. et al. Increased melanogenesis is a risk factor for oxidative DNA
damage—study on cultured melanocytes and atypical nevus cells. Photochem.
Photobiol. 84, 550–555 (2008).
30. Hemesath, T. J., Price, E. R., Takemoto, C., Badalian, T. & Fisher, D. E. MAP kinase
links the transcription factor Microphthalmia to c-Kit signalling in melanocytes.
Nature 391, 298–301 (1998).
Supplementary Information is linked to the online version of the paper at
www.nature.com/nature.
Acknowledgements This work was supported by team science awards by the
Melanoma Research Alliance (J.M.T., N.K.H., H.T. and D.E.F.), the American Cancer
Society (K.M.B., RSG-08-200-01), the National Institutes of Health (NIH; D.E.F.,
AR043369-14; N.K.H., CA88363; H.T., K24CA149202 and P50CA93683), Doris Duke
Medical Foundation (D.E.F.), Dr Miriam and Sheldon G. Adelson Medical Research
Foundation (D.E.F.), US-Israel Binational Science Foundation (D.E.F.), and the Division
of Cancer Epidemiology and Genetics of the National Cancer Institute (K.M.B.). N.K.H.,
D.L.D., S.M. and G.W.M. are supported by National Health and Medical Research
Council of Australia (NHMRC) research fellowships. M.H.L. is supported by Cancer
Australia grant 1011143. The collection of samples in the Leeds-based case–control
study (theMelanomaCohort Study) was fundedbyCancer ResearchUK (Project Grant
C8216/A6129 and Programme awards C588/A4994 and C588/A10589) and by the
NIH (R01 CA83115). Recruitment was facilitated by the UKNational Cancer Research
Network. We thank S. Leake, S. Haynes, S. Waseem for Leeds case–control data
collection; and H. Snowdon and C. Taylor from the Leeds Cancer Research UK Cancer
Centre Genomics Facility for the genotyping of the UK samples. AMFS was supported
by the NHMRC (project grants 566946, 107359, 211172 and program grant number
402761 to G.J.M. and R.F.K.); the Cancer Council New South Wales (project grant 77/
00, 06/10), the Cancer Council Victoria and the Cancer Council Queensland (project
grant371); and theNIH (viaRO1grantCA-83115-01A2 to the internationalMelanoma
Genetics Consortium—GenoMEL). The University of Cambridge SEARCH study was
supported by Cancer Research UK Programme awards (C490/A11021 and C8197/
A10123). A.E.C. is the recipient of an NHMRC public health postdoctoral fellowship
(520018) and a Cancer Institute NSW Early Career Development Fellowship (10/ECF/
2-06).B.K.A. is supportedbyaUniversity ofSydneyMedicalFoundationProgramGrant
and J.L.H. is an Australia Fellow of the NHMRC. We gratefully acknowledge all of the
participants, the work and dedication of the research coordinators, interviewers,
examiners and data management staff, including J. Arbuckle, S. Columbus, M. Lang,
RESEARCH LETTER
1 0 2 | N A T U R E | V O L 4 8 0 | 1 D E C E M B E R 2 0 1 1
Macmillan Publishers Limited. All rights reserved©2011
H.Rodais, C. Ellis (Centre forMEGAEpidemiology);E. A.Holland,C. Agha-Hamilton,C. El
Hayek, L. Morgan, J. Roland, E. Tyler, J. Barton, C. Watts and L. Porter (Westmead
Institute of CancerResearch);M.Hillcoat, K.Holland, P. Saunders, J. Roberts and S. Tait
(Viertel Centre for Research in Cancer Control); A. Kurien, C. Patterson, C. Thoo, S. de
Zwaan, A. Sklavos, S. Manoharan, J. Cahill and S. Brennand (skin examiners).
Author Contributions K.M.B., N.K.H. and J.M.T. designed, analysed and managed
sequencing and genotyping aspects of the study. K.M.B., S.M., S.L.W. and N.K.H. wrote
the paper. D.E.F. designed functional studies and contributed to manuscript
preparation. J.M.T. designed genetic studies. H.T. designed functional studies,
sequencedMITF in melanoma cell lines and contributed to manuscript preparation.
Analysis of whole-genome sequence data was performed by K.H., M.S.S., N.K.H. and
K.M.B. Genotyping ofMITF E318K in all Australian sampleswas performedbyV.Z., with
statistical analyses performed by S.M. and M.H.L. D.C.W., D.L.D., G.W.M., N.K.H. and
N.G.M oversaw collection of the Queensland samples and contributed to statistical
analyses, data interpretationandmanuscript preparation.G.J.M., E.A.H., H.S., J.A.M., J.J.,
M.F., M.A.J., R.F.K., G.G.G., B.K.A, J.F.A. and J.L.H. oversaw collection and contributed to
phenotypic analyses of the AMFS study, with statistical analysis performed by A.E.C.
D.T.B., J.A.N.-B., P.D.P., D.F.E. andA.M.D. designed andmanaged aspects of genotyping
inUK case–control studies, with genotyping performedbyM.H. and statistical analyses
performed by J.C.T. J.M.P. assisted in analysis of Australian melanoma pedigrees.
Sequencing of MITF in and analysis of Australian melanoma pedigrees and cell lines
were performed by L.G.A., S.L.W., M.G., K.D.-R., V.B., M.S.S., J.S., C.S., C.L. and L.O’C. S.Y.
andR.H. performed the sumoylation andMITF-transactivation studies and contributed
to manuscript preparation. G.M.B. generated inducible-MITF melanoma cell lines,
performed phenotypic and global transcript analyses and contributed to manuscript
preparation.
Author Information Expression microarray data are available through the NCBI GEO
website under accession GSE31269. Data for the full genome sequenced from FAM1
has been deposited in NCBI dbGAP under accession phs000419.v1.p1. Reprints and
permissions information is available at www.nature.com/reprints. This paper is
distributed under the terms of the Creative Commons
Attribution-Non-Commercial-Share Alike licence, and is freely available to all readers at
www.nature.com/nature. The authors declare no competing financial interests.
Readers are welcome to comment on the online version of this article at
www.nature.com/nature. Correspondence and requests for materials should be
addressed to K.M.B. (brownkm2@mail.nih.gov).
LETTER RESEARCH
1 D E C E M B E R 2 0 1 1 | V O L 4 8 0 | N A T U R E | 1 0 3
Macmillan Publishers Limited. All rights reserved©2011
METHODS
Melanoma families.Ascertainment and clinical evaluation of Australian and UK
pedigrees with familial melanoma is described elsewhere31–35. In an effort to
maximize the chance of identifying a novel melanoma susceptibility gene, we
restricted inclusion in our study to pedigrees that were mutation negative for both
CDKN2A and CDK4, by single-strand conformation polymorphism (SSCP)
and/or direct sequencing.
Melanoma case–control studies. Australia. Cases were drawn from (1) a
population-based sample from Queensland, unselected for age at onset
(Queensland study of Melanoma: Environment and Genetic Associations;
Q-MEGA36) and (2) a population-based case–control family study of melanoma
diagnosed before age 40 years, ascertained in Brisbane, Melbourne and Sydney
(AMFS)37. Two sets of Australian controls were used. First, a sample of unrelated
individuals was ascertained; they were mainly parents of adolescent twins (80% of
the sample), together with a smaller number of twins and their siblings, recruited
through schools to participate in the Brisbane Adolescent Twin Study38.
Additionally, a set of controls from AMFS were available for genotyping37. The
AMFS and twin controls did not have a personal history of melanoma. Approval
for these as well as the melanoma family studies was obtained from the Human
Research Ethics Committees of Queensland Institute of Medical Research
(QIMR), University of Sydney, University of Melbourne and cancer registries of
New SouthWales, Victoria andQueensland. Informed consent was obtained from
all participants. Most samples had: questionnaire-based naevus count based on a
four point scale: ‘none’, ‘a few’, ‘moderate’ and ‘very many’ (Queensland); or
‘none’, ‘few’, ‘some’ and ‘many’ for AMFS; data on pigmentation variables, includ-
ing: hair colour (fair, light brown, red, dark brown, black), eye colour (blue/grey,
green hazel, brown/black), skin colour (light, medium, dark) and number of
freckles (none, few, some/moderate, many).
United Kingdom. The Leeds-based case-control study recruited population-
based incident melanoma cases diagnosed between September 2000 and
December 2006 from a geographically defined area of Yorkshire and the
Northern region of the UK (63% response rate)9,12,39. Cases were identified by
clinicians and pathology registers and via the Northern and Yorkshire Cancer
Registry and Information Service to ensure overall ascertainment. For all but 18
months of the study period, recruitment was restricted to patients with Breslow
thickness of at least 0.75mm. Controls were ascertained by contacting general
practitioners to identify eligible individuals. These controls were frequency-
matched with cases for age and sex from general practitioners who had also had
cases as a part of their patient register. Overall there was a 55% response rate for
controls. The first 960 of the cases recruited and all controls were examined by
trained interviewers who performed a standardized examination of the skin,
recording naevi by anatomical site and size. For subsequent cases, self-reported
information on naevi was obtained. In total we utilized 1,549 cases and 495 con-
trols from this study. We also used 380 cases and 373 controls recruited by the
University of Cambridge who were genotyped in the replication series. The cases
and controls were recruited as a part of the SEARCH study40,41, an ongoing
population-based study in Eastern England. Cases were ascertained through the
Eastern Cancer Registry and Information Centre, and were aged between 18 and
70 years at diagnosis. Controlswere drawn fromSEARCHandEPIC-Norfolk. The
control set was supplemented with 1,245 additional controls from the Wellcome
Trust Blood Services control set. Details of these studies have been previously
published40–42. Approvals for the Leeds-based family studies, the Leeds case–
control study and the Leeds Melanoma Cohort study were obtained from the
National Research Ethics Service, Northern and Yorkshire Research Ethics
Committee. Approvals for Cambridge case–control studies were obtained from
the Cambridgeshire 4 Research Ethics Committee and the Norwich Local
Research Ethics Committee. Informed consent was obtained from all participants.
Melanoma cell lines. The melanoma tumour cell lines used in this study were
derived from primary cutaneous melanomas or melanoma metastases, as
described previously43. DNA was extracted using QIAGEN QIamp Blood Maxi
kits (Qiagen) according to the manufacturer’s instructions.
DNA Sequencing (whole genome). One affected member from Family 1 was
sequencedbyCompleteGenomics usingananoarray-based short-read sequencing-
by-ligation strategy. Sequencing, genome assembly (to genome build hg18/
NCBI36.1), and variant calling were performed as described previously14.
SequenomMassARRAY genotyping of E318K.MITF E318K was genotyped in
Australian samples as part of a multiplex assay designed using the Sequenom
MassARRAY Assay Design software (version 3.0). The SNP was typed using
Sequenom iPLEX chemistry on a MALDI-TOF Compact Mass Spectrometer
(Sequenom). The 2.5ml PCR reactions were performed in standard 384-well plates
using 12.5 ng genomic DNA, 0.8 units of Taq polymerase (HotStarTaq, Qiagen),
500mmol of each dNTP, 1.625mM of MgCl2 and 100nmol of each PCR primer
(Bioneer). Standard PCR thermal cycling conditions and post-PCR extension
reactions were carried out as described previously10. The iPLEX reaction products
were desalted by diluting samples with 15ml of water and adding 3ml of resin. The
productswere spotted on a SpectroChip (Sequenom), anddatawere processed and
analysed byMassARRAYTYPER3.4 software (Sequenom).DNA from the Family
1 sample in which E318K was identified was included multiple times as a positive
control. As an additional quality control measure, we also confirmed the genotype
of multiple individuals from the Australian case–control study, particularly those
with a family history of melanoma, via Sanger sequencing, identifying no geno-
typing errors.
TaqMan genotyping of E318K. UK samples were genotyped for E318K using a
customTaqMan assay. DNA from the Australian familymember in which E318K
was identified was included as a positive control. Leeds melanoma pedigrees also
were re-screened as a quality control measure using high-resolution melting
(HRM) primers designed to assay E318K, with the results from HRM and
TaqMan matching exactly.
Statistical analyses. Parametric linkage analysis on the multiple case melanoma
families was conducted assuming a dominant model of inheritance, with
penetrances specified as 5%, 95%, 95% for the three genotype classes. The allele
frequency at the disease andmarker locus was specified to be 0.004. Computations
were done using the standard (lod score) parametric linkage routine implemented
in GENEHUNTER-MODSCORE44. For melanoma case–control status, number
of cases carrying the variant was compared to number of controls carrying the
variant using Fisher’s exact test. P values given are two-sided except where noted
otherwise. Sub-phenotypes were tested similarly, with family history, age at onset
and multiple primary melanoma carrier rates compared with that in controls.
Number of blue-eyed individuals carrying the variant was compared to number
of non-blue eyed individuals carrying the variant using Fisher’s exact test. Meta-
analysis for disease/sub-phenotype status and eye colour was done by combining
the raw data. Association with mole count (high versus low where high was
Australian Q-MEGA ‘moderate/many’, Australian AMFS ‘some/many’, UK
‘.25 moles’ and low was Australian Q-MEGA ‘none/few’, Australian AMFS
‘none/few’, UK ‘,25 moles’) was tested using Fisher’s exact test for each sample
individually, due to differences in the exact definition of low/high. Meta-analysis
results for mole count were generated by combining the individual sample ORs
(where the natural log of the odds ratio was weighted for each sample by the
inverse variance of the natural log of the odds ratio). The case–control analysis
corrected for naevus count and eye colour was computed by fitting a logistic
regression with naevus count and eye colour categories as covariates.
Sanger sequencing for E318K. Australian pedigrees for which the proband was
identified as carrying the E318K variant via Sequenom, as well as the panel of
melanoma cell lines, were screened for E318K via Sanger sequencing using the
following primers: forward, 59-CAGGCTCGAGCTCATGGA-39; reverse,
59- TGGGGACACTATAGGCTTGG-39.
MITF sumoylation assay. His–MITF and/or HA–SUMO1 expression vectors,
previously described25, were transfected into COS-7 or NAE cells. The cells were
harvested after three days and 10mg total protein was applied to each lane.
Western blots were performed with anti-MITF monoclonal antibody (C5).
TRPM1 reporter assay. TRPM1 reporter plasmid (100 ng), Renilla luciferase
vector (1 ng) (as internal control), and MITF expression vector (0, 175 or
350ng) were transfected into UACC62 human melanoma cells as previously
described25. After 2 days, luciferase activity was determined. Transfection effi-
ciency was normalized to Renilla luciferase activity. Results are reported as the
average of at least four independent experiments.
Construction of inducibleMITF-expressing cell lines. Stable inducible express-
ion of MITF was achieved using the ViraPower T-REx Lentiviral Expression
System (Invitrogen). Briefly, cell pools were transduced with lentiviral particles
containing pLENTI6/TR, and selected with 3mgml21 blasticidin. Wild-type
MITF was cloned into pLENTI4/TO/V5-DEST using Gateway recombination.
Site-directed mutagenesis of the putative sumolyation site was carried out using
a QuickChange II XL site-directed mutagenesis kit (Stratagene/Agilent
Technologies), and the following primer pair: E318K change: E318K forward,
59- GGTGAATCGGATCATCAAGCAAAAACCCGTTCTTG -39 and E318K
reverse, 59- CAAGAACGGGTTTTTGCTTGATGATCCGATTCACC -39. The
negative control construct was identical except that it encodes the b-galactosidase
gene (Invitrogen). Lentivirus particles were packaged in 293FT cells, before being
titred usingMM96L cells. Target melanoma cell lines were transduced withMITF
and mutant particles using a multiplicity of infection of less than 1, and selected
with 500mgml21 zeocin and 1mgml21 blasticidin for 3 weeks. Cells were main-
tained on 100mgml21 zeocin and 0.5mgml21 blasticidin for all experiments.
Induction of MITF. Cells were treated the day after seeding with 1mgml21
tetracycline to induce MITF expression, and harvested 24 or 48 h afterwards.
RNA was extracted using Qiagen RNeasy mini kit as per manufacturer’s instruc-
tions. RNA concentration was determined using the NanoDrop 2000 (Thermo
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Scientific). For mRNA analyses 0.5mg of total RNA was reverse transcribed using
Superscript III according to the manufacturer’s instructions (Invitrogen) and
MITF, DCT, MLANA, TBSP1 and GAPDH expression analysed using SYBR
Green PCR Master Mix (Applied Biosystems). Primer sequences were MITF
forward, 59-CCAAGTACCACATACAGCAAGC-39 and MITF reverse, 59-TCA
TCCATCTGCATACAGGACG-39, DCT forward 59-CGACTCTGATTAGTCG
GAACTCA-39 and DCT reverse, 59-GGTGGTTGTAGTCATCCAAGC-39,
MLANA forward, 59- GAGAAAAACTGTGAACCTGTGGT-39 and MLANA
reverse, 59- GACTGTTCTGCAGAGAGTTTCTCAT-39, THBS1 forward,
59-CGGTCCAGACACGGACCTGC-39 and THBS1 reverse 59-GGCTTTGG
TCTCCCGCGCTT-39, GAPDH forward, 59-GGCTCTCCAGAACATCATCC
CTGC-39 and GAPDH reverse, 59-GGGTGTCGCTGTTGAAGTCAGAGG -39.
qRT–PCR was performed using a 7900HT Fast Real Time PCR System (Applied
Biosystems).
Generation of constitutive MITF-expressing melanoma cell lines. pcDNA4.1-
HisMax-hMITF (wild type, E318K or K182R/K316R) and pEGFP-C1 (for selec-
tion with G418) were transfected into the UACC62 melanoma cell line. After 5
days of selection with G418, total RNA was collected and MITF target gene
transcript levels assessed by quantitative RT–PCR using the Pfaffl method45.
Expression profiling and analysis. Biotinylated cRNA was prepared with the
Illumina TotalPrep RNA Amplification Kit (Ambion). Labelled cRNA was
hybridized to HumanHT-12 v4 BeadChip Arrays (Illumina), and then washed
and scanned according to standard Illumina protocols. Data were extracted in
GenomeStudio (Illumina) using default analysis settings and no normalization
method. Resulting data were imported into GeneSpring GX v11.5 (Agilent
Technologies). Expression values were normalized using quantile normalization
with default settings.
Entities at least 1.5 fold up- or downregulated following induction of either
wild-type or E318KMITF were determined (C32 wild type, 491; C32 E318K, 705;
HT144wild type, 273;HT144 E318K, 450). Targets similarly up-or downregulated
only by E318K and not wild-type MITF in both of the melanoma cell lines were
identified using Venn diagram (n5 16 entities). Also targets similarly up- or
downregulated only by wild-type and not E318K MITF in both of the melanoma
cell lines were identified usingVenndiagram (n5 2 entities). Entities similarly up-
or downregulated by induction of wild-type and E318K MITF were identified
(C32 wild type and E318K, 244; HT144 wild type and E318K, 150), and those
targets consistently differentially expressed in both of the cell lines identified by
Venn diagram (n5 43 entities representing 37 gene products).
NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/) accession numbers are as fol-
lows: GEO Series reference, GSE31269; GSM774914 HT144wild-type uninduced;
GSM774915 HT144 wild-type 48 h induced; GSM774916 HT144 E318K
uninduced; GSM774917 HT144 E318K 48 h induced; GSM774918 C32 wild-type
uninduced; GSM774919 C32 wild-type 48 h induced; GSM774920 C32 E318K
uninduced; GSM774921 C32 E318K 48 h induced.
Melanin quantification assay.Melanin levels were determined46 after 72 h induc-
tion of wild-type or E318K MITF, and normalized to amounts in uninduced
control cells. Values are from duplicate readings from triplicate independent
experiments.
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Supplementary Results 
 
 
Association of MITF E318K with body site and Breslow thickness 
When we analysed the available data on body site for Australian cases, there was some indication of 
differences by body site for cases that carried the MITF variant compared to those without the MITF 
variant.  Specifically, there was a higher proportion of melanomas on the head and neck and a lower 
proportion on the legs (P = 0.03).  However no clear differences by body site were observed for the UK 
cases (P = 0.46), nor when the UK and Australian data were combined (P = 0.16).  Similar to our 
findings by body site, when we analysed the available data on Breslow thickness for Australian cases, 
those who carried the MITF variant had thinner primary tumours (median 0.38 mm) than those who did 
not (median 0.50 mm, P = 0.003).  Once again, however, no clear differences by Breslow thickness 
were observed for the UK cases (P = 0.80) nor when the UK and Australian data were combined 
(Breslow thickness for cases with variant = 0.80 mm versus without variant = 0.85 mm; P = 0.18). 
 
MITF E318K in melanoma cell lines 
Screening of a panel of 205 cutaneous melanoma cell lines identified seven that carried the MITF 
E318K variant; one was homozygous (the only such sample in the entire study).  The carrier frequency 
(0.034) was higher than in any of the case or control populations from Australia or the UK, thus 
providing further support for an association with melanoma and suggesting that MITF E318K may 
provide an advantage to the establishment of melanoma cell lines in culture. 
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Tumour-associated functions of select genes differentially regulated by MITF E318K 
Several of the non-pigmentation genes that were differentially regulated between wild-type MITF and 
MITF E318K in melanoma cells (Supplementary Figure 1b) have been associated with melanoma or 
other cancer types.  SPINK1 (serine peptidase inhibitor, Kazal type I) expression was activated to a 
greater degree by MITF E318K than wild-type MITF, and is associated with poor survival in ovarian, 
kidney, colorectal, bladder and prostate cancer1,2 and references therein.  SPINK1 also acts as an oncogene to 
regulate proliferation, invasion and intravasation in prostate cancer2.  We also observed more 
pronounced down-regulation of the anti-angiogenic gene (THBS1)3 (validated by qRT-PCR, Fig. 2eiii) 
and cysteine-rich protein-61 (CYR61) with expression of E318K.  THBS1 and CYR61 have recently 
been identified as tumour suppressors in melanoma4, Bonazzi et al., submitted.  
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Supplementary Tables 
 
Supplementary Table 1.  Age of onset, multiple primary melanoma status of probands and MITF 
E318K cosegregation data in melanoma families. 
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Supplementary Table 2.  Nevus association with MITF E318K. 
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Supplementary Table 3.  Eye colour association with MITF E318K. 
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Supplementary Table 4.  Lack of hair colour, skin colour and freckling associations with MITF 
E318K. 
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Supplementary Table 5.  The majority of gene products commonly regulated by wild-type and E318K 
mutant MITF have been previously reported to be MITF target genes. 
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Supplementary Table 6.  Gene products uniquely regulated by either (a) E318K mutant MITF or (b) 
wild-type MITF in melanoma cell lines. 
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Supplementary Figures and Legends 
 
 
 
Supplementary Figure 1.  Gene products commonly regulated by wild-type and E318K mutant MITF.  
Expression of either wild-type or E318K mutant MITF was induced by treatment with tetracycline for 
48 hours prior to RNA extraction and whole genome expression profiling.  A total of 43 entities 
representing 37 gene products were identified as being commonly regulated by wild-type and E318K 
mutant MITF in both of the cell lines.  a, Gene products with less than 1.25-fold difference in 
expression between wild-type and E318K mutant MITF.  b, Gene products with greater than 1.25-fold 
difference between E318K mutant and wild-type MITF in at least one of the two melanoma cell lines 
following induction.  Fold changes are shown compared to the level of gene expression from un-
induced control cells. 
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Supplementary Figure 2.  Quantitative RT-PCR analysis of total RNA isolated from UACC62 human 
melanoma cells which were transfected with control vector, wild-type MITF, or the indicated mutants.  
Each target gene expression level was normalized to ACTB mRNA (Figure 2f shows data normalized 
to MITF expression).  Fold induction is shown as the ratio to each mRNA expression with vector 
control.  Data are mean ± SD of at least three independent experiments. 
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Supplementary Figure 3.  Cosegregation analysis of the MITF E318K variant in melanoma 
families.  Legend as for Fig. 1.  a, Families in which all melanoma cases carry the MITF E318K 
variant (Excluding FAM1).  b. Families in which the MITF E318K variant does not segregate perfectly 
with melanoma.  c.  Families in which the genotype of some melanoma cases is not known. 
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